var title_f34_12_35008="Ipratropium: Pediatric drug information";
var content_f34_12_35008=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ipratropium: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12645307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?18/45/19155?source=see_link\">",
"       Ipratropium (nasal): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?3/59/4021?source=see_link\">",
"       Ipratropium (oral inhalation): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13389 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-AF04787F30-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_12_35008=[""].join("\n");
var outline_f34_12_35008=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?18/45/19155?source=related_link\">",
"      Ipratropium (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?3/59/4021?source=related_link\">",
"      Ipratropium (oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_12_35009="Patient information: Dementia with HIV (The Basics)";
var content_f34_12_35009=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?31/14/31970\">",
"         Patient information: Dementia (including Alzheimer disease) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?31/3/31793\">",
"         Patient information: Evaluating memory and thinking problems (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/25/21907\">",
"         Patient information: HIV/AIDS (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?14/37/14934\">",
"         Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Dementia with HIV (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/dementia-with-hiv-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H12541560\">",
"      <span class=\"h1\">",
"       What is dementia with HIV?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Dementia is a brain disorder that causes thinking and memory problems, plus problems with movement or emotions. These problems make it hard to work or do other daily activities. People who have a virus called &ldquo;HIV&rdquo; can sometimes get dementia. When doctors do not find any other cause for dementia in people with HIV, it is called &ldquo;dementia with HIV.&rdquo; &nbsp;",
"     </p>",
"     <p>",
"      HIV is the virus that causes AIDS. It attacks the body&rsquo;s infection-fighting system, called the &ldquo;immune system.&rdquo; It can cause many different problems, including dementia.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12541575\">",
"      <span class=\"h1\">",
"       What are the symptoms of dementia with HIV?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms of dementia with HIV can start very mild and get worse slowly. Early symptoms can include mild problems with reading, understanding or remembering things, or doing simple math. &nbsp;",
"     </p>",
"     <p>",
"      More severe symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Thinking or understanding things more slowly than before",
"       </li>",
"       <li>",
"        Walking or moving more slowly than before",
"       </li>",
"       <li>",
"        Worse memory problems",
"       </li>",
"       <li>",
"        Problems speaking",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People who have dementia with HIV might also have:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Trouble walking steadily or keeping their balance",
"       </li>",
"       <li>",
"        Leg weakness",
"       </li>",
"       <li>",
"        Shaking (doctors call this &ldquo;tremor&rdquo;) &nbsp;",
"       </li>",
"       <li>",
"        Less energy than usual &ndash; A person who has dementia with HIV might not be as interested in doing things as before.",
"       </li>",
"       <li>",
"        Loss of interest in sex",
"       </li>",
"       <li>",
"        Less emotion than usual &ndash; A person who has dementia with HIV might not care about things or show emotion like he or she used to.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12541590\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. See a doctor or nurse if you think you or someone close to you might have dementia with HIV. The symptoms are sometimes caused by other medical conditions that doctors can treat. Doctors can also give you advice or medicines to help with symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12541605\">",
"      <span class=\"h1\">",
"       Is there a test for dementia with HIV?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No, there is no 1 test. The doctor or nurse can do an exam, ask questions, and decide which tests are best for your individual situation.",
"     </p>",
"     <p>",
"      If a person with HIV has symptoms of dementia, doctors might do a CT scan or MRI of the brain. These are imaging tests that create pictures of the inside of the brain. They can help doctors tell if symptoms are caused by HIV or a different condition.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12541620\">",
"      <span class=\"h1\">",
"       How is dementia with HIV treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main treatment is a group of medicines to treat the HIV. Doctors call these medicines &ldquo;antiretroviral medicines.&rdquo;",
"     </p>",
"     <p>",
"      If you have HIV, you probably take antiretroviral medicines already. Your doctor might give you different medicines if you start to get dementia. He or she will do regular exams, talk to you about your condition, and do tests to see how you are doing.",
"     </p>",
"     <p>",
"      People who have dementia with HIV sometimes also get depressed. Doctors can give medicines to treat the depression. If you take these medicines, the doctor or nurse will check often to make sure they are working correctly and not making you feel sick. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12541643\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/14/31970?source=see_link\">",
"       Patient information: Dementia (including Alzheimer disease) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/3/31793?source=see_link\">",
"       Patient information: Evaluating memory and thinking problems (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/25/21907?source=see_link\">",
"       Patient information: HIV/AIDS (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/37/14934?source=see_link\">",
"       Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?34/12/35009?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83082 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-F1BE05E961-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_12_35009=[""].join("\n");
var outline_f34_12_35009=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12541560\">",
"      What is dementia with HIV?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12541575\">",
"      What are the symptoms of dementia with HIV?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12541590\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12541605\">",
"      Is there a test for dementia with HIV?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12541620\">",
"      How is dementia with HIV treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12541643\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/37/14934?source=related_link\">",
"      Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/14/31970?source=related_link\">",
"      Patient information: Dementia (including Alzheimer disease) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/3/31793?source=related_link\">",
"      Patient information: Evaluating memory and thinking problems (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/25/21907?source=related_link\">",
"      Patient information: HIV/AIDS (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_12_35010="Brain and spine MRI of child with ADEM";
var content_f34_12_35010=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 482px\">",
"   <div class=\"ttl\">",
"    Brain and spine MRI of a child with acute disseminated encephalomyelitis (ADEM)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 462px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     A) Axial MRI of the brain (FLAIR image) in a child with acute disseminated encephalomyelitis (ADEM) demonstrates multifocal areas of hyperintensity in both cerebral hemispheres involving cortical gray matter, centrum semiovale, and deep gray nuclei. B) Sagittal MRI of the spine (T2 image) in the same child demonstrates high signal intrinsic to the spinal cord, consistent with longitudinally extensive transverse myelitis.",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tim Lotze, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_12_35010=[""].join("\n");
var outline_f34_12_35010=null;
var title_f34_12_35011="Multiple bedbug bites";
var content_f34_12_35011=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75123%7EPC%2F79870&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75123%7EPC%2F79870&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bedbug bites",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous papules are present on the trunk of this patient with bedbug bites.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bedbug bites",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A bedbug bite most often appears as a wheal with a central hemorrhagic punctum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Nigel Hill, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_12_35011=[""].join("\n");
var outline_f34_12_35011=null;
var title_f34_12_35012="Thiotepa: Patient drug information";
var content_f34_12_35012=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Thiotepa: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35414?source=see_link\">",
"     see \"Thiotepa: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/42/27302?source=see_link\">",
"     see \"Thiotepa: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691672",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used before a bone marrow transplant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2769899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cancers which have moved to the brain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to thiotepa or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697188",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have bone marrow disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698275",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. You may need drugs to lower this side effect. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698176",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       May not be able to get pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698291",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Other kinds of cancer may rarely happen later in life.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699064",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695944",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may be given into the belly or chest cavity as a wash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696026",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into the bladder.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into the spine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11432 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-219.243.220.100-C38B34FA94-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_12_35012=[""].join("\n");
var outline_f34_12_35012=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021608\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021610\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021609\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021614\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021615\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021617\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021612\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021619\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35414?source=related_link\">",
"      Thiotepa: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/42/27302?source=related_link\">",
"      Thiotepa: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_12_35013="Influenza symptoms and treatment";
var content_f34_12_35013=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/12/35013/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/12/35013/contributors\">",
"     Raphael Dolin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/12/35013/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/12/35013/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/12/35013/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/12/35013/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/12/35013/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Influenza (commonly called the flu) is a highly contagious illness that can occur in children or adults of any age. It occurs more often in the winter months because people spend more time in close contact with one another. The flu is spread easily from person-to-person by coughing, sneezing, or touching surfaces.",
"   </p>",
"   <p>",
"    Every year, complications of the flu require more than 200,000 people in the United States to be hospitalized. Serious illness is more likely in the very young, older adults, pregnant women, and people who have certain health problems such as asthma or other forms of lung disease.",
"   </p>",
"   <p>",
"    There have been several widespread flu outbreaks (called pandemics), which led to the deaths of many people worldwide. These outbreaks occurred when new strains of influenza viruses formed (often from pigs or birds) and humans became infected because they had no immunity to these viruses.",
"   </p>",
"   <p>",
"    This article discusses the symptoms and treatment of seasonal, swine H1N1, and avian flu. Treatments to prevent the flu, including the flu shot, are discussed separately. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/12/39105?source=see_link\">",
"     \"Patient information: Influenza prevention (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     FLU SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of seasonal flu can vary from person to person, but usually include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever (temperature higher than 100&ordm;F or 37.8&ordm;C)",
"     </li>",
"     <li>",
"      Headache and muscle aches",
"     </li>",
"     <li>",
"      Fatigue",
"     </li>",
"     <li>",
"      Cough and sore throat may also be present",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    People with the flu usually have a fever for two to five days. This is different than fever caused by other upper respiratory viruses, which usually resolve after 24 to 48 hours.",
"   </p>",
"   <p>",
"    Most people with the flu have fever and muscle aches, and some people also have cold-like symptoms (runny nose, sore throat). Flu symptoms usually improve over two to five days, although the illness may last for a week or more. Weakness and fatigue may persist for several weeks (",
"    <a class=\"graphic graphic_table graphicRef56899 \" href=\"mobipreview.htm?34/27/35260\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Flu complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of influenza occur in some people; pneumonia is the most common complication. Pneumonia is a serious infection of the lungs, and is more likely to occur in young children, people over the age of 65, people who live in long term care facilities (nursing homes), and those with other illnesses such as diabetes or conditions affecting the heart or lungs. Pneumonia is also more common in people with weakened immune systems, such as those who have had a transplant. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/38/30308?source=see_link\">",
"     \"Patient information: Pneumonia in adults (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     FLU DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Influenza is usually diagnosed based on symptoms (fever, cough and muscle aches). Lab testing for influenza is performed in certain cases, such as during a new influenza outbreak in a community and in patients who are at increased risk for complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     FLU TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     When to seek help",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most people with the flu recover within one to two weeks without treatment. However, serious complications of the flu can occur. Call your doctor or nurse immediately if:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      You feel short of breath or have trouble breathing",
"     </li>",
"     <li>",
"      You have pain or pressure in your chest or stomach",
"     </li>",
"     <li>",
"      You have signs of being dehydrated, such as dizziness when standing or not passing urine",
"     </li>",
"     <li>",
"      You feel confused",
"     </li>",
"     <li>",
"      You cannot stop vomiting or you cannot drink enough fluids",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In children, you should seek help if the child has any of the above or if the child:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Has blue or purplish skin color",
"     </li>",
"     <li>",
"      Is so irritable that he or she does not want to be held",
"     </li>",
"     <li>",
"      Does not have tears when crying (in infants)",
"     </li>",
"     <li>",
"      Has a fever with a rash",
"     </li>",
"     <li>",
"      Does not wake up easily",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are several groups of people who are at increased risk for flu complications. These include pregnant women, young children (&lt;5 years of age, and especially &lt;2 years of age), people &ge;65 years of age, and people with certain diseases such as chronic lung disease (such as asthma), heart disease, diabetes, immunosuppressing conditions (such as HIV infection or transplantation), and some other diseases. If you or your child has flu symptoms and is at increased risk for flu complications, you should call your healthcare provider.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Treat symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treating the symptoms of influenza can help you to feel better, but will not make the flu go away faster.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rest until the flu is fully resolved, especially if the illness has been severe",
"     </li>",
"     <li>",
"      Fluids &mdash; Drink enough fluids so that you do not become dehydrated. One way to judge if you are drinking enough is to look at the color of your urine. Normally, urine should be light yellow to nearly colorless. If you are drinking enough, you should pass urine every three to five hours.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/35/20021?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      (such as Tylenol&reg; and other brands) can relieve fever, headache, and muscle aches.",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/12/6342?source=see_link\">",
"       Aspirin",
"      </a>",
"      , and medicines that include aspirin (eg,",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?28/44/29380?source=see_link\">",
"       bismuth",
"      </a>",
"      subsalicylate; PeptoBismol), are not recommended for children under 18 because aspirin can lead to a serious disease called Reye syndrome.",
"     </li>",
"     <li>",
"      Cough medicines are not usually helpful; cough usually resolves without treatment. We do not recommend cough or cold medicine for children under age six years. (See",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/44/40643?source=see_link\">",
"       \"Patient information: The common cold in children (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Antiviral treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiviral medicines can be used to treat or prevent influenza. When used as a treatment, the medicine does not eliminate flu symptoms, although it can reduce the severity and duration of symptoms by about one day. Not every person with influenza needs an antiviral medicine, but some people do; the decision is based upon several factors. If you are severely ill",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    have risk factors for developing complications of influenza, you will need an antiviral agent. People who are only mildly ill and have no risk factors for complications are usually treated with an antiviral medicine if they have had symptoms for 48 hours or less, but they are not treated if they have had symptoms for more than 48 hours.",
"   </p>",
"   <p>",
"    Antiviral medicines that are used to treat or prevent the flu include",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/16/1285?source=see_link\">",
"     oseltamivir",
"    </a>",
"    (Tamiflu&reg;) and",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/44/16068?source=see_link\">",
"     zanamivir",
"    </a>",
"    (Relenza&reg;). Two other antiviral medicines,",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/11/25780?source=see_link\">",
"     rimantadine",
"    </a>",
"    (Flumadine&reg;) and",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/53/3925?source=see_link\">",
"     amantadine",
"    </a>",
"    (Symmetrel&reg;), were used in the past but are generally no longer effective because most flu viruses are now resistant to them. Antiviral treatment is most effective for seasonal influenza when it is taken within the first 48 hours of flu symptoms.",
"   </p>",
"   <p>",
"    The best antiviral medicine depends upon the type of influenza virus, if the virus could be resistant, and some individual factors. A doctor or nurse should make this decision. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44249?source=see_link\">",
"     \"Prevention of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22250?source=see_link\">",
"     \"Treatment of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26746?source=see_link\">",
"     \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38234?source=see_link\">",
"     \"Treatment and prevention of pandemic H1N1 influenza ('swine influenza')\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/44/16068?source=see_link\">",
"     Zanamivir",
"    </a>",
"    and",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/16/1285?source=see_link\">",
"     oseltamivir",
"    </a>",
"    can cause mild side effects, including nausea and vomiting; zanamivir, which is inhaled, can cause difficulty breathing in some cases. Most people are able to continue the medicine despite the side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotics are",
"    <strong>",
"     NOT",
"    </strong>",
"    useful for treating viral illnesses such as influenza. Antibiotics should only used if there is a bacterial complication of the flu such as bacterial pneumonia, ear infection, or sinusitis. Antibiotics can cause side effects and lead to development of antibiotic resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Complementary and alternative treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a wide variety of herbal, homeopathic, and other complementary and alternative treatments that are marketed for influenza. Unfortunately, there have been few well designed studies to evaluate their efficacy and safety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PREVENTING FLU",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatments to prevent influenza are discussed separately. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/12/39105?source=see_link\">",
"     \"Patient information: Influenza prevention (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H392867\">",
"    <span class=\"h1\">",
"     SWINE H1N1 FLU",
"    </span>",
"    &nbsp;&mdash;&nbsp;A new strain of H1N1 influenza, which contains parts of swine, avian, and human influenza viruses, was first seen in humans in March 2009 in Mexico. Human infections subsequently occurred around the world and caused a pandemic that continued until August 2010. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/2/31786?source=see_link\">",
"     \"Epidemiology of pandemic H1N1 influenza ('swine influenza')\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptoms of infection with the swine H1N1 flu virus and treatment for it were generally similar to those of seasonal flu.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H392874\">",
"    <span class=\"h1\">",
"     AVIAN FLU",
"    </span>",
"    &nbsp;&mdash;&nbsp;Avian influenza (bird flu) is caused by a strain of influenza virus that originally infected birds. Infected birds include chickens, ducks, and geese, among others.",
"   </p>",
"   <p>",
"    There are several strains of avian flu; the H5N1 avian flu virus is the cause of concern since it has led to several deaths, mostly in Asia. To date, avian flu has primarily spread from bird-to-bird, and much less commonly from bird-to-human; human-to-human transmission has occurred rarely. Most humans who became infected with avian flu had direct contact with sick or dead poultry or wild birds, or had very recently visited a live poultry market. No human cases of avian influenza have been described in the United States or elsewhere in North America. &nbsp;",
"   </p>",
"   <p>",
"    Avian flu is frequently severe, and there is little natural immunity in the human population. At least one antiviral medicine (",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/16/1285?source=see_link\">",
"     oseltamivir",
"    </a>",
"    ) might improve the chance of surviving the infection. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Antiviral treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There is a vaccine to prevent avian flu. The vaccine is not commercially available, but has been stockpiled by the United States government in case it is needed in the future.",
"   </p>",
"   <p>",
"    Updated information about avian influenza is available from the United States Centers for Disease Control and Prevention (",
"    <a class=\"external\" href=\"file://www.cdc.gov/flu/avian/\">",
"     www.cdc.gov/flu/avian/",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     WHERE TO GET MORE INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"   </p>",
"   <p>",
"    This article will be updated as needed on our web site (",
"    <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"     www.uptodate.com/patients",
"    </a>",
"    ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"   </p>",
"   <p>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3498689118\">",
"    <span class=\"h2\">",
"     Patient level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2876192\">",
"    <span class=\"h3\">",
"     The Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/47/33522?source=see_link\">",
"     Patient information: Flu (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/43/3763?source=see_link\">",
"     Patient information: Meningitis in children (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/28/24002?source=see_link\">",
"     Patient information: Acute bronchitis (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/59/43955?source=see_link\">",
"     Patient information: Swollen neck nodes in children (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/42/4770?source=see_link\">",
"     Patient information: Severe Acute Respiratory Syndrome (SARS) (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/58/6050?source=see_link\">",
"     Patient information: Bird flu (avian influenza) (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/31/36338?source=see_link\">",
"     Patient information: When to worry about a fever (The Basics)",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2876184\">",
"    <span class=\"h3\">",
"     Beyond the Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/12/39105?source=see_link\">",
"     Patient information: Influenza prevention (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/38/30308?source=see_link\">",
"     Patient information: Pneumonia in adults (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/44/40643?source=see_link\">",
"     Patient information: The common cold in children (Beyond the Basics)",
"    </a>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Professional level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/4/22599?source=see_link\">",
"     Clinical manifestations and diagnosis of avian influenza",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/1/18456?source=see_link\">",
"     Clinical manifestations of seasonal influenza in adults",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/25/5528?source=see_link\">",
"     Diagnosis of seasonal influenza in adults",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/58/15272?source=see_link\">",
"     Epidemiology of influenza",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14090?source=see_link\">",
"     Epidemiology, transmission, and pathogenesis of avian influenza",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19640?source=see_link\">",
"     Pharmacology of antiviral drugs for influenza",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44249?source=see_link\">",
"     Prevention of seasonal influenza in adults",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=see_link\">",
"     Seasonal influenza vaccination in adults",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39032?source=see_link\">",
"     Treatment and prevention of avian influenza",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22250?source=see_link\">",
"     Treatment of seasonal influenza in adults",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/2/31786?source=see_link\">",
"     Epidemiology of pandemic H1N1 influenza ('swine influenza')",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38234?source=see_link\">",
"     Treatment and prevention of pandemic H1N1 influenza ('swine influenza')",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26746?source=see_link\">",
"     Antiviral drugs for the prevention and treatment of seasonal influenza in children",
"    </a>",
"    <br/>",
"    <br/>",
"    The following organizations also provide reliable health information.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Library of Medicine",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/flu.html\">",
"     www.nlm.nih.gov/medlineplus/flu.html",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Institute of Allergy and Infectious Diseases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www3.niaid.nih.gov/topics/Flu/\">",
"     www3.niaid.nih.gov/topics/Flu/",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Centers for Disease Control and Prevention (CDC)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.cdc.gov/flu/\">",
"     file://www.cdc.gov/flu/",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35013/abstract/1\">",
"     1",
"    </a>",
"    ]",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35013/abstract/1\">",
"      Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4010 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-125.39.66.146-C1CFDD43C6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_12_35013=[""].join("\n");
var outline_f34_12_35013=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      FLU SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Flu complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      FLU DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      FLU TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      When to seek help",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Treat symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Antiviral treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Complementary and alternative treatments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PREVENTING FLU",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H392867\">",
"      SWINE H1N1 FLU",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H392874\">",
"      AVIAN FLU",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      WHERE TO GET MORE INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3498689118\">",
"      Patient level information",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2876192\">",
"      - The Basics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2876184\">",
"      - Beyond the Basics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Professional level information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/4010\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PI/4010|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/27/35260\" title=\"table 1\">",
"      Influenza symptoms PI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26746?source=related_link\">",
"      Antiviral drugs for the prevention and treatment of seasonal influenza in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/4/22599?source=related_link\">",
"      Clinical manifestations and diagnosis of avian influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/1/18456?source=related_link\">",
"      Clinical manifestations of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/25/5528?source=related_link\">",
"      Diagnosis of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/58/15272?source=related_link\">",
"      Epidemiology of influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/2/31786?source=related_link\">",
"      Epidemiology of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14090?source=related_link\">",
"      Epidemiology, transmission, and pathogenesis of avian influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/28/24002?source=related_link\">",
"      Patient information: Acute bronchitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/58/6050?source=related_link\">",
"      Patient information: Bird flu (avian influenza) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/47/33522?source=related_link\">",
"      Patient information: Flu (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/12/39105?source=related_link\">",
"      Patient information: Influenza prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/43/3763?source=related_link\">",
"      Patient information: Meningitis in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/38/30308?source=related_link\">",
"      Patient information: Pneumonia in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/42/4770?source=related_link\">",
"      Patient information: Severe Acute Respiratory Syndrome (SARS) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/59/43955?source=related_link\">",
"      Patient information: Swollen neck nodes in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/44/40643?source=related_link\">",
"      Patient information: The common cold in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/31/36338?source=related_link\">",
"      Patient information: When to worry about a fever (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19640?source=related_link\">",
"      Pharmacology of antiviral drugs for influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44249?source=related_link\">",
"      Prevention of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39032?source=related_link\">",
"      Treatment and prevention of avian influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38234?source=related_link\">",
"      Treatment and prevention of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22250?source=related_link\">",
"      Treatment of seasonal influenza in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_12_35014="Oswestry questionnaire";
var content_f34_12_35014=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F63444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F63444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 617px\">",
"   <div class=\"ttl\">",
"    Oswestry questionnaire",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 597px; height: 785px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    For each section of six statements the total score is 5; if the first statement is marked the score = 0; if the last statement is marked it = 5. Intervening statements are scored according to rank. If more than one box is marked in each section, take the highest score. If all 10 sections are completed the score is calculated as follows:",
"    <br>",
"     Example: if 16 (total scored) out of 50 (total possible score) x 100 = 32 percent.",
"     <br>",
"      If one section is missed (or not applicable) the score is calculated:",
"      <br>",
"       Example: 16 (total scored)/45 (total possible score) x 100 = 35.6 percent.",
"       <br>",
"        So the final score may be summarized as:",
"        <br>",
"         (total score/(5 x number of questions answered)) x 100 percent.",
"         <br>",
"          It is suggested rounding the percentage to a whole number for convenience.",
"          <div class=\"footnotes\">",
"          </div>",
"          <div class=\"reference\">",
"           Reproduced with permission from: Fairbank JC, Pynsent PB. The Oswestry Disability Index. Spine 2000; 25:2940. Copyright &copy; 2000 Lippincott Williams &amp; Wilkins.",
"          </div>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_12_35014=[""].join("\n");
var outline_f34_12_35014=null;
var title_f34_12_35015="Unipolar minor depression in adults: Management and treatment";
var content_f34_12_35015=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Unipolar minor depression in adults: Management and treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/12/35015/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/12/35015/contributors\">",
"     Wayne Katon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/12/35015/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/12/35015/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/12/35015/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/12/35015/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/12/35015/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H223901\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The continuum of clinical depression increases in severity from symptoms to minor depression to major depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Minor depression is characterized by fewer symptoms than major depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/4\">",
"     4",
"    </a>",
"    ], as well as shorter episodes, less comorbidity, less psychosocial and physical impairment, and fewer recurrences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/1,2,5\">",
"     1,2,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, minor depression is a common syndrome that causes clinically significant distress and impairs functioning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. In addition, minor depression is associated with somatic symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/7,11\">",
"     7,11",
"    </a>",
"    ], comorbid psychiatric and general medical disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/7,11\">",
"     7,11",
"    </a>",
"    ], and substantial healthcare utilization and costs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/1,11,12\">",
"     1,11,12",
"    </a>",
"    ]. Most patients with minor depression do not seek treatment from a mental health clinician, but are frequently seen in primary care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/6,13\">",
"     6,13",
"    </a>",
"    ]. Although minor depression is at least as prevalent as major depression, fewer patients with minor depression are accurately diagnosed by primary care clinicians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/7,14\">",
"     7,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews the management and treatment of minor depression. The epidemiology, pathogenesis, clinical manifestations, assessment, and diagnosis of minor depression are discussed separately, as are the clinical features, diagnosis, treatment, and prognosis of major depression:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26025?source=see_link\">",
"       \"Unipolar minor depression in adults: Epidemiology, clinical presentation, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link\">",
"       \"Clinical manifestations and diagnosis of depression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=see_link\">",
"       \"Initial treatment of depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27609?source=see_link\">",
"       \"Treatment of resistant depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/19/38201?source=see_link\">",
"       \"Unipolar depression in adults: Prognosis and course of illness\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H224273\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term &ldquo;depression&rdquo; can refer to a mood state, syndrome, or specific disorder; these depressive clinical states are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of depression\", section on 'Terminology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many terms are used to describe clinically significant depressive syndromes that fall short of meeting criteria for major depression, including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/13,15\">",
"     13,15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Minor depression",
"     </li>",
"     <li>",
"      Mild depression",
"     </li>",
"     <li>",
"      Subthreshold depression",
"     </li>",
"     <li>",
"      Subsyndromal depression",
"     </li>",
"     <li>",
"      Subclinical depression",
"     </li>",
"     <li>",
"      Depressive symptoms",
"     </li>",
"     <li>",
"      Depressive disorder not otherwise specified",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The definition of minor depression varies among different studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/13\">",
"     13",
"    </a>",
"    ]. In the most widely used definitions, the number of concurrent symptoms ranges from one to three [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/1,16\">",
"     1,16",
"    </a>",
"    ] or two to four [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/2,8\">",
"     2,8",
"    </a>",
"    ], the symptoms cause clinically significant distress or psychosocial impairment, and the minimum duration of the syndrome is two to four weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/13,17,18\">",
"     13,17,18",
"    </a>",
"    ]. The diagnosis of minor depression is discussed elsewhere in this topic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26025?source=see_link&amp;anchor=H1839470#H1839470\">",
"     \"Unipolar minor depression in adults: Epidemiology, clinical presentation, and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H222383\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most minor depressive episodes are treated by internists and primary care clinicians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/19\">",
"     19",
"    </a>",
"    ], often times in conjunction with counsellors. However, referral to a psychiatrist should be considered for moderate to severe episodes that are unresponsive to multiple (eg, two to three) treatment trials. In addition, referral is often indicated for suicidal patients.",
"   </p>",
"   <p>",
"    Treatment options for minor depression include watchful waiting, psychotherapy, and pharmacotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/20\">",
"     20",
"    </a>",
"    ]. However, the benefits of these interventions are often modest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/17,21,22\">",
"     17,21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, treatments that are effective for unipolar major depression are not necessarily beneficial for minor depression. One example is collaborative (integrated) care, which integrates psychiatric treatment into primary care settings. Collaborative care is administered by a team that generally includes a primary care clinician and mental health specialist; the team provides pharmacotherapy and education about depression and teaches behavioral skills for managing it. Randomized trials have found that for major depression, collaborative care is superior to usual care (typically pharmacotherapy), but that minor depression responds equally well to usual care and collaborative care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Minor depression may progress to major depression. The treatment of unipolar major depression is discussed separately, as is the course of illness in minor depression. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26025?source=see_link&amp;anchor=H796041999#H796041999\">",
"     \"Unipolar minor depression in adults: Epidemiology, clinical presentation, and diagnosis\", section on 'Course of illness'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H222390\">",
"    <span class=\"h2\">",
"     Measurement based care",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest routine monitoring with rating scales during treatment of minor depression. Although there is no evidence demonstrating that this practice improves outcomes, possible benefits include identifying nonresponders, detecting residual or prodromal symptoms, and helping patients recognize improvement. Additional information about measurement based care is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/40/4745?source=see_link\">",
"     \"Using scales to monitor symptoms and treatment of depression (measurement based care)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H222397\">",
"    <span class=\"h1\">",
"     MILD ILLNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild episodes of minor depression are characterized by the absence of suicidal ideation or behavior, and little to no functional impairment.",
"   </p>",
"   <p>",
"    For patients with minor depression who are mildly ill, we suggest watchful waiting, during which the patient is monitored every two to six weeks to ensure that symptoms are not worsening and a major depressive episode has not ensued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/25\">",
"     25",
"    </a>",
"    ]. In addition, it is helpful to educate patients about depression, including the connections between stress, depressive symptoms, and physical symptoms such as abdominal discomfort, fatigue, or headache. However, initiating treatment is a reasonable alternative to watchful waiting. In addition, if symptoms worsen during watchful waiting, such that the minor depressive episode becomes moderate to severe, patients should be treated with active interventions, which are discussed elsewhere in this topic. (See",
"    <a class=\"local\" href=\"#H222404\">",
"     'Moderate to severe illness'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Evidence for the safety of watchful waiting in minor depression (as well as the lack of efficacy of pharmacotherapy) includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of six randomized trials compared antidepressants (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/15/8439?source=see_link\">",
"       isocarboxazid",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      ) with placebo in 468 patients who were treated for 6 to 12 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/21\">",
"       21",
"      </a>",
"      ]. The number of patients who responded (ie, improved 50 percent or more from baseline) to antidepressants or placebo was comparable (41 and 38 percent; relative risk 0.9, 95% CI 0.8-1.1); there was little to no heterogeneity across studies.",
"     </li>",
"     <li>",
"      A 12 week, open label randomized trial compared usual care alone with usual care plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      (20 to 40 mg per day) in 181 patients with either minor depression or mild episodes of major depression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/26\">",
"       26",
"      </a>",
"      ]. Usual care included four visits (each lasting about 15 minutes) with the primary care clinician, who assessed depressive symptoms and psychosocial functioning, provided support and advice, and educated patients about depression and coping skills (eg, exercising, maintaining social activities, and setting achievable goals). At the end of treatment and at the 52 week follow-up, improvement of depression was comparable for the two groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other studies also support watchful waiting for minor depression. A randomized trial in 226 patients with minor depression included a four week, placebo lead-in phase prior to assigning patients to treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/18,27\">",
"     18,27",
"    </a>",
"    ]. At the end of the lead-in phase, depressive symptoms and psychosocial functioning were improved compared with baseline, and remission had occurred in 6 percent; remitted patients tended to be the least severely ill at baseline. Comparable results were found in a second trial (n = 111 patients), which included a one month period of watchful waiting prior to random assignment of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/22\">",
"     22",
"    </a>",
"    ]. At the end of watchful waiting, depressive symptoms were improved compared with baseline, and remission had occurred in 11 percent. Improvement was associated with regularly engaging in pleasant activities (behavioral activation).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H222404\">",
"    <span class=\"h1\">",
"     MODERATE TO SEVERE ILLNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moderate to severe episodes of minor depression are characterized by the presence of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Suicidal ideation or behavior,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"     </li>",
"     <li>",
"      Moderate to severe functional impairment",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H222411\">",
"    <span class=\"h2\">",
"     First line",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with minor depression who are moderately to severely ill, we suggest psychotherapy as first line treatment, based upon randomized trials. We generally use cognitive-behavioral therapy (CBT) because it is the most widely studied option and is frequently more available. However, reasonable alternatives include interpersonal psychotherapy and problem solving therapy. Each of these three therapies is typically administered over a period of two to four months according to a manual, either within an individual or group format. The nature of each therapy is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       CBT",
"      </strong>",
"      &ndash; CBT combines cognitive therapy and behavioral therapy. Cognitive therapy attempts to modify the dysfunctional thoughts, beliefs, and attitudes (eg, &ldquo;I&rsquo;m no good,&rdquo; &ldquo;there&rsquo;s nothing I can do,&rdquo; or &ldquo;my situation is hopeless&rdquo;) that maintain behaviors associated with depression. Behavioral therapy focuses upon modifying the patient&rsquo;s problematic behavioral responses (eg, social isolation and inactivity) to environmental stimuli or dysfunctional thoughts.",
"     </li>",
"     <li>",
"      <strong>",
"       Problem solving therapy",
"      </strong>",
"      &ndash; Problem solving therapy incorporates some CBT strategies and is based upon the principle that depression is connected to social problems. One goal of therapy is to develop rational and effective problem solving skills (positive problem orientation). Patients endeavor to identify and define their problems, and for each problem, consider the barriers to its resolution, set an achievable goal, list and evaluate the advantages and disadvantages for all available solutions (brainstorming), choose one option, develop an action plan and implement it, and evaluate the outcome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Interpersonal therapy",
"      </strong>",
"      &ndash; Interpersonal therapy addresses problematic interpersonal relationships or circumstances that are directly related to the current depressive episode. The therapy focuses upon four types of problems: grief over loss (eg, death of a spouse), role disputes (eg, conflicts at work or home about expectations from the relationship), role transitions (eg, childbirth, divorce, or retirement), and interpersonal skill deficits (pervasive problems starting and maintaining relationships, and chronically impoverished, contentious, and unfulfilling relationships). Interpersonal psychotherapy is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17674?source=see_link\">",
"       \"Interpersonal Psychotherapy (IPT) for depressed adults: Indications, theoretical foundation, general concepts, and efficacy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/20/4425?source=see_link\">",
"       \"Interpersonal Psychotherapy (IPT) for depressed adults: Specific interventions and techniques\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An overview of psychotherapy is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29751?source=see_link\">",
"     \"Overview of psychotherapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence that psychotherapy, particularly CBT, improves minor depression includes the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of seven randomized trials (700 patients) compared psychotherapy with treatment as usual or a waiting list [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/29\">",
"       29",
"      </a>",
"      ]. CBT was used in five trials and interpersonal psychotherapy and problem solving therapy in one trial each. Improvement at the end of treatment was superior with psychotherapy than the control condition, and the difference was clinically small to moderate; there was little to no heterogeneity across studies. At the one year follow-up, there was a trend for a greater reduction of symptoms among patients who received psychotherapy.",
"     </li>",
"     <li>",
"      An eight-week randomized trial compared CBT with usual care (a 40 minute videotape discussing depression) in 49 primary care patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/30\">",
"       30",
"      </a>",
"      ]. After eight weeks, depressive symptoms decreased more in patients who received CBT, and this advantage persisted at the one year follow-up.",
"     </li>",
"     <li>",
"      A randomized trial compared eight sessions of CBT (administered by telephone) plus usual care (a stress reduction program and treatment from other clinicians if desired) with usual care alone in 118 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/31\">",
"       31",
"      </a>",
"      ]. At the end of treatment (assessment after four months), improvement was greater in patients who received CBT, and the clinical difference between CBT and the control condition was moderate to large.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies of problem solving therapy that was adapted for primary care have yielded mixed results. A nine-week randomized trial compared problem solving therapy with usual care in 141 patients, and found that improvement was greater with active treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/28\">",
"     28",
"    </a>",
"    ]. Conversely, an 11-week randomized trial that compared problem solving therapy with pill placebo in 161 patients found that improvement was comparable for the two groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with minor depression, psychotherapy may diminish somatization as part of symptomatic improvement. Somatization is a syndrome of nonspecific physical symptoms that cannot be fully explained by a known general medical condition after appropriate investigation. Evidence that psychotherapy can ameliorate somatization includes an eight-week randomized trial (n = 49) that compared CBT with usual care alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/30\">",
"     30",
"    </a>",
"    ]. At the end of treatment, somatic symptoms decreased more in patients who received CBT, and this benefit persisted at the one year follow-up. Somatization is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/20/5450?source=see_link\">",
"     \"Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/34/18984?source=see_link\">",
"     \"Somatization: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, psychotherapy may possibly prevent minor depression from progressing to major depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of four randomized trials (533 patients with minor depression) compared CBT with treatment as usual, and found that at the one year follow-up, there was a trend for a lower incidence of major depression in patients treated with psychotherapy (incident rate ratio 0.70, 95% CI 0.47-1.03) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A subsequent, six-week randomized trial compared CBT with a control condition (a brochure with information that described depression and local treatment options) in 173 high school students with depressive symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/33\">",
"       33",
"      </a>",
"      ]. At the two year follow-up, major depression occurred in fewer adolescents who received CBT than the control condition (14 versus 23 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No head to head trials have compared CBT (or other forms of psychotherapy) with pharmacotherapy for minor depression. Indirect evidence suggests, however, that CBT is superior. Whereas several randomized trials indicate that CBT is efficacious [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/29-31\">",
"     29-31",
"    </a>",
"    ], other randomized trials indicate that medication monotherapy is not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/21,26,34\">",
"     21,26,34",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H222397\">",
"     'Mild illness'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H222433\">",
"     'Medication monotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H222418\">",
"    <span class=\"h2\">",
"     Second line",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H222426\">",
"    <span class=\"h3\">",
"     Psychotherapy plus pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moderate to severe episodes of minor depression often are not responsive to psychotherapy within four to eight sessions. Based upon clinical experience, we generally add an antidepressant such as a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor for these resistant patients. This approach is consistent with practice guidelines from the United Kingdom National Institute for Health and Clinical Excellence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Although no high quality studies have evaluated the combination of psychotherapy and an antidepressant for minor depression, randomized trials indicate that combination treatment is beneficial for major depression. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=see_link&amp;anchor=H15#H15\">",
"     \"Initial treatment of depression in adults\", section on 'Combined therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Choosing an antidepressant is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=see_link&amp;anchor=H16#H16\">",
"     \"Initial treatment of depression in adults\", section on 'Antidepressants'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For moderate to severe episodes of minor depression that is not responsive to psychotherapy alone, we add pharmacotherapy rather than switching to pharmacotherapy alone because antidepressant monotherapy is generally not beneficial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H222433\">",
"    <span class=\"h3\">",
"     Medication monotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of minor depression with antidepressant medication monotherapy is generally not beneficial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of six randomized trials (468 patients) compared antidepressants with placebo and found that response was comparable for the two groups (41 and 38 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a subsequent 12-week randomized trial that compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      (20",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      with placebo in 47 patients, improvement of symptoms was comparable [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, primary care patients with minor depression who have more severe symptoms and functional impairment may possibly benefit from an antidepressant:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An 11-week randomized trial that compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      (10 to 40",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      with placebo in 138 patients found that improvement was comparable for the two groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/38\">",
"       38",
"      </a>",
"      ]. However, a separate analysis divided patients into three groups according to the severity of depressive symptoms and functional impairment; in the group with the greatest severity, improvement was superior in patients who received the antidepressant rather than placebo.",
"     </li>",
"     <li>",
"      A six-week randomized trial compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      (median dose 125",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      with placebo in 141 patients with major or minor depression who completed at least four weeks of treatment, and found that improvement was superior with active drug. In a separate analysis, patients were divided into three groups according to symptom severity; among patients with either the greatest or intermediate level of severity, amitriptyline was beneficial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/39,40\">",
"       39,40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, antidepressants are often acceptable to patients with minor depression. A meta-analysis of two randomized trials in 186 patients found that the dropout rate for any reason was comparable for antidepressants and placebo (27 and 25 percent); there was little to no heterogeneity across studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35015/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H222440\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical presentation of minor depression often includes somatic, emotional, cognitive, and neurovegetative symptoms, as well as suicidality. Diagnostic criteria are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef87557 \" href=\"mobipreview.htm?8/23/8573\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26025?source=see_link\">",
"       \"Unipolar minor depression in adults: Epidemiology, clinical presentation, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment options for minor depression include watchful waiting, psychotherapy, and pharmacotherapy. However, the benefits of these interventions are often modest. In addition, treatments that are effective for unipolar major depression (eg, collaborative care) are not necessarily beneficial for minor depression. (See",
"      <a class=\"local\" href=\"#H222383\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with minor depression who are mildly ill (no suicidality and little to no functional impairment), we suggest watchful waiting rather than pharmacotherapy or psychotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Patients are monitored every two to six weeks to ensure that symptoms are not worsening; in addition, it is helpful to educate patients about depression. However, initiating psychotherapy is a reasonable alternative to watchful waiting. In addition, if symptoms worsen during watchful waiting such that the minor depressive episode becomes moderate to severe, the patient should be treated. (See",
"      <a class=\"local\" href=\"#H222397\">",
"       'Mild illness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Moderate to severe episodes of minor depression are characterized by the presence of suicidal ideation or behavior,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      moderate to severe functional impairment. For patients with minor depression who are moderately to severely ill, we suggest psychotherapy as a first treatment option rather than pharmacotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We generally use cognitive-behavioral therapy (CBT) because it is the most widely studied option and is frequently more available. However, reasonable alternatives include interpersonal psychotherapy and problem solving therapy. (See",
"      <a class=\"local\" href=\"#H222411\">",
"       'First line'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with moderate to severe episodes of minor depression that does not respond to psychotherapy within four to eight sessions, we suggest adding an antidepressant rather than continuing psychotherapy alone or switching to antidepressant monotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H222426\">",
"       'Psychotherapy plus pharmacotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of mild episodes of minor depression with antidepressant medication monotherapy is typically not beneficial; however, patients with more severe symptoms and functional impairment may possibly benefit from an antidepressant alone. (See",
"      <a class=\"local\" href=\"#H222433\">",
"       'Medication monotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/1\">",
"      Ayuso-Mateos JL, Nuevo R, Verdes E, et al. From depressive symptoms to depressive disorders: the relevance of thresholds. Br J Psychiatry 2010; 196:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/2\">",
"      Kessler RC, Zhao S, Blazer DG, Swartz M. Prevalence, correlates, and course of minor depression and major depression in the National Comorbidity Survey. J Affect Disord 1997; 45:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/3\">",
"      Lewinsohn PM, Klein DN, Durbin EC, et al. Family study of subthreshold depressive symptoms: risk factor for MDD? J Affect Disord 2003; 77:149.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/5\">",
"      Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA 1989; 262:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/6\">",
"      Williams JW Jr, Kerber CA, Mulrow CD, et al. Depressive disorders in primary care: prevalence, functional disability, and identification. J Gen Intern Med 1995; 10:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/7\">",
"      Jackson JL, Passamonti M, Kroenke K. Outcome and impact of mental disorders in primary care at 5 years. Psychosom Med 2007; 69:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/8\">",
"      Judd LL, Paulus MP, Wells KB, Rapaport MH. Socioeconomic burden of subsyndromal depressive symptoms and major depression in a sample of the general population. Am J Psychiatry 1996; 153:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/9\">",
"      Rucci P, Gherardi S, Tansella M, et al. Subthreshold psychiatric disorders in primary care: prevalence and associated characteristics. J Affect Disord 2003; 76:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/10\">",
"      Lyness JM, King DA, Cox C, et al. The importance of subsyndromal depression in older primary care patients: prevalence and associated functional disability. J Am Geriatr Soc 1999; 47:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/11\">",
"      Olfson M, Broadhead WE, Weissman MM, et al. Subthreshold psychiatric symptoms in a primary care group practice. Arch Gen Psychiatry 1996; 53:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/12\">",
"      Cuijpers P, Smit F, Oostenbrink J, et al. Economic costs of minor depression: a population-based study. Acta Psychiatr Scand 2007; 115:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/13\">",
"      Pincus HA, Davis WW, McQueen LE. 'Subthreshold' mental disorders. A review and synthesis of studies on minor depression and other 'brand names'. Br J Psychiatry 1999; 174:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/14\">",
"      Sherbourne CD, Wells KB, Hays RD, et al. Subthreshold depression and depressive disorder: clinical characteristics of general medical and mental health specialty outpatients. Am J Psychiatry 1994; 151:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/15\">",
"      Rodr&iacute;guez MR, Nuevo R, Chatterji S, Ayuso-Mateos JL. Definitions and factors associated with subthreshold depressive conditions: a systematic review. BMC Psychiatry 2012; 12:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/16\">",
"      Pietrzak RH, Kinley J, Afifi TO, et al. Subsyndromal depression in the United States: prevalence, course, and risk for incident psychiatric outcomes. Psychol Med 2012; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/17\">",
"      Barrett JE, Williams JW Jr, Oxman TE, et al. Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18 to 59 years. J Fam Pract 2001; 50:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/18\">",
"      Judd LL, Rapaport MH, Yonkers KA, et al. Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder. Am J Psychiatry 2004; 161:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/19\">",
"      Marcus SC, Olfson M. National trends in the treatment for depression from 1998 to 2007. Arch Gen Psychiatry 2010; 67:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/20\">",
"      Williams JW Jr, Rost K, Dietrich AJ, et al. Primary care physicians' approach to depressive disorders. Effects of physician specialty and practice structure. Arch Fam Med 1999; 8:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/21\">",
"      Barbui C, Cipriani A, Patel V, et al. Efficacy of antidepressants and benzodiazepines in minor depression: systematic review and meta-analysis. Br J Psychiatry 2011; 198:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/22\">",
"      Hegel MT, Oxman TE, Hull JG, et al. Watchful waiting for minor depression in primary care: remission rates and predictors of improvement. Gen Hosp Psychiatry 2006; 28:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/23\">",
"      Katon W, Von Korff M, Lin E, et al. Collaborative management to achieve treatment guidelines. Impact on depression in primary care. JAMA 1995; 273:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/24\">",
"      Katon W, Robinson P, Von Korff M, et al. A multifaceted intervention to improve treatment of depression in primary care. Arch Gen Psychiatry 1996; 53:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/25\">",
"      Kendrick T. Prescribing antidepressants in general practice. BMJ 1996; 313:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/26\">",
"      Hermens ML, van Hout HP, Terluin B, et al. Clinical effectiveness of usual care with or without antidepressant medication for primary care patients with minor or mild-major depression: a randomized equivalence trial. BMC Med 2007; 5:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/27\">",
"      Rapaport MH, Judd LL, Schettler PJ, et al. A descriptive analysis of minor depression. Am J Psychiatry 2002; 159:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/28\">",
"      Oxman TE, Hegel MT, Hull JG, Dietrich AJ. Problem-solving treatment and coping styles in primary care for minor depression. J Consult Clin Psychol 2008; 76:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/29\">",
"      Cuijpers P, Smit F, van Straten A. Psychological treatments of subthreshold depression: a meta-analytic review. Acta Psychiatr Scand 2007; 115:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/30\">",
"      Miranda J, Mu&ntilde;oz R. Intervention for minor depression in primary care patients. Psychosom Med 1994; 56:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/31\">",
"      Furukawa TA, Horikoshi M, Kawakami N, et al. Telephone cognitive-behavioral therapy for subthreshold depression and presenteeism in workplace: a randomized controlled trial. PLoS One 2012; 7:e35330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/32\">",
"      Beekman AT, Smit F, Stek ML, et al. Preventing depression in high-risk groups. Curr Opin Psychiatry 2010; 23:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/33\">",
"      Stice E, Rohde P, Gau JM, Wade E. Efficacy trial of a brief cognitive-behavioral depression prevention program for high-risk adolescents: effects at 1- and 2-year follow-up. J Consult Clin Psychol 2010; 78:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/34\">",
"      Rapaport MH, Nierenberg AA, Howland R, et al. The treatment of minor depression with St. John's Wort or citalopram: failure to show benefit over placebo. J Psychiatr Res 2011; 45:931.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. Quality statement 5: Antidepressants for persistent subthreshold depressive symptoms or mild depression. March, 2011. file://www.nice.org.uk (Accessed on November 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/36\">",
"      Baumeister H. Inappropriate prescriptions of antidepressant drugs in patients with subthreshold to mild depression: time for the evidence to become practice. J Affect Disord 2012; 139:240.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Health &amp; Clinical Excellence. Depression: The treatment and management of depression in adults (updated edition). National clinical practice guideline 90, 2009. file://www.nice.org.uk/ (Accessed on November 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/38\">",
"      Williams JW Jr, Barrett J, Oxman T, et al. Treatment of dysthymia and minor depression in primary care: A randomized controlled trial in older adults. JAMA 2000; 284:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/39\">",
"      Paykel ES, Freeling P, Hollyman JA. Are tricyclic antidepressants useful for mild depression? A placebo controlled trial. Pharmacopsychiatry 1988; 21:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35015/abstract/40\">",
"      Paykel ES, Hollyman JA, Freeling P, Sedgwick P. Predictors of therapeutic benefit from amitriptyline in mild depression: a general practice placebo-controlled trial. J Affect Disord 1988; 14:83.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87127 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-BD1901CB76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_12_35015=[""].join("\n");
var outline_f34_12_35015=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H222440\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H223901\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H224273\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H222383\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H222390\">",
"      Measurement based care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H222397\">",
"      MILD ILLNESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H222404\">",
"      MODERATE TO SEVERE ILLNESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H222411\">",
"      First line",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H222418\">",
"      Second line",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H222426\">",
"      - Psychotherapy plus pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H222433\">",
"      - Medication monotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H222440\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/87127\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/87127|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/23/8573\" title=\"table 1\">",
"      Research criteria for minor depressive disorder",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17674?source=related_link\">",
"      Interpersonal Psychotherapy (IPT) for depressed adults: Indications, theoretical foundation, general concepts, and efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/20/4425?source=related_link\">",
"      Interpersonal Psychotherapy (IPT) for depressed adults: Specific interventions and techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29751?source=related_link\">",
"      Overview of psychotherapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/20/5450?source=related_link\">",
"      Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/34/18984?source=related_link\">",
"      Somatization: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27609?source=related_link\">",
"      Treatment of resistant depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/19/38201?source=related_link\">",
"      Unipolar depression in adults: Prognosis and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26025?source=related_link\">",
"      Unipolar minor depression in adults: Epidemiology, clinical presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/40/4745?source=related_link\">",
"      Using scales to monitor symptoms and treatment of depression (measurement based care)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_12_35016="Randomized clinical trials in rheumatoid arthritis of biologic agents that inhibit IL-1, IL-6, and RANKL";
var content_f34_12_35016=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Randomized clinical trials in rheumatoid arthritis of biologic agents that inhibit IL-1, IL-6, and RANKL",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/12/35016/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/12/35016/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/12/35016/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/12/35016/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/12/35016/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/12/35016/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/12/35016/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the late 1990s, the success of biologic agents in the treatment of rheumatoid arthritis (RA) has dramatically altered the approach to treating this disease and a variety of other inflammatory illnesses. Four biologic approaches have achieved major impact in RA:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tumor necrosis factor (TNF)-alpha inhibition",
"     </li>",
"     <li>",
"      B cell depletion",
"     </li>",
"     <li>",
"      Disruption of T cell costimulation",
"     </li>",
"     <li>",
"      Interleukin (IL)-1 and IL-6 inhibition",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The major clinical trials of biologic agents that inhibit interleukin (IL)-1, IL-6, or the receptor activator of nuclear factor kappa B ligand (RANKL) will be reviewed here. General approaches to the therapy of RA and the major clinical trials of TNF inhibitors, B cell targeted therapies, and T cell targeted therapies and of non-biologic disease modifying antirheumatic drugs (DMARDs) are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/10/10410?source=see_link\">",
"     \"Randomized clinical trials of tumor necrosis factor inhibitors in rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21130?source=see_link\">",
"     \"Rituximab and other B cell targeted therapies for rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/0/9223?source=see_link\">",
"     \"T cell targeted therapies for rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/6/98?source=see_link\">",
"     \"Randomized clinical trials of combinations of nonbiologic DMARDs in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All of the trials included in this review were randomized, double-blind, placebo-controlled investigations. The focus of this review is on the clinical trials that were instrumental in defining the clinical roles of these biologic agents. For each trial, the following features are described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trial name &mdash; Each trial is listed by its acronym, the title of the paper in which the primary results were published, or both.",
"     </li>",
"     <li>",
"      Design &mdash; The duration of the trial, the number of patients studied, and the specific treatment groups are outlined.",
"     </li>",
"     <li>",
"      Patient population &mdash; The entry criteria are summarized, and the type of background therapy permitted is indicated.",
"     </li>",
"     <li>",
"      Primary outcome measures &mdash; The outcome measures specified in advance by the investigators are listed.",
"     </li>",
"     <li>",
"      Important secondary outcome measures &mdash; Other outcome measures essential to understanding the full impact of the intervention and the context of the trial are mentioned.",
"     </li>",
"     <li>",
"      Major results &mdash; The main efficacy results are reviewed. Important adverse effects are also mentioned.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unless otherwise specified, all of the trials outlined below permitted patients to continue to use their baseline nonsteroidal antiinflammatory agents and stable doses of up to 9",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IL-1 INHIBITION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Anakinra",
"    </span>",
"    &nbsp;&mdash;&nbsp;The interleukin-1 receptor antagonist (IL-1Ra) is a naturally occurring glycoprotein inhibitor of IL-1 that binds the high affinity cell surface IL-1 receptor but that has no receptor activation activity.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/294?source=see_link\">",
"     Anakinra",
"    </a>",
"    (rHuIL-1ra), a recombinant human IL-1Ra, differs from the native human protein by having an added N-terminal methionine, and it is not glycosylated. Anakinra, administered daily via subcutaneous injection, operates through competitive binding to the IL-1 receptor.",
"   </p>",
"   <p>",
"    Two major clinical trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    have been conducted in RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35016/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    Trial name &mdash; Treatment of RA with recombinant human IL-1Ra [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35016/abstract/1\">",
"     1",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Design &mdash; Twenty-four week trial involving 472 patients assigned to one of four treatment groups:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Placebo (n = 121)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/294?source=see_link\">",
"       Anakinra",
"      </a>",
"      (30 mg) (n = 119)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/294?source=see_link\">",
"       Anakinra",
"      </a>",
"      (75 mg) (n = 116)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/294?source=see_link\">",
"       Anakinra",
"      </a>",
"      (150 mg) (n = 116)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There was a six-week washout period for DMARDs (including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [MTX]) before enrollment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient population &mdash; Patients had symptoms of RA between six months and eight years. In addition, all patients had 10 or more swollen joints and at least three of the following four criteria:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      At least 10 tender or painful joints",
"     </li>",
"     <li>",
"      Disease activity graded as severe or very severe by the patient",
"     </li>",
"     <li>",
"      Disease activity graded as severe or very severe by the clinician",
"     </li>",
"     <li>",
"      A serum C-reactive protein level &gt;1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary outcome &mdash; American College of Rheumatology 20 percent improvement criteria (ACR20) (",
"      <a class=\"graphic graphic_table graphicRef64036 \" href=\"mobipreview.htm?25/30/26091\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Important secondary outcomes &mdash; Paulus criteria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35016/abstract/3\">",
"       3",
"      </a>",
"      ], Health Assessment Questionnaire (HAQ) score [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35016/abstract/4,5\">",
"       4,5",
"      </a>",
"      ], and a variety of other clinical measures. Radiological outcomes were assessed by the Larsen score [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35016/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Major results &mdash; Only 43 percent of patients in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/294?source=see_link\">",
"       anakinra",
"      </a>",
"      150 mg group achieved ACR20 responses, compared with 34, 39, and 27 percent in the 75 mg, 30 mg, and placebo groups, respectively. Only the 150 mg group versus placebo group comparison was statistically significant. Forty-four percent of patients in the 150 mg group met the Paulus criteria, compared with 21 percent of those in the placebo group.",
"      <br/>",
"      <br/>",
"      Statistically significant improvements were seen in the combined anakinra groups in the number of swollen joints, in the number of tender joints, in the investigator&rsquo;s and patient&rsquo;s assessments of disease activity, in the pain score on a visual analog scale, in the duration of morning stiffness, in the HAQ score, in the C-reactive protein level, and in the erythrocyte sedimentation rate.",
"      <br/>",
"      <br/>",
"      The rate of radiologic progression in the patients receiving anakinra was significantly less than in the placebo group at 24 weeks, as evidenced by the Larsen score and the erosive joint count. Anakinra was well-tolerated, and no serious adverse events were observed. Injection site reactions led to withdrawal from the study in 5 percent of the patients receiving IL-1Ra at 150",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Trial name &mdash;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/294?source=see_link\">",
"     Anakinra",
"    </a>",
"    , a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35016/abstract/2\">",
"     2",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Design &mdash; Six-month trial involving 1414 patients assigned in a 4:1 ratio to receive either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/294?source=see_link\">",
"       anakinra",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or placebo. Permitted background medications included traditional DMARDs, glucocorticoids, and nonsteroidal antiinflammatory drugs (NSAIDs), alone or in combination. Changes in background medications were permitted at the discretion of the treating clinician.",
"      <br/>",
"      <br/>",
"      The six-month double-blind phase of the trial was followed by a 30-month open-label phase.",
"     </li>",
"     <li>",
"      Patient population &mdash; Patients had RA for at least three months and had active disease, defined by the presence of at least three swollen joints and at least three tender joints or by at least 45 minutes of morning stiffness.",
"     </li>",
"     <li>",
"      Primary outcome &mdash; The primary outcome related to the safety of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/294?source=see_link\">",
"       anakinra",
"      </a>",
"      . Adverse events were grouped according to the body system affected, according to a modified World Health Organization adverse reaction term dictionary [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35016/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Major results &mdash; Safety was evaluated in 1399 patients during the initial six-month, double-blind, placebo-controlled phase. These included 1116 patients in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/294?source=see_link\">",
"       anakinra",
"      </a>",
"      group and 283 in the placebo group. Serious adverse events occurred at a similar rate in the anakinra group and in the placebo group (7.7 and 7.8 percent, respectively).",
"      <br/>",
"      <br/>",
"      Serious infectious episodes were observed more frequently in the anakinra group (2.1 versus 0.4 percent). No infection was attributed to opportunistic microorganisms or resulted in death. The rate of withdrawal due to adverse events was 13.4 in the anakinra group and 9.2 in the placebo group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Risk of serious infection &mdash; The increased frequency of serious infections seen with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/294?source=see_link\">",
"       anakinra",
"      </a>",
"      was confirmed in a meta-analysis of four trials of 2771 patients, in which it was dose-dependent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35016/abstract/8\">",
"       8",
"      </a>",
"      ]. The risk of serious infections in all patients who received anakinra compared with placebo was similar (1.4 versus 0.5 percent). The risk of serious infection was increased, however, for patients receiving a high dose of anakinra (&ge;100",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      compared with a low dose and compared with placebo (pooled odds ratios of 9.6 and 3.4, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The serious infections observed in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    -treated patients included pneumonia, osteomyelitis, cellulitis, bursitis, herpes zoster, an infected bunion, and gangrene. There were no related deaths or opportunistic infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     IL-6 INHIBITION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Tocilizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"     Tocilizumab",
"    </a>",
"    is a humanized anti-human IL-6 receptor antibody of the immunoglobulin G1 (IgG1) subclass. The medication is made by grafting the complementarity-determining regions of a mouse anti-human IL-6 receptor mAb onto human IgG1. Tocilizumab competes for both the membrane-bound and the soluble forms of human IL-6 receptor, thereby inhibiting the binding of the native cytokine to its receptor and interfering with the cytokine&rsquo;s effects.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"     Tocilizumab",
"    </a>",
"    has been approved for use in rheumatoid arthritis (RA) and systemic onset juvenile idiopathic arthritis (JIA) in the United States. It is also available in Europe and Japan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35016/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The use of tocilizumab in systemic onset JIA is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/9/5274?source=see_link&amp;anchor=H12929866#H12929866\">",
"     \"Systemic onset juvenile idiopathic arthritis: Treatment\", section on 'IL-6 inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"     Tocilizumab",
"    </a>",
"    has been evaluated in a number of randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35016/abstract/11-17\">",
"     11-17",
"    </a>",
"    ]. The efficacy of tocilizumab was demonstrated in a systematic review of randomized trials involving 3334 patients, in which patients receiving tocilizumab (8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    administered intravenously every four weeks) were significantly more likely than those receiving placebo to achieve an ACR50 response while also receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) (38.8 versus 9.6 percent, relative risk [RR] 3.2, 95% CI 2.7-3.7) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35016/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The drug may cause dyslipidemia but is generally well-tolerated. In the systematic review noted above, patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    were more likely to experience an elevation in the ratios of low-density lipoprotein (LDL) to high-density lipoprotein (HDL) cholesterol (20 versus 12 percent, RR 1.7, 95% CI 1.2-2.2) and of total to HDL cholesterol (12 versus 7 percent, RR 1.7, 95% CI 1.2-2.6), but they were less likely, for any reason, to withdraw from treatment (8.1 versus 14.9 percent, RR 0.6, 95% CI 0.5-0.8) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35016/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another systematic review and meta-analysis of randomized trials found that adverse events were increased in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    (8",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    plus MTX compared with placebo plus MTX (odds ratio [OR] 1.5, 95% CI 1.3 to 1.9), as was the rate of infection (OR 1.3, 95% CI 1.1 to 1.6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35016/abstract/19\">",
"     19",
"    </a>",
"    ]. However, there was no significant increase in the rates of malignancy, tuberculosis reactivation, or hepatitis.",
"   </p>",
"   <p>",
"    Representative trials include the following:",
"   </p>",
"   <p>",
"    Trial name &mdash; The CHARISMA Trial: Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    , in European patients with rheumatoid arthritis who had an incomplete response to MTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35016/abstract/11\">",
"     11",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Design &mdash; Four-month trial involving 359 patients, assigned to one of seven treatment groups:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      MTX plus placebo, 10 to 25",
"      <span class=\"nowrap\">",
"       mg/week",
"      </span>",
"      (n = 49)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"       Tocilizumab",
"      </a>",
"      plus placebo (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every four weeks) (n = 53)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"       Tocilizumab",
"      </a>",
"      plus placebo (4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every four weeks) (n = 54)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"       Tocilizumab",
"      </a>",
"      plus placebo (8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every four weeks) (n = 52)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"       Tocilizumab",
"      </a>",
"      (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every four weeks) plus MTX (n = 52)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"       Tocilizumab",
"      </a>",
"      (4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every four weeks) plus MTX (n = 49)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"       Tocilizumab",
"      </a>",
"      (8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every four weeks) plus MTX (n = 50)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"     Tocilizumab",
"    </a>",
"    is administered via intravenous infusion over one hour.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient population &mdash; RA patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35016/abstract/20\">",
"       20",
"      </a>",
"      ] with active disease refractory to MTX. Active RA was defined as:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      At least six swollen joints",
"     </li>",
"     <li>",
"      At least six tender joints",
"     </li>",
"     <li>",
"      An erythrocyte sedimentation rate &gt;27",
"      <span class=\"nowrap\">",
"       mm/hour",
"      </span>",
"      or a serum C-reactive protein level &gt;0.9",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary outcomes &mdash; ACR20 at week 16 (",
"      <a class=\"graphic graphic_table graphicRef64036 \" href=\"mobipreview.htm?25/30/26091\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Important secondary outcomes &mdash; ACR50, ACR70 (",
"      <a class=\"graphic graphic_table graphicRef64036 \" href=\"mobipreview.htm?25/30/26091\">",
"       table 1",
"      </a>",
"      ), Disease Activity Score (DAS28), and HAQ",
"     </li>",
"     <li>",
"      Major results &mdash; ACR20 responses were achieved by 61 and 63 percent of patients receiving 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      and 8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"       tocilizumab",
"      </a>",
"      as monotherapy, respectively, and by 63 and 74 percent of patients receiving those doses of tocilizumab plus MTX. In contrast, only 41 percent of patients receiving MTX plus placebo achieved ACR20 responses.",
"      <br/>",
"      <br/>",
"      Statistically significant ACR50 and ACR70 responses were observed in patients receiving combination therapy with either 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      or 8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of tocilizumab plus MTX but were not observed in the 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      group or in the tocilizumab groups that did not receive MTX. A dose-related reduction in the DAS28 was observed after week four in all patients except those who received monotherapy with 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of tocilizumab.",
"      <br/>",
"      <br/>",
"      In terms of adverse events, the following observations were made:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Alanine transaminase and aspartate transaminase levels rose and fell in all patients between infusions. The elevations were accentuated among patients receiving both",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"       tocilizumab",
"      </a>",
"      and MTX.",
"     </li>",
"     <li>",
"      Among the 310 patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"       tocilizumab",
"      </a>",
"      , 127 experienced elevated alanine aminotransferase (ALT) levels during the study. Eighteen patients had ALT levels &gt;100 international",
"      <span class=\"nowrap\">",
"       units/L.",
"      </span>",
"     </li>",
"     <li>",
"      Among the 127 patients with elevated ALT levels, the levels had returned to normal one month after the final trial infusion.",
"     </li>",
"     <li>",
"      There were also moderate but reversible increases in the nonfasting total cholesterol and triglyceride levels, and there were reversible reductions in the high-density lipoprotein cholesterol and neutrophil levels.",
"     </li>",
"     <li>",
"      There were two cases of sepsis, both of which occurred in patients who were receiving combination therapy with 8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"       tocilizumab",
"      </a>",
"      plus MTX.",
"     </li>",
"     <li>",
"      Anti-",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"       tocilizumab",
"      </a>",
"      antibodies developed in 25 patients receiving low doses of tocilizumab monotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Trial name &mdash; The OPTION study: Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    , in European patients with rheumatoid arthritis who had an incomplete response to MTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35016/abstract/12\">",
"     12",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Design &mdash; Six-month trial involving 623 patients, all of whom were receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (MTX) at a stable dose, but no other DMARDS or biologic agents at the time of entry into the study. Stable doses of glucocorticoids (&le;10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or equivalent)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      NSAIDs were permitted. Patients were randomly assigned to one of three groups:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      MTX plus intravenous (IV) infusion of placebo every four weeks (n = 204)",
"     </li>",
"     <li>",
"      MTX plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"       tocilizumab",
"      </a>",
"      4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every four weeks (n = 213)",
"     </li>",
"     <li>",
"      MTX plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"       tocilizumab",
"      </a>",
"      8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every four weeks (n = 205)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient population &mdash; RA patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35016/abstract/20\">",
"       20",
"      </a>",
"      ] with active disease refractory to MTX. Active RA was defined as:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      At least six swollen joints",
"     </li>",
"     <li>",
"      Plus, at least eight tender joints",
"     </li>",
"     <li>",
"      Plus, an erythrocyte sedimentation rate &ge;28",
"      <span class=\"nowrap\">",
"       mm/hour",
"      </span>",
"      or a serum C-reactive protein level &ge;1",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [&ge;10",
"      <span class=\"nowrap\">",
"       mg/L]",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary outcomes &mdash; ACR20 at week 24 (",
"      <a class=\"graphic graphic_table graphicRef64036 \" href=\"mobipreview.htm?25/30/26091\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Important secondary outcomes &mdash; ACR50, ACR70 (",
"      <a class=\"graphic graphic_table graphicRef64036 \" href=\"mobipreview.htm?25/30/26091\">",
"       table 1",
"      </a>",
"      ), DAS28, proportion of patients in remission (ie, DAS28 &lt;2.6), DAS28 response by European League Against Rheumatism (EULAR) criteria, and HAQ",
"     </li>",
"     <li>",
"      Major results &mdash; ACR20 responses were achieved in 48 and 59 percent of patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"       tocilizumab",
"      </a>",
"      4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      and tocilizumab 8",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      respectively. In contrast, only 26 percent of patients receiving MTX plus placebo achieved ACR20 responses.",
"      <br/>",
"      <br/>",
"      Statistically significant differences in ACR50 responses, ACR70 responses, and EULAR DAS28 remissions were observed in patients receiving combination therapy with either 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      or 8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of tocilizumab plus MTX when compared with those receiving MTX plus placebo:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      ACR50 in 31, 44, and 11 percent (4",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      8",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      and placebo groups)",
"     </li>",
"     <li>",
"      ACR70 in 12, 22, and 2 percent",
"     </li>",
"     <li>",
"      DAS28 &lt;2.6 in 13, 27, and 0.8 percent",
"     </li>",
"     <li>",
"      EULAR &ldquo;good&rdquo; response (decrease in DAS of 1.2 and final score of &lt;3.2) in 21, 38, and 3 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In terms of adverse events, the following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The incidence of serious adverse events during the study was similar in the three groups (6 percent). Incidence rates of serious infections were higher in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"       tocilizumab",
"      </a>",
"      -treated groups (3, 6, and 2.3 per 100 patient-years in the 4",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      8",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      and placebo groups, respectively). None of the serious infections were tuberculosis.",
"     </li>",
"     <li>",
"      Laboratory abnormalities were more commonly noted in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"       tocilizumab",
"      </a>",
"      plus MTX groups. Elevation of serum transaminases to more than three times the upper limit of the normal occurred in 5 to 6 percent of those receiving MTX plus tocilizumab compared with 0.5 to 1 percent of those receiving MTX plus placebo. Elevations in transaminases were not accompanied by other signs or symptoms of hepatitis or by elevation of serum bilirubin or alkaline phosphatase.",
"      <br/>",
"      <br/>",
"      Elevation of serum cholesterol levels (affecting total, LDL, and HDL cholesterol) were frequently noted in tocilizumab-treated patients. Cholesterol lowering intervention was necessary in 26, 21, and 3 percent of the 4",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      8",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      and placebo groups, respectively.",
"      <br/>",
"      <br/>",
"      Transient decreases in neutrophil counts below normal values were observed in 37 and 67 patients in tocilizumab 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      and 8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      groups, respectively, versus four patients in the placebo group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Trial name &mdash; The RADIATE study: Double-blind, randomized, controlled clinical trial of the IL-6 receptor antagonist,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    , in European and North American patients with RA who had an incomplete response to MTX alone and failure to respond or intolerance to one or more tumor necrosis factor (TNF) alpha inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35016/abstract/13\">",
"     13",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Design &mdash; Trial of 24 weeks&rsquo; duration involving 499 patients, all of whom were receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (MTX) at a stable dose but no other DMARDs or biologic agents at the time of entry. Stable doses of glucocorticoids (&le;10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or equivalent)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      NSAIDs were permitted. The patients were randomly assigned to one of three groups:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      MTX plus intravenous (IV) infusion of placebo every four weeks (n = 158)",
"     </li>",
"     <li>",
"      MTX plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"       tocilizumab",
"      </a>",
"      4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every four weeks (n = 161)",
"     </li>",
"     <li>",
"      MTX plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"       tocilizumab",
"      </a>",
"      8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every four weeks (n = 170)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rescue therapy of MTX plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every four weeks was offered to non-responders (&lt;20 percent improvement in both swollen and tender joint count) at week 16.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient population &mdash; RA patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35016/abstract/20\">",
"       20",
"      </a>",
"      ] with active disease refractory to MTX who failed to respond to or who did not tolerate TNF inhibitors. Active RA was defined as:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      At least six swollen joints",
"     </li>",
"     <li>",
"      Plus, at least eight tender joints",
"     </li>",
"     <li>",
"      At least one of the following: erythrocyte sedimentation rate &gt;28",
"      <span class=\"nowrap\">",
"       mm/hour",
"      </span>",
"      or serum C-reactive protein level &gt;1",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [&ge;10",
"      <span class=\"nowrap\">",
"       mg/L]",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary outcomes &mdash; ACR20 at week 24 (",
"      <a class=\"graphic graphic_table graphicRef64036 \" href=\"mobipreview.htm?25/30/26091\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Important secondary outcomes &mdash; ACR50, ACR70 (",
"      <a class=\"graphic graphic_table graphicRef64036 \" href=\"mobipreview.htm?25/30/26091\">",
"       table 1",
"      </a>",
"      ), DAS28, proportion of patients in remission (ie, DAS28 &lt;2.6) or with low disease activity (DAS28 &lt;3.2), HAQ, and safety data",
"     </li>",
"     <li>",
"      Major results &mdash; ACR20 responses were achieved in 50 and 30 percent of patients receiving MTX plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"       tocilizumab",
"      </a>",
"      8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      and 4",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      respectively. In contrast, only 10 percent of patients receiving MTX plus placebo achieved ACR20 responses.",
"      <br/>",
"      <br/>",
"      Statistically significant differences in ACR50 responses and in DAS28 remissions were observed in patients receiving combination therapy with either 8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      or 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of tocilizumab plus MTX when compared with those receiving MTX plus placebo, and statistically significant differences in ACR70 responses were observed in those receiving 8",
"      <span class=\"nowrap\">",
"       mg/kg.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      ACR50 in 29 and 17 percent versus 4 percent (8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      and 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      versus placebo groups)",
"     </li>",
"     <li>",
"      ACR70 in 12 and 5 percent versus 1 percent",
"     </li>",
"     <li>",
"      DAS28 &lt;2.6 (remission) in 30 and 8 percent versus 2 percent",
"     </li>",
"     <li>",
"      DAS28 &lt;3.2 (low disease activity) in 51 and 15 percent versus 5 percent",
"     </li>",
"     <li>",
"      HAQ values improved by -0.39 and -0.31 versus -0.05",
"     </li>",
"     <li>",
"      Rescue therapy in 13.2 and 21.7 percent versus 49.6 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With respect to adverse events, the following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The incidences of total and of related serious adverse events (SAE) during the study were similar in the three groups (14 to 19 percent and 2 to 3 percent, respectively). Rates of serious infections were similar in the 8",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      4",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      and placebo groups (10.0, 5.7, and 9.6 per 100 patient-years).",
"     </li>",
"     <li>",
"      Laboratory abnormalities were more commonly noted in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"       tocilizumab",
"      </a>",
"      plus MTX groups. Elevation of serum transaminases to more than three times the upper limit of the normal occurred in 2 to 3 percent of those receiving MTX plus tocilizumab compared with less than 1 percent of those receiving MTX plus placebo. None of the increases to this level were sustained for more than two visits, and most patients continued tocilizumab. Elevations in transaminases were not accompanied by other signs or symptoms of hepatitis.",
"      <br/>",
"      <br/>",
"      Elevations of serum high density lipoprotein (HDL) &ge;60",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      and low density lipoprotein (LDL) &ge;160",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      levels were noted in 8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      and 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      tocilizumab-treated patients compared with controls (17 and 12 percent, 14 and 15 percent, and 4 and 4 percent, respectively). An increase in the",
"      <span class=\"nowrap\">",
"       LDL/HDL",
"      </span>",
"      index of &gt;30 percent was seen more often in the tocilizumab patients compared with controls (22, 19, and 10 percent). Comparable proportions of patients, however, experienced a &gt;30 percent increase in the apolipoprotein B",
"      <span class=\"nowrap\">",
"       (ApoB)/ApoA",
"      </span>",
"      atherogenic index.",
"      <br/>",
"      <br/>",
"      Transient neutropenia was observed in 28 and 20 percent of patients in tocilizumab 8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      and 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      groups, respectively, versus &lt;1 percent in the placebo group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional trials that have evaluated the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    have been performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35016/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. The following is an abbreviated overview of one of the larger trials of tocilizumab monotherapy. Tocilizumab has demonstrated efficacy as monotherapy in the AMBITION (Actemra versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    double-blind investigative trial in monotherapy) study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35016/abstract/15\">",
"     15",
"    </a>",
"    ]. In this trial, 673 patients with active RA were randomly assigned to receive either tocilizumab (8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every four weeks either at study onset or after treatment with placebo for eight weeks) or methotrexate (MTX) (titrated from 7.5 up to 20",
"    <span class=\"nowrap\">",
"     mg/week",
"    </span>",
"    within eight weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35016/abstract/15\">",
"     15",
"    </a>",
"    ]. The patients who received tocilizumab, in comparison with MTX, were significantly more likely at week 24 to achieve an ACR20 (70 versus 53 percent) or clinical remission (DAS28 less than 2.6, 34 versus 12 percent).",
"   </p>",
"   <p>",
"    The frequency of serious adverse events and serious infections were similar between the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    - and MTX-treated groups (3.8 versus 2.8 percent and 1.4 versus 0.7 percent, respectively). More patients on tocilizumab experienced a reversible neutropenia (3.1 versus 0.4 percent) and an increased incidence of total cholesterol greater than 240",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (6.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    (13.2 versus 0.4 percent). Increased aminotransferases occurred in both groups, but the majority improved following dose modification. Four patients on MTX and one on tocilizumab discontinued medications due to these changes. Bilirubin elevations, without increases in the aminotransferase levels, were more common with tocilizumab.",
"   </p>",
"   <p>",
"    Caution should be exercised when interpreting trial results because",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    has pronounced effects on levels of acute phase reactants. The use of composite indices, such as the DAS28, which give relatively greater weight to levels of acute phase reactants, can overestimate the clinical response compared with the use of measures that rely less or not at all on acute phase reactants, such as the Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35016/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is relatively limited information regarding the effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    on radiographic progression of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35016/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. In a two-year randomized trial involving 1196 patients with active RA despite ongoing treatment with MTX, results after 52 weeks showed significantly less radiographic progression in patients receiving tocilizumab (8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or 4",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    plus MTX compared with placebo plus MTX (mean change in total Genant-modified Sharp score of 0.29 and 0.34 versus 1.13) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35016/abstract/17\">",
"     17",
"    </a>",
"    ]. The proportion of patients without radiographic progression was also significantly greater in the patients receiving tocilizumab (84 and 81 percent versus 67 percent). Further and longer-term radiographic and safety data will be needed to better assess the role of tocilizumab relative to other biologic agents in RA treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     BINDING RANKL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The receptor activator of nuclear factor kappa B (RANK) stimulates differentiation of osteoclast precursors. Osteoclasts are important effector cells that lead to osteopenia and erosive lesions. The ligand for RANK (RANK-ligand or RANKL) may be rendered inactive when bound by anti-RANKL antibodies.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    is a monoclonal antibody that has been used to treat osteoporosis and is being investigated for possible usefulness in treating RA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Denosumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    is a humanized monoclonal antibody against RANKL that reduces osteoclastogenesis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22040?source=see_link\">",
"     \"Denosumab for osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    is administered by subcutaneous injection every six months. The dose used in clinical trials for osteoporosis has been 60 mg.",
"   </p>",
"   <p>",
"    A total of 218 patients with RA were randomly assigned to receive either placebo or one of two doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    (60 mg or 180 mg) by subcutaneous injection every six months for one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35016/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The primary end point was the change from baseline in the magnetic resonance imaging (MRI) erosion score at six months.",
"   </p>",
"   <p>",
"    At six months, the increase in the MRI erosion score from baseline was significantly lower in both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    groups (mean changes of 0.13 and 0.06 in the 60 mg and 180 mg dose groups, respectively) than in the placebo group (mean change 1.75). A significant difference was also noted in the modified Sharp erosion score at the end of six months in the 180 mg denosumab group when compared with the placebo group and at 12 months in both the 60 mg and the 180 mg denosumab groups when compared with the placebo group. Surrogate markers of bone turnover were suppressed. There was no evidence of an effect of denosumab on cartilage damage as assessed by joint space narrowing or on measures of RA disease activity. Rates of adverse events were comparable between the denosumab and placebo groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5106412\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The interleukin (IL)-1 receptor antagonist",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/294?source=see_link\">",
"       anakinra",
"      </a>",
"      is a naturally occurring glycoprotein inhibitor of IL-1, which can be used as a biologic disease-modifying antirheumatic drug (DMARD). It is administered daily via subcutaneous injection and acts through competitive binding to the IL-1 receptor, but it has no receptor activation activity. It exhibits modest clinical efficacy and a dose-dependent increased risk of serious infection in patients with rheumatoid arthritis (RA) compared with placebo. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'IL-1 inhibition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"       Tocilizumab",
"      </a>",
"      is a biologic DMARD that is humanized anti-human IL-6 receptor antibody; it competes for both the membrane-bound and the soluble forms of human IL-6 receptor, thereby inhibiting the binding of the native cytokine to its receptor and interfering with the cytokine&rsquo;s effects. It is therapeutically effective in patients with RA and in systemic onset juvenile idiopathic arthritis compared with placebo when administered by intravenous infusion every four weeks. The drug may cause dyslipidemia but is generally well-tolerated. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'IL-6 inhibition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"       Denosumab",
"      </a>",
"      is a humanized monoclonal antibody against the ligand for receptor activator of nuclear factor kappa B (RANKL). It has been used to treat osteoporosis based upon its capacity to reduce osteoclastogenesis and is being investigated for use in RA. It is administered subcutaneously every six months. Compared with placebo, it appears to reduce the progression of erosive changes in bone in affected joints in patients with RA. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Binding RANKL'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35016/abstract/1\">",
"      Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41:2196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35016/abstract/2\">",
"      Fleischmann RM, Schechtman J, Bennett R, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum 2003; 48:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35016/abstract/3\">",
"      Paulus HE, Egger MJ, Ward JR, Williams HJ. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group. Arthritis Rheum 1990; 33:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35016/abstract/4\">",
"      Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35016/abstract/5\">",
"      Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982; 9:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35016/abstract/6\">",
"      Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) 1977; 18:481.",
"     </a>",
"    </li>",
"    <li>",
"     WHO Adverse Drug Reaction Terminology (WHO-ART). Uppsala, Sweden: Uppsala Monitoring Centre (WHO Collaborating Centre for International Drug Marketing); 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35016/abstract/8\">",
"      Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009; 68:25.",
"     </a>",
"    </li>",
"    <li>",
"     FDA approves new drug for rheumatoid arthritis. January 11, 2010. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm197108.htm (Accessed on January 28, 2010).",
"    </li>",
"    <li>",
"     Committee for medicinal products for human use. January 2009 plenary meeting monthly report. EMEA/39660/2009 January 29, 2009. www.emea.europa.eu/pdfs/human/press/pr/3966009en.pdf (Accessed on January 29, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35016/abstract/11\">",
"      Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006; 54:2817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35016/abstract/12\">",
"      Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35016/abstract/13\">",
"      Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008; 67:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35016/abstract/14\">",
"      Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008; 58:2968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35016/abstract/15\">",
"      Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010; 69:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35016/abstract/16\">",
"      Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007; 66:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35016/abstract/17\">",
"      Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011; 63:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35016/abstract/18\">",
"      Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol 2011; 38:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35016/abstract/19\">",
"      Campbell L, Chen C, Bhagat SS, et al. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford) 2011; 50:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35016/abstract/20\">",
"      Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35016/abstract/21\">",
"      Smolen JS, Aletaha D. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. Arthritis Rheum 2011; 63:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35016/abstract/22\">",
"      Cohen SB, Dore RK, Lane NE, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008; 58:1299.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7496 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-6DAE62D42F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_12_35016=[""].join("\n");
var outline_f34_12_35016=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5106412\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IL-1 INHIBITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Anakinra",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      IL-6 INHIBITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Tocilizumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      BINDING RANKL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Denosumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5106412\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7496\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7496|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/30/26091\" title=\"table 1\">",
"      ACR RA response criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22040?source=related_link\">",
"      Denosumab for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=related_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/6/98?source=related_link\">",
"      Randomized clinical trials of combinations of nonbiologic DMARDs in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/10/10410?source=related_link\">",
"      Randomized clinical trials of tumor necrosis factor inhibitors in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21130?source=related_link\">",
"      Rituximab and other B cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/9/5274?source=related_link\">",
"      Systemic onset juvenile idiopathic arthritis: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/0/9223?source=related_link\">",
"      T cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_12_35017="Overview of the complications of chronic lymphocytic leukemia";
var content_f34_12_35017=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the complications of chronic lymphocytic leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/12/35017/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/12/35017/contributors\">",
"     Kanti R Rai, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/12/35017/contributors\">",
"     Michael J Keating, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/12/35017/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/12/35017/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/12/35017/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/12/35017/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/12/35017/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic lymphocytic leukemia (CLL) is characterized by the progressive accumulation of monoclonal, functionally incompetent lymphocytes. Patients with CLL commonly develop complications associated with the intrinsic immune dysfunction that results in immunodeficiency and the development of autoimmune disorders.",
"   </p>",
"   <p>",
"    The major complications of CLL will be discussed here. The diagnosis of CLL and treatment of the underlying disorder are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/38/35431?source=see_link\">",
"     \"Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29352?source=see_link\">",
"     \"Overview of the treatment of chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/46/30442?source=see_link\">",
"     \"Treatment of relapsed or refractory chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INFECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Immune defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CLL have abnormal cellular and humoral-mediated immune responses due to quantitative and qualitative defects in immune effector cells. These defects can be due to the underlying disease process or to chemoimmunotherapy used for treatment. This is described in more detail separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Incidence and infectious agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections account for up to 50 percent of all deaths in patients with CLL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35017/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. The incidence of major infection increases with disease stage and active treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35017/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Most infections occur late in the disease course, due to a combination of bone marrow infiltration and therapy-induced immune dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35017/abstract/1,2,7\">",
"     1,2,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The infectious agents seen depend partially upon the underlying immunodeficiency and the immune deficiency produced by the treatment regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35017/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. All patients with CLL have an increased frequency and severity of bacterial infections, most commonly due to encapsulated organisms such as Streptococcus pneumoniae, Staphylococcus aureus, and Haemophilus influenzae. Reactivation of herpes viruses is also common, with Herpes zoster being more frequent than Herpes simplex. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35017/abstract/8,9\">",
"     8,9",
"    </a>",
"    ] Patients treated with specific chemotherapy agents are also at risk of infection from the following organisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients treated with purine analogs (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      ) are at increased risk of infections due to Listeria, mycobacterial species, Nocardia, Candida, Aspergillus, Cryptococcus, herpes viruses (cytomegalovirus, Herpes zoster, Herpes simplex), and Pneumocystis jirovecii (previously Pneumocystis carinii). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/25/410?source=see_link\">",
"       \"Overview of infectious complications following purine analog therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients treated with alkylator-based regimens (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      ) have frequent infections of the respiratory tract, most commonly due to Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35017/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. When such patients also demonstrate neutropenia and hypogammaglobulinemia, they are at increased risk of becoming infected with encapsulated gram positive and gram negative organisms such as those seen in patients treated with purine analogs.",
"     </li>",
"     <li>",
"      Patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      are at increased risk of infections due to herpes viruses (cytomegalovirus, Herpes zoster, Herpes simplex), Candida, Aspergillus, and Pneumocystis jirovecii.",
"     </li>",
"     <li>",
"      Patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      have no definitive change in the spectrum of infection, but are at increased risk for the reactivation of hepatitis B",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hepatitis C. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=see_link\">",
"       \"Hepatitis B virus reactivation associated with immunosuppression\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CLL who develop signs of symptoms concerning for infection should undergo an initial evaluation that includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A thorough general physical examination",
"     </li>",
"     <li>",
"      A complete blood cell count with differential, transaminases, bilirubin, electrolytes, BUN and creatinine, blood cultures, sputum Gram stain and culture, and urine Gram stain and culture",
"     </li>",
"     <li>",
"      A chest x-ray",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If localizing signs or symptoms are present, other tests should be considered for further investigation. Lumbar puncture is not necessary routinely but should be performed in patients who have a change in mental status. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/56/28552?source=see_link\">",
"     \"Diagnostic approach to the adult presenting with neutropenic fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Opportunistic infections should be considered in any patient who develops persistent fever or unexplained pulmonary infiltrates. For patients with unexplained or unresponsive pulmonary infiltrates, we advocate the use of bronchoscopy with bronchoalveolar lavage or transbronchial biopsy to identify opportunistic pathogens such as Cytomegalovirus, Herpes simplex virus, Pneumocystis jirovecii, or mycobacterial infections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/49/21273?source=see_link\">",
"     \"Pulmonary infections in immunocompromised patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/51/25402?source=see_link\">",
"     \"Approach to the immunocompromised patient with fever and pulmonary infiltrates\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of infections in patients with CLL depends upon the patient's risk factors for life-threatening infections (eg, neutropenia, recent therapy) and whether or not the patient appears septic or toxic at presentation.",
"   </p>",
"   <p>",
"    Patients who are septic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    have an absolute neutrophil count less than 500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    should be treated emergently with empiric broad spectrum coverage. If an organism is later identified, the spectrum of therapy can be narrowed to cover the identified pathogen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13930?source=see_link\">",
"     \"Overview of neutropenic fever syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/37/22106?source=see_link\">",
"     \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who are not septic and have an absolute neutrophil count above 500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    can often be treated with antibiotics directed at the most likely pathogen given the presenting signs and symptoms.",
"   </p>",
"   <p>",
"    As an example, patients with signs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptoms of a sinobronchial infection can often be treated with conventional antibiotics used for the general population. Most patients respond to such treatment, but some patients develop chronic sinusitis that may require referral to an ear, nose, and throat specialist. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/15/2297?source=see_link\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Herpes simplex and herpes zoster infection often complicate advanced stage disease. Early institution of treatment with antivirals should be instituted. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/8/23688?source=see_link\">",
"     \"Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/20/33096?source=see_link\">",
"     \"Treatment of herpes zoster in the immunocompetent host\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/40/36488?source=see_link\">",
"     \"Treatment of herpes simplex virus type 1 infection in immunocompetent patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the high rate of infection and associated morbidity and mortality among patients with CLL, attempts have been made to decrease the rate of infection by using vaccines, intravenous immunoglobulin, prophylactic antimicrobials, and myeloid growth factors. While most clinicians agree that patients with CLL should receive appropriate vaccinations, the use of other prophylactic measures is more controversial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CLL should have yearly influenza vaccines and a pneumococcal vaccine every five years. Live vaccines should NOT be given to patients with CLL. Live vaccines include oral polio, oral typhoid, yellow fever, measles, mumps, rubella, bacillus calmette guerin (BCG), and herpes zoster. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/25/410?source=see_link&amp;anchor=H29#H29\">",
"     \"Overview of infectious complications following purine analog therapy\", section on 'Immunizations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/37/30296?source=see_link&amp;anchor=H9#H9\">",
"     \"Immunizations in patients with cancer\", section on 'Influenza vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the antibody response is reduced in many CLL patients, an individual may mount a suboptimal response and still obtain a benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35017/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Furthermore, there is no evidence that influenza or pneumococcal vaccination is associated with a higher risk of reaction compared with a normal population. Antibody response to pneumococcal vaccination may be suboptimal and prolonged penicillin prophylaxis for pneumococcus should be administered if recurrent pneumococcal infections occur. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1177?source=see_link\">",
"     \"Prevention of sepsis in the asplenic patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Antimicrobials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of prophylactic antimicrobials in patients with CLL depends upon the treatment regimen and its associated immunodeficiencies. There have been no randomized trials evaluating the use of prophylactic antimicrobials in this population. The majority of data come from trials investigating various chemotherapy regimens in patients with CLL and clinical experience.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antimicrobial prophylaxis is not advocated for patients with CLL who are not receiving active therapy. Instead, such patients are candidates for vigilant observation and early initiation of treatment once symptoms develop.",
"     </li>",
"     <li>",
"      Patients receiving a purine analog (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      ) based treatment regimen are at increased risk for several opportunistic infections. The use of antimicrobials in these patients is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/25/410?source=see_link&amp;anchor=H19#H19\">",
"       \"Overview of infectious complications following purine analog therapy\", section on 'Prevention of infections'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      are at increased risk for opportunistic infections, including cytomegalovirus (CMV) reactivation. Both antibacterial and antiviral prophylaxis are given routinely in addition to periodic screening for CMV reactivation. This is discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/46/30442?source=see_link&amp;anchor=H7#H7\">",
"       \"Treatment of relapsed or refractory chronic lymphocytic leukemia\", section on 'Alemtuzumab'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/20/32071?source=see_link\">",
"       bendamustine",
"      </a>",
"      are not routinely given antibiotic prophylaxis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     IVIG",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, the majority of patients with CLL will develop hypogammaglobulinemia at some point in the course of their disease. The use of prophylactic intravenous immune globulin (IVIG, IGIV) to restore IgG levels remains controversial. We generally reserve IVIG for selected patients who have recurrent, serious infections.",
"   </p>",
"   <p>",
"    Several small, randomized trials have evaluated the use of prophylactic IVIG in patients with CLL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35017/abstract/13-17\">",
"     13-17",
"    </a>",
"    ]. IVIG has not been directly compared with the use of prophylactic antimicrobials. The randomized trials of prophylactic IVIG reported that patients who receive IVIG have a decrease in the incidence of major bacterial infections. However, IVIG does not appear to increase quality of life or survival.",
"   </p>",
"   <p>",
"    The largest study was a double-blind randomized trial in 84 patients with CLL who were at increased risk of bacterial infection due to hypogammaglobulinemia, a history of infection, or both [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35017/abstract/13\">",
"     13",
"    </a>",
"    ]. Patients received IVIG (400",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    or placebo, each administered every three weeks for one year. The administration of IVIG resulted in fewer bacterial infections (23 versus 42), and an increased time to first infection on therapy, but no difference in nonbacterial infections. There was no decrease in major infections or mortality.",
"   </p>",
"   <p>",
"    Potential toxicities related to IVIG include anaphylaxis, fever, chills, \"flu-like\" symptoms, and headache. In addition, potentially severe hemolytic reactions may be seen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/32/38409?source=see_link\">",
"     \"Intravenous immune globulin: Adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For most patients with CLL, we suggest NOT using prophylactic IVIG.",
"     </li>",
"     <li>",
"      For patients with CLL who have had recurrent infections requiring intravenous (IV) antibiotics or hospitalization who also demonstrate a serum IgG &lt;500",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      we suggest the administration of IVIG. The usual dose is 200 to 400",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      by IV infusion, given at three- to four-week intervals. We aim at maintaining the trough serum IgG in treated patients above 500 to 700",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      as a general guideline. If there is a substantial decrease in the incidence of infections, treatment at gradually extended intervals may be considered. This is discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14087?source=see_link&amp;anchor=H12#H12\">",
"       \"Immune globulin therapy in primary immunodeficiency\", section on 'Administration and dosing'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28857?source=see_link\">",
"       \"General principles in the use of immune globulin\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Growth factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of growth factors, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) or granulocyte macrophage colony-stimulating factor (GM-CSF), in patients with CLL who have neutropenia should follow established guidelines for the management of infections in such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35017/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. A trial of antibiotics is usually sufficient initially, but a poor response to antibiotics with persistent neutropenia should lead to the use of these cytokines. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/31/16890?source=see_link&amp;anchor=H9#H9\">",
"     \"Introduction to recombinant hematopoietic growth factors\", section on 'Indications for treatment with hematopoietic growth factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/9/33945?source=see_link\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ANEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia is a common complication of advanced CLL and it is often multifactorial. Causes of anemia in patients with CLL include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Gastrointestinal blood loss secondary to the use of corticosteroids, thrombocytopenia, mucositis or coagulopathy",
"     </li>",
"     <li>",
"      Hypersplenism",
"     </li>",
"     <li>",
"      Marrow suppression secondary to the use of chemotherapy",
"     </li>",
"     <li>",
"      Marrow infiltration by advanced disease",
"     </li>",
"     <li>",
"      Hemolytic anemia (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Autoimmune hemolytic anemia'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Red blood cell aplasia (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Red cell aplasia'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The initial evaluation of a patient with CLL who develops anemia should include a complete blood count (CBC) with red cell indices, white blood cell count with differential, platelet count, reticulocyte count, direct antiglobulin test (DAT), serum bilirubin, lactate dehydrogenase (LDH), haptoglobin, and a review of the peripheral blood smear. Further studies, including iron studies, a urine hemosiderin or bone marrow aspiration and biopsy may be required for further evaluation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29418?source=see_link\">",
"     \"Approach to the adult patient with anemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/22/23914?source=see_link\">",
"     \"Hematologic consequences of malignancy: Anemia and bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Autoimmune hemolytic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of autoimmune hemolytic anemia (AIHA) in patients with CLL is difficult to determine with certainty. As many as one-third of patients with CLL may develop AIHA over the course of their illness unrelated to treatment modality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35017/abstract/20\">",
"     20",
"    </a>",
"    ], although most series suggest a rate in the range of 4 to 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35017/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. The prevalence increases with disease stage, from a rate of approximately 4 percent in Binet stage A to 10 percent in stages B and C (",
"    <a class=\"graphic graphic_table graphicRef80421 graphicRef56284 \" href=\"mobipreview.htm?8/45/8924\">",
"     table 1A-B",
"    </a>",
"    ). The incidence of AIHA may be higher following purine analog treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/29/8665?source=see_link&amp;anchor=H2#H2\">",
"     \"Autoimmune complications following purine analog therapy\", section on 'Autoimmunity in CLL'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of AIHA is typically made in a patient with an isolated fall in hemoglobin and a positive Coombs' test, indirect hyperbilirubinemia, reticulocytosis, and elevation of serum lactate dehydrogenase (LDH). However, not all patients with AIHA will demonstrate these laboratory findings. In one study, only 18 percent of those patients with CLL and hemolytic anemia had a positive direct antiglobulin (Coombs') test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35017/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19256?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features and diagnosis of autoimmune hemolytic anemia: Warm agglutinins\", section on 'Etiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/29/8665?source=see_link&amp;anchor=H2#H2\">",
"     \"Autoimmune complications following purine analog therapy\", section on 'Autoimmunity in CLL'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CLL who develop autoimmune hemolytic anemia (AIHA) are treated with medical therapies similar to those used for other patients with AIHA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35017/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. This subject is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/29/8665?source=see_link&amp;anchor=H9#H9\">",
"     \"Autoimmune complications following purine analog therapy\", section on 'Treatment of FA-AIHA'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/62/14313?source=see_link\">",
"     \"Treatment of autoimmune hemolytic anemia: Warm agglutinins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Red cell aplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pure red cell aplasia (PRCA) is characterized by the disappearance of red cell precursors from the bone marrow and a profound reduction in the absolute reticulocyte count [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35017/abstract/26\">",
"     26",
"    </a>",
"    ]. The exact incidence of PRCA among patients with CLL is incompletely understood. Most studies have suggested that it is a rare complication of CLL, occurring in approximately 0.5 percent of patients. However, if this disorder is specifically sought for with a bone marrow aspiration and absolute reticulocyte count, PRCA may be found in up to 6 percent of patients with CLL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35017/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Identification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of pure red cell aplasia (PRCA) is made based upon an evaluation of a peripheral blood smear and a bone marrow biopsy. Before attributing the PRCA to an autoimmune phenomenon, the patient should be evaluated for viral infections which have been associated with PRCA. These include cytomegalovirus, Epstein-Barr virus, and parvovirus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/1/17433?source=see_link&amp;anchor=H18#H18\">",
"     \"Acquired pure red cell aplasia\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of patients with pure red cell aplasia (PRCA) includes the judicious use of red cell transfusions and immunosuppressants, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . The majority of patients with CLL and PRCA will have a complete response to treatment with oral cyclosporine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35017/abstract/26,28\">",
"     26,28",
"    </a>",
"    ]. The usual dose is 10 to 14",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in two divided doses, with adjustment according to trough serum levels, response, and tolerance. In particular, renal and hepatic function and serum magnesium levels need to be closely monitored. Patients with refractory acquired PRCA may respond to therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35017/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/1/17433?source=see_link&amp;anchor=H20#H20\">",
"     \"Acquired pure red cell aplasia\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a series of 31 patients with CLL and anemia or thrombocytopenia of presumed autoimmune etiology (19 of whom had prior therapy for this complication), oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (300 mg daily) resulted in responses in over 60 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35017/abstract/30\">",
"     30",
"    </a>",
"    ]. The initial, maximal, and duration of response were 3 weeks, 10 weeks, and 10 months, respectively. Elevation of creatinine (&le; grade II) was observed in six patients, requiring dose adjustment.",
"   </p>",
"   <p>",
"    Transfusion of packed red cells is usually indicated in patients who are clinically symptomatic from severe anemia. The risks of transfusion are similar in patients with CLL to those in other patients. Transfusion reactions are not common in patients with CLL. Leukocyte-depleted and, in rare instances, washed red cell products should be considered for patients who have repeated episodes of transfusion reactions. Irradiated blood products have been used in severely immunosuppressed patients in an attempt to reduce the risk of transfusion-related graft-versus-host disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11769?source=see_link\">",
"     \"Immunologic blood transfusion reactions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21081?source=see_link&amp;anchor=H13#H13\">",
"     \"Use of red blood cells for transfusion\", section on 'Specialized RBC components'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Chemotherapy induced anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of chemotherapy-induced anemia in patients with CLL depends upon the chemotherapy regimen used. Management of symptomatic anemia from chemotherapy-induced myelosuppression includes transfusion of packed red blood cells",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the administration of recombinant erythropoietin or darbepoetin. Issues surrounding the use of ESAs versus transfusion are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21081?source=see_link\">",
"     \"Use of red blood cells for transfusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38138?source=see_link\">",
"     \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As mentioned above, the risks of transfusion are similar in patients with CLL to those in other patients. Leukocyte-depleted and irradiated red cell products should be considered for all CLL patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11769?source=see_link\">",
"     \"Immunologic blood transfusion reactions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21081?source=see_link&amp;anchor=H13#H13\">",
"     \"Use of red blood cells for transfusion\", section on 'Specialized RBC components'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     THROMBOCYTOPENIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia can occur at any time in the disease course of CLL. If it is present at the time of diagnosis, it is typically mild. A platelet count below",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    usually occurs only late in the disease. The causes of thrombocytopenia in patients with CLL include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Suppression of platelet production in the presence of extensive tumor burden",
"     </li>",
"     <li>",
"      Autoimmune destruction",
"     </li>",
"     <li>",
"      Hypersplenism",
"     </li>",
"     <li>",
"      Infection (particularly sepsis and associated disseminated intravascular coagulation)",
"     </li>",
"     <li>",
"      Chemotherapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The initial evaluation of thrombocytopenia in a patient with CLL should include a complete blood count (CBC) and examination of the peripheral smear. The peripheral smear should be analyzed for an estimation of platelet numbers, morphology, presence or absence of platelet clumping, as well as evaluation of associated white and red blood cell changes. In patients with infections or fever, coagulation parameters should be checked, including the PT, aPTT, and fibrinogen. A bone marrow aspiration and biopsy can help to determine the underlying cause in difficult cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/19/15674?source=see_link\">",
"     \"Approach to the adult patient with thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Advanced disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with thrombocytopenia due to advanced disease typically demonstrate extensive infiltration of the bone marrow on bone marrow aspiration and biopsy. Thrombocytopenia due to extensive tumor burden often improves with chemotherapy. However, if patients are refractory to the chemotherapy chosen, thrombocytopenia may be worsened by treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29352?source=see_link\">",
"     \"Overview of the treatment of chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/46/30442?source=see_link\">",
"     \"Treatment of relapsed or refractory chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Immune thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically significant immune thrombocytopenia (ITP) develops in 2 to 5 percent of patients with CLL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35017/abstract/31\">",
"     31",
"    </a>",
"    ]. Up to one-third of cases will have concurrent autoimmune hemolytic anemia, the combination of which is referred to as Evan's syndrome. The diagnosis of ITP is suggested by a rapid, unexplained fall in platelets in the absence of bone marrow failure or hypersplenism. Bone marrow aspirate and biopsy demonstrates an increase in bone marrow megakaryocytes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/13/30938?source=see_link\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of ITP in the context of CLL is similar to that of patients with ITP who do not have CLL. Approximately half of patients will respond to initial therapy and 20 percent will have refractory disease despite trials of several agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35017/abstract/8,30,32\">",
"     8,30,32",
"    </a>",
"    ]. Treatment options are presented in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=see_link\">",
"     \"Treatment and prognosis of immune thrombocytopenia (ITP) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Hypersplenism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypersplenism refers to the sequestration of platelets in a palpably enlarged spleen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/34/34346?source=see_link&amp;anchor=H21#H21\">",
"     \"Approach to the adult patient with splenomegaly and other splenic disorders\", section on 'Splenic imaging for size estimation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of patients with hypersplenism will have an improvement in their platelet count and decrease in their platelet transfusion requirements following splenectomy, whether or not they have splenic enlargement clinically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35017/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Ideally two to three weeks prior to splenectomy, patients should be vaccinated against pneumococcus, Haemophilus influenzae B, and meningococcus. In addition, many clinicians advocate lifelong penicillin (or equivalent) prophylaxis for pneumococcus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/46/30442?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of relapsed or refractory chronic lymphocytic leukemia\", section on 'Splenectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PSYCHOLOGICAL DISTRESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of leukemia is an emotional challenge to patients. A discussion of the natural history of the disorder and positive reinforcement of the rapidly increasing range of treatment options will be sufficient to allay the fears of most patients. However, formal psychological counseling is appropriate for some patients to enable them to cope with the stress of knowing that they have leukemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31080?source=see_link\">",
"     \"Diagnosis of psychiatric and psychologic disorders in patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/1/27673?source=see_link\">",
"     \"Management of psychiatric and psychologic disorders in patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SECOND CANCERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several retrospective studies have suggested that patients with CLL have a higher risk of developing other hematologic and solid malignancies. It is unknown how much of this increased risk is due to the underlying disease and accompanying chronic immunosuppression and how much is due to the treatments given.",
"   </p>",
"   <p>",
"    Five to 10 percent of patients with CLL will have their disease transform into an aggressive large-cell lymphoma (Richter's transformation) or prolymphocytic leukemia. In addition, patients treated for CLL can develop therapy-related myelodysplastic syndrome or acute myeloid leukemia. These are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3609?source=see_link\">",
"     \"Pathobiology and treatment of Richter's transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39480?source=see_link\">",
"     \"Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/33/35354?source=see_link\">",
"     \"Pathogenesis of acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with",
"    <span class=\"nowrap\">",
"     CLL/SLL",
"    </span>",
"    may also have a higher risk of developing secondary solid tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35017/abstract/36-42\">",
"     36-42",
"    </a>",
"    ]. The tumor types that have demonstrated increased rates have varied among studies.",
"   </p>",
"   <p>",
"    The largest retrospective study was an analysis of 16,367 patients with CLL enrolled in the Surveillance, Epidemiology and End Results (SEER) program and followed for an average of 5.2 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35017/abstract/39\">",
"     39",
"    </a>",
"    ]. Eleven percent developed a second solid tumor, a rate that was significantly higher than that for the general population (odds ratio of 1.20, 95% CI 1.15 to 1.26). The highest excess rates were noted for Kaposi's sarcoma, malignant melanoma, cancers of the larynx, and cancers of the lung.",
"   </p>",
"   <p>",
"    There have been no studies of cancer screening in patients with CLL. Patients with CLL should undergo age and sex appropriate screening measures for solid tumors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37962?source=see_link\">",
"     \"Overview of preventive medicine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with",
"    <span class=\"nowrap\">",
"     CLL/SLL",
"    </span>",
"    who develop a solid tumor may have inferior survival when compared with patients with solid tumors who do not have a pre-existing diagnosis of CLL.",
"   </p>",
"   <p>",
"    An analysis of more than 2.3 million patients with cancers of the breast, colorectum, prostate, lung, kidney, pancreas, or ovary enrolled in the SEER program identified 4494 cases (0.19 percent) with a prior diagnosis of CLL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35017/abstract/43\">",
"     43",
"    </a>",
"    ]. After adjusting for age, sex, race, and disease stage, patients with pre-existing CLL had inferior overall survival when compared with those without CLL following a diagnosis of cancer of the breast (hazard ratio [HR] 1.70; 95% CI 1.51-1.91), colorectum (HR 1.65; 95% CI 1.53-1.79), or prostate (HR 1.92; 95% CI 1.73-2.13). This inferior survival remained when CLL-related deaths were excluded.",
"   </p>",
"   <p>",
"    It is unknown why patients with CLL who have a solid tumor appear to have worse survival. Solid tumors that develop in patients with CLL may be biologically different from those that develop in the general population. This could be related to the patient&rsquo;s underlying genetics or the impact of prior therapy for CLL. Alternatively, patients with CLL may be less able to tolerate preferred treatment strategies due to underlying cytopenias or immunosuppression. Further study is needed to determine whether the approach to treatment should differ from the standard approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     LEUKOSTASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukostasis is a medical emergency characterized by an extremely elevated white blood cell (WBC) count and symptoms of decreased tissue perfusion. While a significant proportion of patients with CLL present with a high WBC count, symptoms of leukostasis are rare unless the WBC count exceeds",
"    <span class=\"nowrap\">",
"     400x10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    <span class=\"nowrap\">",
"     (400,000/microL).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/7/19576?source=see_link\">",
"     \"Hyperleukocytosis and leukostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     TUMOR LYSIS SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor lysis syndrome (TLS) is characterized by hyperphosphatemia, hypocalcemia, hyperkalemia, and renal insufficiency. The inciting cause seems to be release of large amounts of phosphate from lysed blasts, which coprecipitates with calcium in the kidneys, leading to hypocalcemia and sometimes to oliguric renal failure. Hyperuricemia further contributes to this problem. The incidence of TLS in CLL varies with the treatment given. Some regimens require prophylaxis for TLS while others do not. The investigational cyclin-dependent kinase inhibitor flavopiridol is highly active in refractory CLL, but has been associated with dramatic instances of hyperacute tumor lysis syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35017/abstract/44\">",
"     44",
"    </a>",
"    ]. The diagnosis and treatment of TLS is presented in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/1/19481?source=see_link\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/10/6309?source=see_link\">",
"       \"Patient information: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic lymphocytic leukemia (CLL) commonly develop complications associated with their intrinsic immune dysfunction resulting in immunodeficiency and autoimmune disorders. The most common complications are infection, anemia, and thrombocytopenia. Rare, but potentially life-threatening complications include leukostasis, tumor lysis syndrome, and second cancers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with CLL are at increased risk for infections due to Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, and herpes viruses. Additional pathogens of concern vary depending upon the treatment regimen used. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Incidence and infectious agents'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients with CLL should receive yearly influenza vaccines and pneumococcal vaccination every five years. Live vaccines should NOT be given to patients with CLL. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Vaccination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with CLL, we suggest NOT using prophylactic intravenous immunoglobulin (IVIG) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'IVIG'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with CLL who have had recurrent infections requiring intravenous antibiotics or hospitalization who also demonstrate a serum IgG &lt;500",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      we suggest the administration of IVIG (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'IVIG'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of prophylactic antimicrobials depends upon the treatment regimen planned and its associated immune dysfunction. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Antimicrobials'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The management of infections in patients with CLL depends upon the patient's risk factors for life-threatening infections (eg, neutropenia, recent therapy) and whether or not they appear septic or toxic at presentation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who are septic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      have an absolute neutrophil count less than 500",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      should be treated emergently with empiric broad spectrum coverage. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13930?source=see_link\">",
"       \"Overview of neutropenic fever syndromes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/37/22106?source=see_link\">",
"       \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who are not septic and have an absolute neutrophil count above 500",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      can often be treated with antibiotics directed at the most likely pathogen given the presenting signs and symptoms. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia is a common complication of advanced CLL and may be due to hypersplenism, marrow infiltration, gastrointestinal blood loss, chemotherapy-induced bone marrow suppression, hemolytic anemia, or red blood cell aplasia. Treatment should be directed at the underlying cause. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Anemia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of thrombocytopenia in patients with CLL include extensive tumor burden, autoimmune destruction, and hypersplenism. Treatment should be directed at the underlying cause. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Thrombocytopenia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Other complications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tumor lysis syndrome (TLS) is characterized by hyperphosphatemia, hypocalcemia, hyperkalemia, and renal insufficiency. The incidence of TLS varies with the treatment given and some regimens require prophylaxis for TLS. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/1/19481?source=see_link\">",
"       \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Leukostasis is a medical emergency characterized by an extremely elevated white blood cell (WBC) count and symptoms of decreased tissue perfusion. This complication is rarely seen in patients with CLL unless the WBC count exceeds",
"      <span class=\"nowrap\">",
"       400x10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      <span class=\"nowrap\">",
"       (400,000/microL).",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/7/19576?source=see_link\">",
"       \"Hyperleukocytosis and leukostasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with CLL may have a higher risk of developing other hematologic and solid malignancies. Patients with CLL should undergo age- and sex-appropriate screening. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Second cancers'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/1\">",
"      Tsiodras S, Samonis G, Keating MJ, Kontoyiannis DP. Infection and immunity in chronic lymphocytic leukemia. Mayo Clin Proc 2000; 75:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/2\">",
"      Perkins JG, Flynn JM, Howard RS, Byrd JC. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer 2002; 94:2033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/3\">",
"      Ahmed S, Siddiqui AK, Rossoff L, et al. Pulmonary complications in chronic lymphocytic leukemia. Cancer 2003; 98:1912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/4\">",
"      Molica S. Infections in chronic lymphocytic leukemia: risk factors, and impact on survival, and treatment. Leuk Lymphoma 1994; 13:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/5\">",
"      Francis S, Karanth M, Pratt G, et al. The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia. Cancer 2006; 107:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/6\">",
"      Anaissie EJ, Kontoyiannis DP, O'Brien S, et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 1998; 129:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/7\">",
"      Hensel M, Kornacker M, Yammeni S, et al. Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia. Br J Haematol 2003; 122:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/8\">",
"      Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2008; :450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/9\">",
"      Morrison VA. Management of infectious complications in patients with chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2007; :332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/10\">",
"      Sinisalo M, Aittoniemi J, K&auml;yhty H, Vilpo J. Vaccination against infections in chronic lymphocytic leukemia. Leuk Lymphoma 2003; 44:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/11\">",
"      Hartkamp A, Mulder AH, Rijkers GT, et al. Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia. Vaccine 2001; 19:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/12\">",
"      Sinisalo M, Aittoniemi J, Oivanen P, et al. Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia. Br J Haematol 2001; 114:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/13\">",
"      Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. N Engl J Med 1988; 319:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/14\">",
"      Boughton BJ, Jackson N, Lim S, Smith N. Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia. Clin Lab Haematol 1995; 17:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/15\">",
"      Molica S, Musto P, Chiurazzi F, et al. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica 1996; 81:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/16\">",
"      Chapel H, Dicato M, Gamm H, et al. Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes. Br J Haematol 1994; 88:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/17\">",
"      Griffiths H, Brennan V, Lea J, et al. Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. Blood 1989; 73:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/18\">",
"      Lyman GH, Kleiner JM. Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy. Cancer Treat Res 2011; 157:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/19\">",
"      Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24:3187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/20\">",
"      Bergsagel DE. The chronic leukemias: a review of disease manifestations and the aims of therapy. Can Med Assoc J 1967; 96:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/21\">",
"      D&uuml;hrsen U, Augener W, Zwingers T, Brittinger G. Spectrum and frequency of autoimmune derangements in lymphoproliferative disorders: analysis of 637 cases and comparison with myeloproliferative diseases. Br J Haematol 1987; 67:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/22\">",
"      Mauro FR, Foa R, Cerretti R, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood 2000; 95:2786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/23\">",
"      Borthakur G, O'Brien S, Wierda WG, et al. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors. Br J Haematol 2007; 136:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/24\">",
"      Gribben JG. How I treat CLL up front. Blood 2010; 115:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/25\">",
"      Hodgson K, Ferrer G, Pereira A, et al. Autoimmune cytopenia in chronic lymphocytic leukaemia: diagnosis and treatment. Br J Haematol 2011; 154:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/26\">",
"      Chikkappa G, Pasquale D, Phillips PG, et al. Cyclosporin-A for the treatment of pure red cell aplasia in a patient with chronic lymphocytic leukemia. Am J Hematol 1987; 26:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/27\">",
"      Diehl LF, Ketchum LH. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 1998; 25:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/28\">",
"      Tura S, Finelli C, Bandini G, et al. Cyclosporin A in the treatment of CLL associated PRCA and bone marrow hypoplasia. Nouv Rev Fr Hematol 1988; 30:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/29\">",
"      Ghazal H. Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia. Blood 2002; 99:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/30\">",
"      Cortes J, O'Brien S, Loscertales J, et al. Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia. Cancer 2001; 92:2016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/31\">",
"      Visco C, Ruggeri M, Laura Evangelista M, et al. Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood 2008; 111:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/32\">",
"      Hegde UP, Wilson WH, White T, Cheson BD. Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood 2002; 100:2260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/33\">",
"      Seymour JF, Cusack JD, Lerner SA, et al. Case/control study of the role of splenectomy in chronic lymphocytic leukemia. J Clin Oncol 1997; 15:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/34\">",
"      Delpero JR, Gastaut JA, Letreut YP, et al. The value of splenectomy in chronic lymphocytic leukemia. Cancer 1987; 59:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/35\">",
"      Ferrant A, Michaux JL, Sokal G. Splenectomy in advanced chronic lymphocytic leukemia. Cancer 1986; 58:2130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/36\">",
"      Tsimberidou AM, Wen S, McLaughlin P, et al. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol 2009; 27:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/37\">",
"      Manusow D, Weinerman BH. Subsequent neoplasia in chronic lymphocytic leukemia. JAMA 1975; 232:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/38\">",
"      Greene MH, Hoover RN, Fraumeni JF Jr. Subsequent cancer in patients with chronic lymphocytic leukemia--a possible immunologic mechanism. J Natl Cancer Inst 1978; 61:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/39\">",
"      Hisada M, Biggar RJ, Greene MH, et al. Solid tumors after chronic lymphocytic leukemia. Blood 2001; 98:1979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/40\">",
"      Royle JA, Baade PD, Joske D, et al. Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study. Br J Cancer 2011; 105:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/41\">",
"      Travis LB, Curtis RE, Hankey BF, Fraumeni JF Jr. Second cancers in patients with chronic lymphocytic leukemia. J Natl Cancer Inst 1992; 84:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/42\">",
"      Sch&ouml;llkopf C, Rosendahl D, Rostgaard K, et al. Risk of second cancer after chronic lymphocytic leukemia. Int J Cancer 2007; 121:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/43\">",
"      Solomon BM, Rabe KG, Slager SL, et al. Overall and Cancer-Specific Survival of Patients With Breast, Colon, Kidney, and Lung Cancers With and Without Chronic Lymphocytic Leukemia: A SEER Population-Based Study. J Clin Oncol 2013; 31:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35017/abstract/44\">",
"      Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007; 109:399.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4504 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-806F72AFFC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_12_35017=[""].join("\n");
var outline_f34_12_35017=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Immune defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Incidence and infectious agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Vaccination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Antimicrobials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - IVIG",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Growth factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ANEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Autoimmune hemolytic anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Red cell aplasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Identification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Chemotherapy induced anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      THROMBOCYTOPENIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Advanced disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Immune thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PSYCHOLOGICAL DISTRESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SECOND CANCERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      LEUKOSTASIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      TUMOR LYSIS SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Other complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4504\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4504|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/50/811\" title=\"table 1A\">",
"      Binet staging system CLL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/23/10619\" title=\"table 1B\">",
"      Rai staging system CLL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/1/17433?source=related_link\">",
"      Acquired pure red cell aplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/15/2297?source=related_link\">",
"      Acute sinusitis and rhinosinusitis in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/34/34346?source=related_link\">",
"      Approach to the adult patient with splenomegaly and other splenic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/19/15674?source=related_link\">",
"      Approach to the adult patient with thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/51/25402?source=related_link\">",
"      Approach to the immunocompromised patient with fever and pulmonary infiltrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/29/8665?source=related_link\">",
"      Autoimmune complications following purine analog therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19256?source=related_link\">",
"      Clinical features and diagnosis of autoimmune hemolytic anemia: Warm agglutinins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/13/30938?source=related_link\">",
"      Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31080?source=related_link\">",
"      Diagnosis of psychiatric and psychologic disorders in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/56/28552?source=related_link\">",
"      Diagnostic approach to the adult presenting with neutropenic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/8/23688?source=related_link\">",
"      Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28857?source=related_link\">",
"      General principles in the use of immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/22/23914?source=related_link\">",
"      Hematologic consequences of malignancy: Anemia and bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/7/19576?source=related_link\">",
"      Hyperleukocytosis and leukostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14087?source=related_link\">",
"      Immune globulin therapy in primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/37/30296?source=related_link\">",
"      Immunizations in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11769?source=related_link\">",
"      Immunologic blood transfusion reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/32/38409?source=related_link\">",
"      Intravenous immune globulin: Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/31/16890?source=related_link\">",
"      Introduction to recombinant hematopoietic growth factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/1/27673?source=related_link\">",
"      Management of psychiatric and psychologic disorders in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/25/410?source=related_link\">",
"      Overview of infectious complications following purine analog therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13930?source=related_link\">",
"      Overview of neutropenic fever syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37962?source=related_link\">",
"      Overview of preventive medicine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29352?source=related_link\">",
"      Overview of the treatment of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3609?source=related_link\">",
"      Pathobiology and treatment of Richter's transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/33/35354?source=related_link\">",
"      Pathogenesis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/38/35431?source=related_link\">",
"      Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/10/6309?source=related_link\">",
"      Patient information: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/49/21273?source=related_link\">",
"      Pulmonary infections in immunocompromised patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38138?source=related_link\">",
"      Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39480?source=related_link\">",
"      Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/37/22106?source=related_link\">",
"      Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=related_link\">",
"      Treatment and prognosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/62/14313?source=related_link\">",
"      Treatment of autoimmune hemolytic anemia: Warm agglutinins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/40/36488?source=related_link\">",
"      Treatment of herpes simplex virus type 1 infection in immunocompetent patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/20/33096?source=related_link\">",
"      Treatment of herpes zoster in the immunocompetent host",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/46/30442?source=related_link\">",
"      Treatment of relapsed or refractory chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/1/19481?source=related_link\">",
"      Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/9/33945?source=related_link\">",
"      Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21081?source=related_link\">",
"      Use of red blood cells for transfusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_12_35018="Prevention of sexually transmitted infections";
var content_f34_12_35018=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of sexually transmitted infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/12/35018/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/12/35018/contributors\">",
"     Cynthia L Gay, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/12/35018/contributors\">",
"     Myron S Cohen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/12/35018/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/12/35018/contributors\">",
"     Noreen A Hynes, MD, MPH, DTM&amp;H",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/12/35018/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/12/35018/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/12/35018/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexually transmitted infections (STIs) are common and preventable causes of morbidity and serious complications. Untreated chlamydial and gonococcal infection may result in pelvic inflammatory disease, which can lead to infertility, ectopic pregnancy, and chronic pelvic pain in 10 to 20 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/1\">",
"     1",
"    </a>",
"    ]. STIs can also result in adverse outcomes in pregnancy, including spontaneous abortion, still birth, premature birth, and congenital infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/2\">",
"     2",
"    </a>",
"    ]. Finally, the presence of STIs can facilitate HIV transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Thus, primary prevention of STIs needs to be given high priority.",
"   </p>",
"   <p>",
"    This topic addresses issues related to the prevention of sexually transmitted infections. Screening for sexually transmitted infections is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/30/490?source=see_link\">",
"     \"Screening for sexually transmitted infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A key strategy in the prevention of STIs involves the screening, diagnosis, and treatment of patients, as well as their sexual partners, to interrupt transmission. Routine sexual histories are critical to allow targeted STI screening and prevention counseling. Assessment of any history of substance abuse, which can lead to disinhibition and risk-taking behaviors, is also important. Risk factors are listed below:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Unmarried status",
"     </li>",
"     <li>",
"      Residence in an urban area",
"     </li>",
"     <li>",
"      New sex partner(s)",
"     </li>",
"     <li>",
"      Multiple sexual partners (concurrent)",
"     </li>",
"     <li>",
"      History of a prior STI",
"     </li>",
"     <li>",
"      Illicit drug use",
"     </li>",
"     <li>",
"      Contact with sex workers",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All patients who have a history of, or risk factors for, an STI should be offered HIV testing. Conversely, anyone who is identified as HIV-seropositive should undergo testing for other STIs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/6\">",
"     6",
"    </a>",
"    ]. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/55/20345?source=see_link\">",
"     \"Diagnostic assays for HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Preventive Services Task Force (USPSTF) and the Centers for Disease Control and Prevention recommend periodic sexual risk assessment to determine which patients are most likely to benefit from STI screening or risk reduction counseling.",
"   </p>",
"   <p>",
"    All sexually active adolescents are at increased risk for STIs and should be offered counseling. Adults should be considered at increased risk if they have a current or past history of a sexually transmitted infection or a history of multiple sex partners. In areas of high prevalence for STIs, all sexually active patients in nonmonogamous relationships may be considered at increased risk. (See",
"    <a class=\"local\" href=\"#H41\">",
"     'Counseling and other prevention modalities'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Centers for Disease Control and Prevention (CDC) created a national surveillance system to monitor risk-taking behaviors in adolescents, which may increase their risk of acquiring an STI. A study conducted from 2004 to 2006 found that 47.4 percent of high school students had a history of sexual intercourse, and 39.8 percent of sexually active students reported not using a condom at their last sexual encounter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/7\">",
"     7",
"    </a>",
"    ]. Furthermore, each year approximately one half of the estimated 19 million incident STI infections in the United States occur in young people ages 15 to 24 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the prevalence of STIs among adolescents, providers frequently fail to inquire about sexual behavior or counsel about risk reduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/9\">",
"     9",
"    </a>",
"    ]. The American Academy of Pediatrics recommends asking adolescents about sexual activity at annual clinic visits, and offering STI screening to all sexually active adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/30/490?source=see_link&amp;anchor=H2#H2\">",
"     \"Screening for sexually transmitted infections\", section on 'Taking a sexual history'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3283061\">",
"    <span class=\"h3\">",
"     Men who have sex with men",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men who have sex with men (MSM) are at high risk for HIV infection and other viral and bacterial STIs due to unsafe sexual practices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/9\">",
"     9",
"    </a>",
"    ]. Increased rates of syphilis, gonorrhoeae, and chlamydial infections, mostly in HIV-infected MSM, have been reported in many cities in the United States and Europe. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/9/37017?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of early syphilis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/18/18728?source=see_link\">",
"     \"Genital Chlamydia trachomatis infections in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/49/3865?source=see_link\">",
"     \"Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/35/26166?source=see_link\">",
"     \"Diagnosis of gonococcal infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/3/19514?source=see_link\">",
"     \"Treatment of uncomplicated gonococcal infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Increased risk of HIV acquisition was reported in association with HSV-2 infection in a study of 4295 MSM who had a median follow-up of three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/11\">",
"     11",
"    </a>",
"    ]. Risk factors for HSV-2 infection included African-American race, unprotected receptive anal intercourse, having an HIV-positive male sex partner, and six or more male partners in the prior six months. Acquisition of HIV was associated with recent incident (Hazard Ratio [HR] 3.6, 95% Confidence Interval [CI] 1.7-7.8), remote incident (HR 1.7, 95% CI 0.8-3.3), and prevalent HSV-2 infection (HR 1.5, 95% CI 1.1-2.1) compared with HSV-2 seronegative individuals. A strong association between HSV-2 seropositivity and HIV infection was also demonstrated in a cross-sectional surveillance survey of 3280 MSM in Peru [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians need to assess sexual risk for all male patients through careful sexual history-taking and counseling on risk reduction at regular clinic visits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Clinicians should also routinely ask patients about symptoms consistent with common STIs, including urethral discharge, dysuria, ulcers, or anorectal symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/30/490?source=see_link&amp;anchor=H2#H2\">",
"     \"Screening for sexually transmitted infections\", section on 'Taking a sexual history'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3280264\">",
"    <span class=\"h3\">",
"     HIV-infected patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;A substantial number of HIV-infected individuals remain sexually active and acquire STIs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/15\">",
"     15",
"    </a>",
"    ]. Concurrent or recurrent STI infections (eg, herpes simplex virus) are particularly important as they increase HIV shedding, and increase the risk of HIV transmission to sexual partners. Accordingly, routine screening and treatment of STIs in HIV-infected persons is recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/9\">",
"     9",
"    </a>",
"    ]. Patients with repeated STIs need enhanced behavioral counseling. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/30/490?source=see_link&amp;anchor=H17#H17\">",
"     \"Screening for sexually transmitted infections\", section on 'Screening special populations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Community-based trials to assess the effect of either improved individual-focused clinical care or mass community treatment of STIs on HIV transmission have been conducted in East Africa; a meta-analysis of four trials found no overall reduction in HIV incidence, although clinically significant reductions in syphilis and gonorrhea were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sexual transmission of HCV can occur, particularly among HIV-infected patients. Common practices associated with clusters of acute HCV infection that have been reported in the United States and Europe include serosorting (ie, HIV-infected men having sex with one another), group sex, and the use of cocaine and other nonintravenous drugs during sex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     VACCINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunizations are available for the prevention of hepatitis A, hepatitis B, and human papillomavirus. Individuals with advanced immunodeficiency may have an impaired response to vaccination. In general, vaccines should be administered to HIV-infected individuals when the CD4 count is &gt;200 to 300",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/17\">",
"     17",
"    </a>",
"    ]. Vaccines administered at a CD4 count &lt;200 should be repeated after CD4 count is above 200 to 300",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hepatitis A",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccination",
"    against hepatitis A is recommended by the CDC for MSM, injection drug users, and patients with chronic liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/9\">",
"     9",
"    </a>",
"    ]. In 2006, hepatitis A vaccination was incorporated into the routine childhood vaccination schedule in the United States. Postvaccination serologic testing is not recommended in immunocompetent individuals because most persons respond to the vaccine. In persons with advanced immunodeficiency and a likelihood of an impaired humoral response, postvaccination serologic testing after one month is indicated to assess the need for supplemental doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/17\">",
"     17",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Hepatitis A virus replicates in the liver and is shed in high concentrations in feces from two weeks before to one week after the onset of clinical illness. Since sexual transmission of hepatitis A probably occurs because of fecal-oral contact, barrier measures, such as condoms, are ineffective in preventing acquisition of this disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/38/1641?source=see_link\">",
"     \"Hepatitis A virus vaccination and postexposure prophylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immunization is also recommended for HIV-infected patients who have chronic liver disease or are at risk for hepatitis A (MSM, injection drug users, or patients with a history of hemophilia).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/30/44518?source=see_link\">",
"     Hepatitis A vaccine",
"    </a>",
"    is safe and effective in HIV-infected patients, particularly when administered before onset of advanced immunosuppression. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37273?source=see_link\">",
"     \"Immunizations in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hepatitis B",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary risk factors that have been associated with hepatitis B infection among adolescents and adults are unprotected sex with an infected partner, unprotected sex with more than one partner, and history of other STIs. MSM and injection drug users are considered high risk groups for HBV acquisition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Advisory Committee on Immunization Practices (ACIP) recommends universal hepatitis B immunization for all unvaccinated adults presenting to an STI clinic, including those who did not complete their immunization series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/18\">",
"     18",
"    </a>",
"    ]. Patients with a history of HBV vaccination should have either documentation of immunization or serologic testing for hepatitis B surface antibody. Appropriate screening tests and the vaccine administration schedule are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31690?source=see_link\">",
"     \"Hepatitis B virus vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although this vaccine is quite effective and safe, studies indicate that many high risk patients are not immunized. In a cross-sectional study of 682 STI clients, 23 percent had antibody to hepatitis B core antigen, indicating previous infection, and 9 percent had antibody to hepatitis B surface antigen, indicating past vaccination; however, the vast majority were still susceptible to hepatitis B infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All pregnant women receiving STI services should be tested for HBsAg, regardless of whether they have been previously tested or vaccinated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/1/42010?source=see_link\">",
"     \"Initial prenatal assessment and patient education\"",
"    </a>",
"    .) The Global Advisory Group of the Expanded Program on Immunization and the WHO recommend routine hepatitis B vaccination among neonates&nbsp;as part of national immunization programs. Adoption in the US is expected to alter the epidemiology of carrier rates and complications of chronic hepatitis B infection as shown in other countries with early adoption of the recommendation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    All HIV-infected patients should receive HBV immunization. Although the vaccine is safe, efficacy can be affected by the presence of HIV RNA and advanced immunosuppression. Accordingly, antibody to hepatitis B surface antigen should be checked at least one month after completion of the vaccine series, and patients with titer levels &le;10",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    should be revaccinated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37273?source=see_link\">",
"     \"Immunizations in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16185?source=see_link\">",
"     \"Treatment of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Human papillomavirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two human papillomavirus (HPV) vaccines are available for the prevention of HPV infection in women: a bivalent vaccine (Cervarix), which protects against HPV types 16 and 18 and a quadrivalent vaccine (Gardasil), which protects against types 6, 11, 16 and 18. Both vaccines offer protection against the HPV types that cause 70 percent of cervical cancers (eg, types 16 and 18) and the quadrivalent HPV vaccine also protects against HPV types that are associated with genital warts (eg, types 6 and 11). Only the quadrivalent vaccine (Gardasil) is approved in the US for use in males. &nbsp;",
"   </p>",
"   <p>",
"    Immunization with HPV vaccine is recommended by the CDC's Advisory Committee on Immunization Practices (ACIP) in girls and women 9 to 26 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The quadrivalent vaccine can also be used in males aged 9 to 26 years to prevent genital warts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/9\">",
"     9",
"    </a>",
"    ]. Clinical trial data, dosing and administration of the vaccines, and side effects are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/17/19738?source=see_link\">",
"     \"Recommendations for the use of human papillomavirus vaccines\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/10/13480?source=see_link\">",
"     \"Clinical trials of human papillomavirus vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Human immunodeficiency virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;No vaccine is currently available for HIV prevention, although multiple candidates are being actively developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/34/5674?source=see_link\">",
"     \"Immunology of HIV-1 infection\"",
"    </a>",
"    .) After disappointing results from prior studies, results from an HIV vaccine trial in 2009 suggested the first, albeit moderate, protection from heterosexual HIV transmission; intention to treat analysis excluding HIV-infected patients at baseline showed vaccine efficacy was 31.2 percent (95% CI 1.1-52.1; p = 0.04) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3300097\">",
"    <span class=\"h2\">",
"     Hepatitis C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although no vaccine is available to prevent hepatitis C virus (HCV) infection, investigative work using microculture assays has revealed new insights into the efficiency of transmission through intravenous drug use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/27\">",
"     27",
"    </a>",
"    ]. Using this culture technique, investigators demonstrated that the type of syringe used had a significant effect on the duration of viable virus (7 days with insulin syringes versus 63 days with tuberculin syringes). These findings could have significant impact on the already demonstrated ability of needle-exchange programs to reduce transmission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CONDOM USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most important means of preventing STIs is through condom use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/28\">",
"     28",
"    </a>",
"    ]. The amount of protection provided by condom use for the prevention of HIV and other STIs is difficult to establish given the ethical limitations of conducting randomized controlled trials. Both the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) assert the protective value of condoms in preventing STIs, and the WHO has incorporated condoms as an essential component in public health strategies to prevent STIs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/9,29\">",
"     9,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2000, the National Institutes of Health convened an expert panel to critically review available scientific literature on the effectiveness of condoms to prevent STIs, including HIV, chlamydia, gonorrhoeae, syphilis, human papillomavirus, chancroid, trichomonas, and genital herpes simplex virus. The panel concluded that condom use prevented HIV transmission in both men and women during vaginal intercourse and prevented gonorrhoeae in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/30\">",
"     30",
"    </a>",
"    ]. The panel felt there was insufficient data to draw conclusions on the ability of condoms to prevent other STIs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/30\">",
"     30",
"    </a>",
"    ]. Of note, most data on the efficacy of condoms are related to male condom use rather than female condom use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, since publication of the expert panel's findings in 2000, multiple other prospective studies have been reported that have contributed substantially to understanding the protective role of condoms in other STIs, including chlamydia, gonorrhoea, herpes simplex type 2, trichomoniasis, and human papillomavirus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Human immunodeficiency virus (HIV)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV can be transmitted through anal, penile-vaginal, and oral intercourse, but the far greatest risk is with anal intercourse. The presence of ulcerative genital lesions also increases the risk of HIV transmission. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/50/26410?source=see_link\">",
"     \"Nonoccupational exposure to HIV in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Effectiveness of condoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro studies of latex and polyurethane condoms have demonstrated that they are impenetrable to HIV viral particles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/32\">",
"     32",
"    </a>",
"    ]; however the majority of evidence for condom effectiveness derives from observational studies. In a meta-analysis of 12 studies of HIV heterosexual serodiscordant couples, condom usage was classified in three categories: always, sometimes, or none. HIV seroconversion rates were much higher in those who never used condoms versus those who always did (0.9 seroconversions versus 6.7 seroconversions per 100 person years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/33\">",
"     33",
"    </a>",
"    ]. The authors estimated that condoms provided an 85 percent reduction in transmission risk. Based on these data, the National Institutes of Health's expert panel concluded that condoms are effective for preventing HIV infection in women and men when used consistently and correctly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/30\">",
"     30",
"    </a>",
"    ]. A similar Cochrane review estimated that the consistent use of male latex condoms, defined as using a condom for all acts of penetrative vaginal intercourse, reduces HIV incidence by 80 percent, based on several longitudinal female-to-male and male-to-female serodiscordant couples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/34\">",
"     34",
"    </a>",
"    ]. In 2009, a collaborative statement from the American College of Physicians and the HIV Medicine Association also called for wider availability of condoms and education about their proper use to minimize the risk of HIV transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Barrier methods are strongly emphasized in Uganda's \"ABC strategy\" of abstinence, being faithful, and condom use, which is credited for making a significant impact on transmission rates in that country [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/36\">",
"     36",
"    </a>",
"    ]. However, in order for condom use to be effective in decreasing HIV prevalence, they need to be used consistently, with ongoing exposures, particularly in areas of high prevalence. To increase the effectiveness of condoms in reducing HIV transmission, others have argued that partner reduction should be emphasized as well, particularly in highly endemic areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since women are often unable to convince their partners to use a condom, there is a need to assess other barrier methods that women can initiate. Female condoms are impervious to viruses, including HIV; however, there are few data regarding efficacy in prevention of HIV transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/38\">",
"     38",
"    </a>",
"    ] and no randomized controlled trials have been conducted on the protective effect of female condoms against HIV infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Gonorrhea, chlamydia, and trichomonas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gonorrhoeae, Chlamydia, and trichomonas cause the vast majority of sexually transmitted infections worldwide.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although the infectious dose of N. gonorrhoeae is not known, one ejaculate from an infected male contains approximately six million bacteria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/39\">",
"       39",
"      </a>",
"      ]. Data suggest an average transmission of one infection for every two exposures. Transmission from male to female is approximately fourfold more efficient than female to male [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chlamydia infection is the most common bacterial STI in the United States, with approximately three million cases per year. Like gonorrhoeae, chlamydia is more efficiently transmitted from males to females. Although easily treated, many patients are undiagnosed due to lack of symptoms. Asymptomatic disease contributes to spread of infection.",
"     </li>",
"     <li>",
"      Trichomonas is a protozoon that is responsible for approximately 160 million cases of vaginitis worldwide. Transmission rates have not been measured, but are thought to be high; the infectious dose is not known [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The NIH expert panel concluded in 2000 that epidemiologic studies suggested that consistent condom use may reduce the risk of gonorrhoeae in men; data were lacking for conclusion regarding chlamydia and trichomoniasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/31\">",
"     31",
"    </a>",
"    ]. Subsequently, several studies suggest a protective effect of condoms against gonorrhoeae, chlamydia, and trichomoniasis infection, as illustrated below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Studies of regular STI evaluation and treatment and provision of condoms in female sex workers in Peru showed that condom use promotion was associated with a significantly decreased risk of gonorrhoeae, chlamydia and trichomonas infections among female sex workers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/31,40,41\">",
"       31,40,41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A significant reduction in the combined incidence of gonorrhoea, chlamydial infection, or trichomoniasis was also observed in a study of adolescent African-American females [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/42\">",
"       42",
"      </a>",
"      ]. In this study, 17.8 percent of females reporting 100 percent condom use developed a recurrent STI compared with 30 percent of females who did not use condoms consistently.",
"     </li>",
"     <li>",
"      A study of mass treatment for STIs in Uganda revealed a significant reduction in the prevalence of syphilis, gonorrhoea, and chlamydia, or both, in men and women reporting consistent condom use, compared to the nonuse of condoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 30 percent reduction in trichomonas infection was reported among women attending an STI clinic who reported using condoms as a method of contraception (106 of 1021 patients) compared with those who did not use barrier methods (525 of 4660 patients) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a subsequent review of all studies published from 1966 to 2004 that evaluated the effectiveness of condom use in preventing gonorrhoeae and chlamydia, most have demonstrated a reduced risk of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Genital herpes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both herpes simplex viruses type 1 and type 2 can cause painful genital ulcerations. Transmission can occur during symptomatic and asymptomatic periods due to intermittent viral shedding.",
"   </p>",
"   <p>",
"    The effect of condom use on transmission of HSV infection has been evaluated in two large studies of heterosexual discordant couples. Both trials demonstrated that condoms were effective in preventing HSV transmission, although only one of the studies demonstrated a protective effect in women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/32/7690?source=see_link\">",
"     \"Treatment of genital herpes simplex virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HSV acquisition is also associated with an increased risk of HIV acquisition. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/10/9386?source=see_link&amp;anchor=H20#H20\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\", section on 'HSV-2 and risk of HIV transmission'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Human papillomavirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Condom use has been associated with a reduction in the risk of acquiring HPV infection, clearance of infection, and higher rates of regression of cervical intraepithelial neoplasia and penile lesions in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/46-49\">",
"     46-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of condom use in preventing HPV infection has been studied in women and men:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The efficacy of male condoms in reducing HPV infection was evaluated in a study of 82 women who reported their first sexual encounter after study entry or two weeks before enrollment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/46\">",
"       46",
"      </a>",
"      ]. The risk of developing HPV infection was reduced by 70 percent in women whose partners consistently used condoms compared to women whose partners used condoms less than 5 percent of the time. Condom use was also effective in preventing cervical intraepithelial lesions. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/6/21610?source=see_link&amp;anchor=H25826411#H25826411\">",
"       \"Epidemiology of human papillomavirus infections\", section on 'Risk factors for transmission'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a study of 463 men who answered questionnaires regarding condom use during vaginal sex, consistent use of condoms within the past three months was associated with a 50 percent lower prevalence of HPV detection compared with men who used them less frequently [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Chancroid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chancroid causes genital ulcer disease and is primarily found in resource-limited settings. In experimental models, the infectious dose is only a few Hemophilus ducreyi organisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/51\">",
"     51",
"    </a>",
"    ]. Transmission occurs in approximately 70 percent of sexual exposures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/28/10696?source=see_link\">",
"     \"Chancroid\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Epidemiologic data suggest a protective effect of condoms, but the lack of microbiologic confirmation in the few studies that have been performed has prevented firm conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treponema pallidum does not invade intact skin; however, only a few organisms are required to infect a person through abraded skin. The primary chancre is often painless, but teeming with spirochetes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/9/37017?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of early syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study of women considered to be at high risk for STIs, the consistent and correct use of male condoms or female condoms was associated with a statistically significant reduction in the combined incidence of gonorrhoeae, chlamydia, and syphilis when compared to women who used condoms less than 50 percent of the time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subsequent meta-analysis of condom use and risk of STIs determined that only two studies were rigorously designed as longitudinal assessments of incident syphilis; one study suggested a significantly reduced risk of syphilis among condom users [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pelvic inflammatory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study of 684 women diagnosed with pelvic inflammatory disease (PID), consistent use of condoms led to lower rates of recurrent PID, chronic pelvic pain, and infertility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Condom regulations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Condoms are regulated as medical devices. Each latex condom manufactured in the United States is tested electronically for holes before packaging. Failure of condoms usually results from inconsistent or incorrect use rather than condom breakage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Patient education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be advised that condoms must be used consistently and correctly to be effective in preventing STIs. Advice should be given regarding proper use of condoms and water-based lubricants; oil-based lubricants (petroleum jelly,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13316?source=see_link\">",
"     mineral oil",
"    </a>",
"    ) can weaken latex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women also need to be counseled that contraceptive methods that are not mechanical barriers offer no protection against HIV or other STIs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Spermicide use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Condoms lubricated with spermicides are no more effective than other lubricated condoms in protecting against the transmission of HIV and other STIs. Studies of spermicides containing nonoxynol-9 (N-9) have produced conflicting results on the ability to prevent STIs other than HIV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. However, two randomized controlled trials reported an increased risk of HIV acquisition with the use of N-9, possibly due to disruption of the genital epithelium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3300133\">",
"    <span class=\"h2\">",
"     Other physical barrier methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Male condoms were superior in the prevention of new STIs compared with other barrier methods in four randomized controlled trials; one study in Kenya and another in Thailand reported very low uptake of the female condom [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3280947\">",
"    <span class=\"h1\">",
"     MALE CIRCUMCISION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous studies suggest a decreased risk of STI acquisition in males who have been circumcised; this is particularly evident for HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/56\">",
"     56",
"    </a>",
"    ]. Three randomized controlled trials in Africa demonstrated that circumcision reduces the likelihood of female-to-male HIV transmission by 50 to 60 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonsurgical methods appear to be safe and effective means of circumcision but have not yet been studied for their effect on HIV or STI prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3280974\">",
"    <span class=\"h2\">",
"     HIV infection in men",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on encouraging observational studies, which demonstrated that male circumcision may provide protection against HIV infection, three randomized controlled trials were conducted in Africa. In these trials, men were randomly assigned to an intervention group, in which immediate circumcision was offered, or a control group, in which circumcision was delayed until the end of the study. In all cases, circumcisions were performed by clinicians experienced in the procedure and were rarely associated with moderate or severe adverse effects. These three trials were all ended early because of evidence of reduced HIV incidence in the intervention groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trial in Orange Farm, South Africa, circumcision reduced the risk of HIV infection by 60 percent among 3274 men aged 18 to 24 years (20 versus 48 new infections in the circumcision and control groups, respectively, after a mean follow-up of 18 months) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/59\">",
"       59",
"      </a>",
"      ]. The investigators controlled for behavioral factors, condom use, and health-seeking behaviors.",
"     </li>",
"     <li>",
"      In a trial in Kisumu, Kenya, circumcision reduced the risk of HIV infection by 53 percent among 2784 men aged 18 to 24 years (22 versus 47 new infections in the circumcision and control groups, respectively, after a median follow-up of 24 months) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a trial in Rakai, Uganda, circumcision reduced the risk of HIV infection by 51 percent among 4996 men aged 15 to 49 years (0.66 versus 1.33 new infections per 100 person years in the circumcision and control groups, respectively, over 24 months) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/61\">",
"       61",
"      </a>",
"      ]. Following trial closure, the majority of uncircumcised men underwent circumcision. After five years, circumcision remained associated with a lower HIV risk (0.5 versus 1.93 new infections per 100 person years in circumcised and uncircumcised men, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data from the United States are limited. One study examined visit records of heterosexual African-American men who underwent HIV testing while attending STI clinics in Baltimore from 1993 to 2000 and analyzed the association between circumcision and the risk of HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/63\">",
"     63",
"    </a>",
"    ]. \"Known\" HIV risk was defined as patient notification by either their sexual partner or by an intervention specialist from the partner notification system of recent HIV exposure. Among 394 visits by patients with known exposure, circumcision was significantly associated with lower HIV prevalence (10.2 percent versus 22 percent; adjusted prevalence rate ratio, 0.49 [95% CI 0.26-0.93]).",
"   </p>",
"   <p>",
"    These results demonstrate that male circumcision reduces the risk of heterosexual men becoming infected with HIV. The biologic basis for this observation may be related to a high density of HIV target cells in foreskin, including Langerhans cells and macrophages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/64\">",
"     64",
"    </a>",
"    ]. The potential beneficial effect of male circumcision in MSM has not been studied in countries where the predominant mode of HIV transmission is through male-to-male sexual contact [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In light of these data, various professional societies in resource-rich countries have re-examined their guideline recommendations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/66\">",
"     66",
"    </a>",
"    ]. The WHO has published documents on operational guidance and several countries have integrated this strategy into HIV prevention programs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Any policy to promote circumcision to protect against HIV infection needs to take into account cultural and human rights considerations, the risk of complications from the procedure performed in various settings, the prevalence of infection, and the potential to undermine existing protective behaviors and prevention strategies that reduce the risk of HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/60,68\">",
"     60,68",
"    </a>",
"    ]. Results from observational studies of men who underwent circumcision suggest that this prevention intervention is not necessarily offset by an adverse behavioral impact [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. One study compared sexual behaviors of 324 recently circumcised and 324 uncircumcised Kenyan men at 1, 3, 6, 9, and 12 months after study enrollment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/69\">",
"     69",
"    </a>",
"    ]. Circumcised men did not engage in more risky behaviors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3280981\">",
"    <span class=\"h2\">",
"     HIV infection in women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although male circumcision reduces HIV acquisition in men, a similar effect on HIV acquisition in women has not been demonstrated.",
"   </p>",
"   <p>",
"    In Uganda, 922 HIV-seropositive men (aged 15 to 49 years) with CD4 cell counts &ge;350 cells were randomly assigned to immediate (n = 474) versus delayed circumcision for 24 months (control arm; n = 448) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/71\">",
"     71",
"    </a>",
"    ]. HIV-seronegative female partners of the men were concurrently enrolled and followed for onset of HIV acquisition at 6, 12, and 24 months by male treatment assignment.",
"   </p>",
"   <p>",
"    Circumcision did not reduce HIV transmission to female partners; over a 24-month period, the cumulative probability of female acquisition of HIV was 22 percent in the intervention group and 13 percent in the control group (adjusted HR 1.49; 0.52-3.57). In addition, excess HIV transmission occurred within the first six months in the male circumcision arm, particularly among those who resumed intercourse prior to wound healing. These findings suggest sexual abstinence or condom use should be strongly advised until surgical recovery (estimated at six weeks).",
"   </p>",
"   <p>",
"    The Ugandan male circumcision study also evaluated the effect of male circumcision on STIs in female partners of circumcised men and those randomized to no intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/72\">",
"     72",
"    </a>",
"    ]. At one year, female partners assigned to the circumcision intervention group reported lower rates of genital ulcers and reduced risk of trichomonas and bacterial vaginosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3280988\">",
"    <span class=\"h2\">",
"     HIV infection in MSM",
"    </span>",
"    &nbsp;&mdash;&nbsp;To date, no randomized controlled studies of male circumcision have been conducted among men who have sex with men.",
"   </p>",
"   <p>",
"    A meta-analysis was performed of 15 observational studies among 53,567 MSM (52 percent of whom were circumcised) to determine the strength of the association between circumcision and the risk of HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/73\">",
"     73",
"    </a>",
"    ]. The odds of being HIV-seropositive were 14 percent lower among circumcised versus uncircumcised MSM, but the difference was not statistically significant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3280995\">",
"    <span class=\"h2\">",
"     Other sexually transmitted infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of male circumcision on acquisition of other STIs, such as herpes simplex virus, human papillomavirus, and syphilis, has also been examined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/61,71,74,75\">",
"     61,71,74,75",
"    </a>",
"    ]. Results suggest that male circumcision is associated with a reduced risk of viral STIs including HSV-2 and HPV, but not of gonorrhea or chlamydia. This variation may result from the site of infection since gonorrhea and chlamydia infect the urethra, while viral infections tend to involve the foreskin where dendritic cells play a prominent role.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3281002\">",
"    <span class=\"h3\">",
"     Herpes simplex virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Male circumcision may decrease the risk of transmission of HSV as illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In an analysis of two Ugandan trials of circumcision for the prevention of HIV, among the 3393 men who were both HIV and HSV-2 seronegative at baseline, immediate compared with delayed circumcision was associated with a lower risk of HSV-2 seroconversion after 24 months (7.8 versus 10.3 percent probability of seroconversion, respectively; adjusted HR 0.72; 95% CI 0.56-0.92) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In a trial of 2787 HIV-infected men in Uganda who were randomly assigned to immediate versus delayed circumcision, HSV-2 acquisition after two years was lower in the immediate circumcision arm (7.6 versus 10.1 percent, RR 0.75) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/76\">",
"       76",
"      </a>",
"      ]. The female partners of the men in the immediate intervention arm also had significantly lower rates of symptomatic GUD, trichomonas and bacterial vaginosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In a study of 3274 males who had been recruited for a circumcision trial, the presence of HSV-2 infection in either partner increased the risk of female-to-male transmission of HIV infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/74\">",
"       74",
"      </a>",
"      ]. Conversely, HIV in either partner increased the risk of female-to-male transmission of HSV-2. However, male circumcision was associated with a decreased probability of either event (RR of 0.24, 95% CI 0.11-0.44; and RR of 0.59, 95% CI 0.36-0.91, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, in a trial of 2784 men in Kenya, although circumcision reduced the incidence of genital ulcer disease overall, it did not reduce the incidence of HSV-2 infection specifically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/77\">",
"     77",
"    </a>",
"    ]. The reasons for these discrepant results are unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3281009\">",
"    <span class=\"h3\">",
"     Syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review and meta-analysis of 26 articles related to genital ulcer disease found that circumcised men are at lower risk of syphilis and chancroid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/78\">",
"     78",
"    </a>",
"    ]. However, the large prospective trial of male circumcision in Uganda noted above did not demonstrate any difference between the intervention and control arms on the incidence of syphilis, possibly due to low rates of syphilis among the study population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/75\">",
"     75",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3281002\">",
"     'Herpes simplex virus'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3281016\">",
"    <span class=\"h3\">",
"     Gonorrhea, chlamydia, and trichomonas",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of male circumcision on incident nonulcerative STIs was also examined among 2655 Kenyan males participating in the HIV prevention trial noted above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/60\">",
"     60",
"    </a>",
"    ]. Circumcision did not reduce risk of gonorrhea, chlamydia, and trichomonas during two years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3281023\">",
"    <span class=\"h3\">",
"     Human papillomavirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two randomized controlled trials in both HIV-seronegative and HIV-seropositive men have demonstrated that male circumcision reduces acquisition and increases clearance of high-risk HPV types among men who were circumcised compared with no intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. The Rakai circumcision trials for the prevention of HIV infection (discussed above) also demonstrated effectiveness in preventing HPV transmission to female sex partners [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/82\">",
"     82",
"    </a>",
"    ]. At 24 months of follow-up, the incidence of high risk HPV infection in the 1,032 female partners who were enrolled in the circumcision trials was lower in the intervention group than in the control group (21 infections versus 27 infections per 100 person-years; incidence rate ratio = 0.77, 0.63-0.93). Despite these findings, these studies did not address whether circumcision prevents HPV acquisition or decreases the duration of HPV infection or shedding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/66,75\">",
"     66,75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3280414\">",
"    <span class=\"h1\">",
"     ANTIMICROBIAL-BASED PREVENTION STRATEGIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3280534\">",
"    <span class=\"h2\">",
"     Post-exposure prophylaxis for victims of sexual assault",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some controversy regarding empiric prophylactic postexposure treatment for sexually transmitted infections. However, the CDC and others recommend empiric antibiotic prophylaxis since many assault victims will not return for a follow-up visit, and treatment based upon culture results is therefore problematic. In addition, patients often prefer immediate treatment.",
"   </p>",
"   <p>",
"    Empiric therapy for gonorrhea and chlamydia includes",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    250 mg IM and either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    1 gram PO (single dose) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    100 mg PO twice daily for seven days.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     Metronidazole",
"    </a>",
"    2 grams PO (single dose) is also recommended to treat trichomoniasis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/7/20601?source=see_link\">",
"     \"Evaluation and management of adult sexual assault victims\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/30/1509?source=see_link\">",
"     \"Patient information: Care after sexual assault (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3281470\">",
"    <span class=\"h2\">",
"     Antiretroviral prophylaxis against HIV",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3280541\">",
"    <span class=\"h3\">",
"     Post-exposure prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although data are limited, observational studies have suggested a possible benefit of antiretroviral prophylaxis in reducing the risk of HIV infection following sexual or other nonoccupational exposure to HIV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/83-88\">",
"     83-88",
"    </a>",
"    ]. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/50/26410?source=see_link\">",
"     \"Nonoccupational exposure to HIV in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3280548\">",
"    <span class=\"h3\">",
"     Pre-exposure prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For HIV-uninfected patients who are at high risk for sexually-acquired HIV and are committed to medication adherence and close follow-up, pre-exposure antiretroviral prophylaxis may be an effective strategy for prevention of HIV infection. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34041?source=see_link\">",
"     \"Pre-exposure prophylaxis against HIV infection\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Suppressive therapy for HSV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suppressive therapy for HSV has been evaluated for both prevention of HSV and HIV acquisition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Prevention of HSV transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suppressive therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    (500 mg once daily) for genital HSV was demonstrated to decrease the risk of transmission to the uninfected sex partner. Asymptomatic shedding of HSV was also documented in the source patient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/32/7690?source=see_link\">",
"     \"Treatment of genital herpes simplex virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Prevention of HIV transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic and biologic studies have suggested that HSV-2 facilitates transmission and acquisition of HIV-1. For example, in a male circumcision trial conducted in South Africa, subjects who were HSV-2 seropositive at enrollment had a significant risk of HIV acquisition compared to those who remained HSV-2 seronegative throughout the study (incidence rate ratio 3.3; 95% CI 1.5-7.4) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HSV suppression with antiviral therapy is associated with decreased HIV RNA in plasma and in genital secretions, in some but not all studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/90-92\">",
"     90-92",
"    </a>",
"    ]. Three large trials have evaluated whether HSV-2 suppression with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    maintenance therapy (400 mg twice daily) may reduce HIV acquisition:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one large placebo-controlled trial, study participants (n = 3251) included MSM from the United States and Peru and heterosexual women from Africa who were HIV-seronegative and HSV-2-seropositive on study entry [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/93\">",
"       93",
"      </a>",
"      ]. Despite good adherence and decreased rates of genital ulcer disease,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      did not prevent HIV acquisition.",
"     </li>",
"     <li>",
"      Similar results were obtained in a study of 3408 discordant couples enrolled from 14 sites in Africa; daily",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      did not reduce the risk of HIV transmission, despite a reduction in plasma HIV RNA of 0.25 log(10)",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      and a 73 percent reduction in the occurrence of genital ulcers due to HSV-2 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/94\">",
"       94",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a smaller but similarly designed study in Tanzania, 821 female study participants were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      versus placebo with a mean follow-up of approximately 18 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/95\">",
"       95",
"      </a>",
"      ]. The incidence of HIV infection was similar in both arms (27 participants in the acyclovir arm; 28 in the placebo arm).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite a sound rationale for these interventions, and a consistent reduction of HIV RNA by 0.25 to 0.5 log(10)",
"    <span class=\"nowrap\">",
"     copies/mL,",
"    </span>",
"    these trials have yielded disappointing results. Reductions of HIV RNA were originally thought to be indirectly related to HSV-2 suppression; however, subsequent in vitro studies have shown that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    may directly inhibit HIV replication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/96\">",
"     96",
"    </a>",
"    ]. However, the lack of efficacy of acyclovir in reducing HIV transmission suggests that a greater reduction in HIV RNA levels is needed to reduce the risk of transmission to the seronegative sex partner. These data have significant implications for the development of HIV vaccines directed at reducing HIV viral load setpoints [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Topical microbicides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical microbicides have been proposed as STI preventive agents by providing chemical, biological, and physical barriers to infection at the mucosal surface (eg, vagina or rectum) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/97\">",
"     97",
"    </a>",
"    ]. Classes of microbicides include surfactants, membrane disruptors, vaginal milieu protectors, viral entry inhibitors, and reverse transcriptase inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/98\">",
"     98",
"    </a>",
"    ]. Delivery systems include gel formulations and vaginal rings, which are engineered for sustained drug release [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Clinical trials of microbicides",
"    </span>",
"    &nbsp;&mdash;&nbsp;For approximately two decades, clinical trials of several candidate microbicide agents failed to demonstrate effectiveness in the prevention of HIV transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/100-102\">",
"     100-102",
"    </a>",
"    ]. One of the largest studies was of PRO2000 vaginal gel, which had been shown to be efficacious in macaques; however, a clinical trial among 5747 sexually active women in Africa did not show a decreased incidence of HIV infection among those who were randomly assigned to the intervention compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in 2010, a double-blind, randomized controlled trial (CAPRISA 004) demonstrated significant effectiveness of a 1 percent vaginal gel formulation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , a nucleotide reverse transcriptase inhibitor (NRTI), for the prevention of HIV acquisition in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/104\">",
"     104",
"    </a>",
"    ]. Women assigned to use the tenofovir gel within 12 hours before and after sex had a 39 percent reduction in the risk of HIV acquisition (5.6 versus 9.1 infections per 1000 person years in women assigned to placebo). Further data on the use of tenofovir vaginal gel for chemoprophylaxis against HIV infection in women are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34041?source=see_link&amp;anchor=H5844460#H5844460\">",
"     \"Pre-exposure prophylaxis against HIV infection\", section on 'Vaginal chemoprophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical trials of microbicides for the prevention of other STIs, including gonorrhea, chlamydia, and syphilis, have not demonstrated substantial efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Effect of seminal plasma on efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of a few microbicidal agents in vitro and in a murine model of herpes simplex virus (HSV) infection suggest that efficacy may also be compromised by exogenous factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/106\">",
"     106",
"    </a>",
"    ]. In vitro, seminal plasma competitively inhibited binding of these microbicides to the HSV-2 envelope protein; this observation translated into a loss of protection in the mouse model. These data suggest that seminal plasma may compromise the antiviral effects of microbicides on HSV transmission, and by extension, to HIV transmission as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The healthy human vagina has an acidic environment, with a pH ranging from 3.5 to 4.5, due to lactic acid and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    production by lactobacilli. When semen enters the vagina, the pH increases to approximately 7.0 because of the buffering activity of ejaculate. Thus women are exposed to various sexually transmitted pathogens under optimal conditions for transmission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Other concerns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corrosive effects on rectal mucosa have also been demonstrated after application of hyperosmolar sexual lubricants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/108\">",
"     108",
"    </a>",
"    ]. Whether use of such lubricants leads to increased acquisition of HIV is unknown, although plausible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Barrier methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;An open label, randomized controlled trial of a combined intervention with latex diaphragm, lubricant gel and condoms compared with condoms alone among women in South Africa and Zimbabwe found that diaphragm and lubricant provided no additive effect in preventing HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/109\">",
"     109",
"    </a>",
"    ]. In the same trial, reported condom use was statistically lower in the intervention arm compared with the condom only arm (54 versus 85 percent of visits, p &lt;0.0001). The intervention arm also did not have any significant effect on incident chlamydia or gonorrhea infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     COUNSELING AND OTHER PREVENTION MODALITIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4100632\">",
"    <span class=\"h2\">",
"     Behavioral interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have examined the effect of counseling on STI risk reduction. One meta-analysis of a variety of behavioral interventions suggested a modest reduction in bacterial STIs at 12 months among high-risk adults receiving moderate to high-intensity counseling programs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/111\">",
"     111",
"    </a>",
"    ]. Low-intensity programs may include simple interventions such as the distribution of educational brochures. High-intensity interventions are characterized by multiple sessions, with a cumulative duration of three to nine hours, and are most often offered among groups. Five of six trials reviewed by the United States Preventive Services Task Force (USPSTF) demonstrated significant reductions in confirmed STIs at 6 and 12 months after intensive interventions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The USPSTF recommends high-intensity behavioral counseling to prevent STIs for all sexually active adolescents and for adults at increased risk for STIs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/112\">",
"     112",
"    </a>",
"    ]. The task force concluded that the evidence was insufficient to assess the potential impact of behavioral counseling in non-sexually active persons. There are also no studies available in pregnant women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If high-intensity behavioral counseling interventions are not available in the surrounding health sector or community, physicians should continue one-on-one education. For example, one study demonstrated a reduction in STIs after only two 20-minute counseling sessions before and after HIV testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/113\">",
"     113",
"    </a>",
"    ]. Patients should be counseled regarding high-risk sexual practices, particularly anal intercourse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/114\">",
"     114",
"    </a>",
"    ]. They should also be educated about the risks of using alcohol and illicit drugs, which can lead to disinhibition and risky behaviors. Patients with multiple sex partners should be counseled regarding associated risks of STIs, particularly HIV infection.",
"   </p>",
"   <p>",
"    Syphilis rates have increased among MSM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/115-118\">",
"     115-118",
"    </a>",
"    ] and in association with high-risk sexual behavior and HIV coinfection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/117,119-122\">",
"     117,119-122",
"    </a>",
"    ]. Increases in syphilis in the United States and Europe have been associated with meeting new and anonymous sex partners on the Internet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/123-125\">",
"     123-125",
"    </a>",
"    ]. In response to this trend, some public health initiatives have created website-based prevention interventions and online syphilis testing recruitment programs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/126,127\">",
"     126,127",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/49/3865?source=see_link\">",
"     \"Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Counseling should also encourage abstinence from sexual intercourse until the course of antibiotics for the specific STI has been completed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3280245\">",
"    <span class=\"h2\">",
"     Strategies to improve sexual health",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some experts have argued that sexual health interventions in the United States are currently fragmented, leading to poor health outcomes (eg, STIs, teen pregnancy), decreased productivity among young adults, and overall higher health care costs. Some experts have suggested that a unified sexual health strategy should be developed to help decrease stigma, improve the delivery of care, enhance sex education, and ensure access to contraceptives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9473717\">",
"    <span class=\"h2\">",
"     Anti-poverty measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poverty has been shown to contribute to a woman&rsquo;s risk of HIV infection and other STIs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/129\">",
"     129",
"    </a>",
"    ]. A cluster-randomized trial in young women in Malawi suggests that anti-poverty measures and economic development can be important tools in STI prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/130,131\">",
"     130,131",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h1\">",
"     PARTNER NOTIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Through partner notification, the provider or public health officials learn from the patient about their sex partner or partners and help to arrange for evaluation and treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/9\">",
"     9",
"    </a>",
"    ]. The intensity of this effort varies among agencies and geographic areas. From a public health standpoint, partner notification can potentially decrease the spread of STIs and lower the risk of reinfection of the index patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Chlamydia and gonorrhoeae",
"    </span>",
"    &nbsp;&mdash;&nbsp;When medical evaluation cannot be arranged for particular circumstances, another option is patient-delivered partner therapy (PDPT), in which partners of the patient are treated without medical evaluation or prevention counseling. Two randomized controlled trials of PDPT reported a 25 to 62 percent reduction in gonorrhea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chlamydia reinfection of the index patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/132,133\">",
"     132,133",
"    </a>",
"    ]; however, other studies have produced variable results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/46/42728?source=see_link\">",
"     \"Genital Chlamydia trachomatis infections in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/18/18728?source=see_link\">",
"     \"Genital Chlamydia trachomatis infections in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/3/19514?source=see_link\">",
"     \"Treatment of uncomplicated gonococcal infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual transmission of syphilis only occurs when mucocutaneous syphilitic lesions are present. However, persons exposed sexually to a patient who has syphilis in any stage should be evaluated clinically and serologically. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/9/37017?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of early syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Centers for Disease Control and Prevention recommends that public health surveillance programs be actively linked to partner services for all persons who test positive for HIV and early syphilis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/52/23362?source=see_link\">",
"       \"Patient information: Chlamydia and gonorrhea (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/25/21906?source=see_link\">",
"       \"Patient information: Genital herpes (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/14/24802?source=see_link\">",
"       \"Patient information: Chlamydia (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/3/36916?source=see_link\">",
"       \"Patient information: Genital herpes (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the following recommendations of the United States Centers for Disease Control and Prevention as proposed in the 2010 sexually transmitted infection (STI) treatment guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/12/35018/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinicians need to assess sexual risk for all patients during routine clinical visits, particularly in adolescents and men who have sex with men (MSM). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk groups'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients being evaluated for STIs should be offered counseling and testing for HIV. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend hepatitis B immunization in susceptible MSM, persons with a history of multiple sex partners, HIV-infected patients, and persons with risk factors for an STI (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Vaccines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend hepatitis A immunization in seronegative MSM and in HIV-infected patients with chronic liver disease or risk factors for hepatitis A, including injection drug use (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Vaccines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend human papillomavirus (HPV) immunization to decrease the risk of cervical infection and cytologic abnormalities (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Immunization should be offered to girls, women, boys, and men 9 to 26 years of age, as recommended by the Advisory Committee on Immunization Practices. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Vaccines'",
"      </a>",
"      above.) The use of the vaccine is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/17/19738?source=see_link\">",
"       \"Recommendations for the use of human papillomavirus vaccines\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      STI prevention efforts should include the use of barrier methods, including male and female condoms. Use of male condoms has been associated with a decreased risk of transmission of HIV, chlamydia, gonorrhoea, herpes simplex virus, and HPV. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Condom use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Male circumcision can reduce HIV transmission, as illustrated by several trials from Africa. It has also been associated with a decreased risk of infection with herpes simplex virus and HPV. (See",
"      <a class=\"local\" href=\"#H3280947\">",
"       'Male circumcision'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Post-exposure prophylaxis and pre-exposure prophylaxis with antiretroviral agents are possible options for the prevention of HIV infection in high-risk individuals. These are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/50/26410?source=see_link\">",
"       \"Nonoccupational exposure to HIV in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34041?source=see_link\">",
"       \"Pre-exposure prophylaxis against HIV infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend suppressive therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      (500 mg daily) in patients with genital HSV who are in a monogamous discordant relationship (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Suppressive therapy for HSV'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/1\">",
"      Westr&ouml;m L. Incidence, prevalence, and trends of acute pelvic inflammatory disease and its consequences in industrialized countries. Am J Obstet Gynecol 1980; 138:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/2\">",
"      Goldenberg RL, Andrews WW, Yuan AC, et al. Sexually transmitted diseases and adverse outcomes of pregnancy. Clin Perinatol 1997; 24:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/3\">",
"      Galvin SR, Cohen MS. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol 2004; 2:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/4\">",
"      Wasserheit JN. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis 1992; 19:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/5\">",
"      R&oslash;ttingen JA, Cameron DW, Garnett GP. A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known? Sex Transm Dis 2001; 28:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/6\">",
"      Centers for Disease Control and Prevention (CDC). Recommendations for partner services programs for HIV infection, syphilis, gonorrhea, and chlamydial infection. MMWR Recomm Rep 2008; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/7\">",
"      Eaton DK, Kann L, Kinchen S, et al. Youth risk behavior surveillance - United States, 2011. MMWR Surveill Summ 2012; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/8\">",
"      Weinstock H, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health 2004; 36:6.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/std/treatment/2010/default.htm (Accessed on January 03, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/10\">",
"      American Academy of Pediatrics. Recommendations for preventive pediatric health care. Pediatrics 2000; 105:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/11\">",
"      Brown EL, Wald A, Hughes JP, et al. High risk of human immunodeficiency virus in men who have sex with men with herpes simplex virus type 2 in the EXPLORE study. Am J Epidemiol 2006; 164:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/12\">",
"      Lama JR, Lucchetti A, Suarez L, et al. Association of herpes simplex virus type 2 infection and syphilis with human immunodeficiency virus infection among men who have sex with men in Peru. J Infect Dis 2006; 194:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/13\">",
"      Crepaz N, Marks G, Liau A, et al. Prevalence of unprotected anal intercourse among HIV-diagnosed MSM in the United States: a meta-analysis. AIDS 2009; 23:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/14\">",
"      Johnson WD, Diaz RM, Flanders WD, et al. Behavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with men. Cochrane Database Syst Rev 2008; :CD001230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/15\">",
"      Guimar&atilde;es MD, Grinsztejn B, Chin-Hong PV, et al. Behavior surveillance: prevalence and factors associated with high-risk sexual behavior among HIV-infected men in Brazil in the post-HAART era. AIDS Behav 2008; 12:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/16\">",
"      Ng BE, Butler LM, Horvath T, Rutherford GW. Population-based biomedical sexually transmitted infection control interventions for reducing HIV infection. Cochrane Database Syst Rev 2011; :CD001220.",
"     </a>",
"    </li>",
"    <li>",
"     United States Department of Health and Human Services, Health Resources and Services Administration. Guide for HIV/AIDS Clinical Care, January 2011. file://hab.hrsa.gov/deliverhivaidscare/clinicalguide11/ (Accessed on October 16, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/18\">",
"      Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/19\">",
"      Trepka MJ, Weisbord JS, Zhang G, Brewer T. Hepatitis B virus infection risk factors and immunity among sexually transmitted disease clinic clients. Sex Transm Dis 2003; 30:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/20\">",
"      Poovorawan Y, Chongsrisawat V, Theamboonlers A, et al. Long-term benefit of hepatitis B vaccination among children in Thailand with transient hepatitis B virus infection who were born to hepatitis B surface antigen-positive mothers. J Infect Dis 2009; 200:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/21\">",
"      Liang X, Bi S, Yang W, et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China. J Infect Dis 2009; 200:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/22\">",
"      Chang MH, You SL, Chen CJ, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009; 101:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/23\">",
"      Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/24\">",
"      Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/25\">",
"      Johnston MI, Fauci AS. An HIV vaccine--evolving concepts. N Engl J Med 2007; 356:2073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/26\">",
"      Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/27\">",
"      Paintsil E, He H, Peters C, et al. Survival of hepatitis C virus in syringes: implication for transmission among injection drug users. J Infect Dis 2010; 202:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/28\">",
"      Hook EW 3rd. An ounce of prevention. Ann Intern Med 2005; 143:751.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Guidelines for the management of sexually transmitted infections. Geneva: World Health Organization 2003. www.who.int/reproductive-health/publications/rhr_01_10/0110.pdf (Accessed on November 15, 2011).",
"    </li>",
"    <li>",
"     Workshop summary: scientific evidence on condom effectiveness for sexually transmitted diseases (STD) prevention. National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Service, Herndon, VA 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/31\">",
"      Holmes KK, Levine R, Weaver M. Effectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ 2004; 82:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/32\">",
"      Van de Perre P, Jacobs D, Sprecher-Goldberger S. The latex condom, an efficient barrier against sexual transmission of AIDS-related viruses. AIDS 1987; 1:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/33\">",
"      Davis KR, Weller SC. The effectiveness of condoms in reducing heterosexual transmission of HIV. Fam Plann Perspect 1999; 31:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/34\">",
"      Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002; :CD003255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/35\">",
"      Lubinski C, Aberg J, Bardeguez AD, et al. HIV policy: the path forward--a joint position paper of the HIV Medicine Association of the Infectious Diseases Society of America and the American College of Physicians. Clin Infect Dis 2009; 48:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/36\">",
"      Okware S, Kinsman J, Onyango S, et al. Revisiting the ABC strategy: HIV prevention in Uganda in the era of antiretroviral therapy. Postgrad Med J 2005; 81:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/37\">",
"      Shelton JD. Confessions of a condom lover. Lancet 2006; 368:1947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/38\">",
"      Drew WL, Blair M, Miner RC, Conant M. Evaluation of the virus permeability of a new condom for women. Sex Transm Dis 1990; 17:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/39\">",
"      Isbey SF, Alcorn TM, Davis RH, et al. Characterisation of Neisseria gonorrhoeae in semen during urethral infection in men. Genitourin Med 1997; 73:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/40\">",
"      S&aacute;nchez J, Campos PE, Courtois B, et al. Prevention of sexually transmitted diseases (STDs) in female sex workers: prospective evaluation of condom promotion and strengthened STD services. Sex Transm Dis 2003; 30:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/41\">",
"      Garc&iacute;a PJ, Holmes KK, C&aacute;rcamo CP, et al. Prevention of sexually transmitted infections in urban communities (Peru PREVEN): a multicomponent community-randomised controlled trial. Lancet 2012; 379:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/42\">",
"      Crosby RA, DiClemente RJ, Wingood GM, et al. Value of consistent condom use: a study of sexually transmitted disease prevention among African American adolescent females. Am J Public Health 2003; 93:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/43\">",
"      Ahmed S, Lutalo T, Wawer M, et al. HIV incidence and sexually transmitted disease prevalence associated with condom use: a population study in Rakai, Uganda. AIDS 2001; 15:2171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/44\">",
"      Rosenberg MJ, Davidson AJ, Chen JH, et al. Barrier contraceptives and sexually transmitted diseases in women: a comparison of female-dependent methods and condoms. Am J Public Health 1992; 82:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/45\">",
"      Warner L, Stone KM, Macaluso M, et al. Condom use and risk of gonorrhea and Chlamydia: a systematic review of design and measurement factors assessed in epidemiologic studies. Sex Transm Dis 2006; 33:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/46\">",
"      Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 2006; 354:2645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/47\">",
"      Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis 2002; 29:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/48\">",
"      Hogewoning CJ, Bleeker MC, van den Brule AJ, et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int J Cancer 2003; 107:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/49\">",
"      Bleeker MC, Hogewoning CJ, Voorhorst FJ, et al. Condom use promotes regression of human papillomavirus-associated penile lesions in male sexual partners of women with cervical intraepithelial neoplasia. Int J Cancer 2003; 107:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/50\">",
"      Nielson CM, Harris RB, Nyitray AG, et al. Consistent condom use is associated with lower prevalence of human papillomavirus infection in men. J Infect Dis 2010; 202:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/51\">",
"      Al-Tawfiq JA, Harezlak J, Katz BP, Spinola SM. Cumulative experience with Haemophilus ducreyi 35000 in the human model of experimental infection. Sex Transm Dis 2000; 27:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/52\">",
"      Koss CA, Dunne EF, Warner L. A systematic review of epidemiologic studies assessing condom use and risk of syphilis. Sex Transm Dis 2009; 36:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/53\">",
"      Ness RB, Randall H, Richter HE, et al. Condom use and the risk of recurrent pelvic inflammatory disease, chronic pelvic pain, or infertility following an episode of pelvic inflammatory disease. Am J Public Health 2004; 94:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/54\">",
"      Wilkinson D, Tholandi M, Ramjee G, Rutherford GW. Nonoxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: systematic review and meta-analysis of randomised controlled trials including more than 5000 women. Lancet Infect Dis 2002; 2:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/55\">",
"      Wetmore CM, Manhart LE, Wasserheit JN. Randomized controlled trials of interventions to prevent sexually transmitted infections: learning from the past to plan for the future. Epidemiol Rev 2010; 32:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/56\">",
"      Siegfried N, Muller M, Deeks J, et al. HIV and male circumcision--a systematic review with assessment of the quality of studies. Lancet Infect Dis 2005; 5:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/57\">",
"      Gostin LO, Hankins CA. Male circumcision as an HIV prevention strategy in sub-Saharan Africa: sociolegal barriers. JAMA 2008; 300:2539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/58\">",
"      Mutabazi V, Kaplan SA, Rwamasirabo E, et al. HIV prevention: male circumcision comparison between a nonsurgical device to a surgical technique in resource-limited settings: a prospective, randomized, nonmasked trial. J Acquir Immune Defic Syndr 2012; 61:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/59\">",
"      Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005; 2:e298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/60\">",
"      Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007; 369:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/61\">",
"      Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007; 369:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/62\">",
"      Gray R, Kigozi G, Kong X, et al. The effectiveness of male circumcision for HIV prevention and effects on risk behaviors in a posttrial follow-up study. AIDS 2012; 26:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/63\">",
"      Warner L, Ghanem KG, Newman DR, et al. Male circumcision and risk of HIV infection among heterosexual African American men attending Baltimore sexually transmitted disease clinics. J Infect Dis 2009; 199:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/64\">",
"      Donoval BA, Landay AL, Moses S, et al. HIV-1 target cells in foreskins of African men with varying histories of sexually transmitted infections. Am J Clin Pathol 2006; 125:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/65\">",
"      Schillinger JA, McKinney CM, Garg R, et al. Seroprevalence of herpes simplex virus type 2 and characteristics associated with undiagnosed infection: New York City, 2004. Sex Transm Dis 2008; 35:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/66\">",
"      Golden MR, Wasserheit JN. Prevention of viral sexually transmitted infections--foreskin at the forefront. N Engl J Med 2009; 360:1349.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Operational guidance for scaling up male circumcision services for HIV prevention, updated January 16, 2009. file://www.who.int/hiv/pub/malecircumcision/op_guidance/en/index.html (Accessed on January 16, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/68\">",
"      Sawires SR, Dworkin SL, Fiamma A, et al. Male circumcision and HIV/AIDS: challenges and opportunities. Lancet 2007; 369:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/69\">",
"      Agot KE, Kiarie JN, Nguyen HQ, et al. Male circumcision in Siaya and Bondo Districts, Kenya: prospective cohort study to assess behavioral disinhibition following circumcision. J Acquir Immune Defic Syndr 2007; 44:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/70\">",
"      Kong X, Kigozi G, Nalugoda F, et al. Assessment of changes in risk behaviors during 3 years of posttrial follow-up of male circumcision trial participants uncircumcised at trial closure in Rakai, Uganda. Am J Epidemiol 2012; 176:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/71\">",
"      Wawer MJ, Makumbi F, Kigozi G, et al. Circumcision in HIV-infected men and its effect on HIV transmission to female partners in Rakai, Uganda: a randomised controlled trial. Lancet 2009; 374:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/72\">",
"      Gray RH, Kigozi G, Serwadda D, et al. The effects of male circumcision on female partners' genital tract symptoms and vaginal infections in a randomized trial in Rakai, Uganda. Am J Obstet Gynecol 2009; 200:42.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/73\">",
"      Millett GA, Flores SA, Marks G, et al. Circumcision status and risk of HIV and sexually transmitted infections among men who have sex with men: a meta-analysis. JAMA 2008; 300:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/74\">",
"      Mahiane SG, Legeai C, Taljaard D, et al. Transmission probabilities of HIV and herpes simplex virus type 2, effect of male circumcision and interaction: a longitudinal study in a township of South Africa. AIDS 2009; 23:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/75\">",
"      Tobian AA, Serwadda D, Quinn TC, et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med 2009; 360:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/76\">",
"      Tobian AA, Charvat B, Ssempijja V, et al. Factors associated with the prevalence and incidence of herpes simplex virus type 2 infection among men in Rakai, Uganda. J Infect Dis 2009; 199:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/77\">",
"      Mehta SD, Moses S, Parker CB, et al. Circumcision status and incident herpes simplex virus type 2 infection, genital ulcer disease, and HIV infection. AIDS 2012; 26:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/78\">",
"      Weiss HA, Thomas SL, Munabi SK, Hayes RJ. Male circumcision and risk of syphilis, chancroid, and genital herpes: a systematic review and meta-analysis. Sex Transm Infect 2006; 82:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/79\">",
"      Mehta SD, Moses S, Agot K, et al. Adult male circumcision does not reduce the risk of incident Neisseria gonorrhoeae, Chlamydia trachomatis, or Trichomonas vaginalis infection: results from a randomized, controlled trial in Kenya. J Infect Dis 2009; 200:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/80\">",
"      Gray RH, Serwadda D, Kong X, et al. Male circumcision decreases acquisition and increases clearance of high-risk human papillomavirus in HIV-negative men: a randomized trial in Rakai, Uganda. J Infect Dis 2010; 201:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/81\">",
"      Serwadda D, Wawer MJ, Makumbi F, et al. Circumcision of HIV-infected men: effects on high-risk human papillomavirus infections in a randomized trial in Rakai, Uganda. J Infect Dis 2010; 201:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/82\">",
"      Wawer MJ, Tobian AA, Kigozi G, et al. Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomised trial in Rakai, Uganda. Lancet 2011; 377:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/83\">",
"      Schechter M, do Lago RF, Mendelsohn AB, et al. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr 2004; 35:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/84\">",
"      Kahn JO, Martin JN, Roland ME, et al. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study. J Infect Dis 2001; 183:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/85\">",
"      Heuker J, Sonder GJ, Stolte I, et al. High HIV incidence among MSM prescribed postexposure prophylaxis, 2000-2009: indications for ongoing sexual risk behaviour. AIDS 2012; 26:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/86\">",
"      Mayer KH, Mimiaga MJ, Gelman M, Grasso C. Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence. J Acquir Immune Defic Syndr 2012; 59:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/87\">",
"      Sonder GJ, Prins JM, Regez RM, et al. Comparison of two HIV postexposure prophylaxis regimens among men who have sex with men in Amsterdam: adverse effects do not influence compliance. Sex Transm Dis 2010; 37:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/88\">",
"      Diaz-Brito V, Le&oacute;n A, Knobel H, et al. Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine. Antivir Ther 2012; 17:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/89\">",
"      Sobngwi-Tambekou J, Taljaard D, Lissouba P, et al. Effect of HSV-2 serostatus on acquisition of HIV by young men: results of a longitudinal study in Orange Farm, South Africa. J Infect Dis 2009; 199:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/90\">",
"      Delany S, Mlaba N, Clayton T, et al. Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS 2009; 23:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/91\">",
"      Mayaud P, Legoff J, Weiss HA, et al. Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: a randomized placebo-controlled trial. J Infect Dis 2009; 200:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/92\">",
"      Paz-Bailey G, Sternberg M, Puren AJ, et al. Improvement in healing and reduction in HIV shedding with episodic acyclovir therapy as part of syndromic management among men: a randomized, controlled trial. J Infect Dis 2009; 200:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/93\">",
"      Celum C, Wald A, Hughes J, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371:2109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/94\">",
"      Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010; 362:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/95\">",
"      Watson-Jones D, Weiss HA, Rusizoka M, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008; 358:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/96\">",
"      McMahon MA, Siliciano JD, Lai J, et al. The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation. J Biol Chem 2008; 283:31289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/97\">",
"      Pirrone V, Thakkar N, Jacobson JM, et al. Combinatorial approaches to the prevention and treatment of HIV-1 infection. Antimicrob Agents Chemother 2011; 55:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/98\">",
"      Cutler B, Justman J. Vaginal microbicides and the prevention of HIV transmission. Lancet Infect Dis 2008; 8:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/99\">",
"      Saxena BB, Han YA, Fu D, et al. Sustained release of microbicides by newly engineered vaginal rings. AIDS 2009; 23:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/100\">",
"      Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/101\">",
"      Van Damme L, Govinden R, Mirembe FM, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008; 359:463.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.mdp.mrc.ac.uk/archive.html (Accessed on January 11, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/103\">",
"      McCormack S, Ramjee G, Kamali A, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 2010; 376:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/104\">",
"      Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/105\">",
"      Obiero J, Mwethera PG, Wiysonge CS. Topical microbicides for prevention of sexually transmitted infections. Cochrane Database Syst Rev 2012; 6:CD007961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/106\">",
"      Patel S, Hazrati E, Cheshenko N, et al. Seminal plasma reduces the effectiveness of topical polyanionic microbicides. J Infect Dis 2007; 196:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/107\">",
"      Rohan LC, Hillier SL, Dezzutti CS. Preventing the sexual transmission of HIV-1 with topical microbicides: another piece of the equation. J Infect Dis 2007; 196:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/108\">",
"      Fuchs EJ, Lee LA, Torbenson MS, et al. Hyperosmolar sexual lubricant causes epithelial damage in the distal colon: potential implication for HIV transmission. J Infect Dis 2007; 195:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/109\">",
"      Padian NS, van der Straten A, Ramjee G, et al. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet 2007; 370:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/110\">",
"      Ramjee G, van der Straten A, Chipato T, et al. The diaphragm and lubricant gel for prevention of cervical sexually transmitted infections: results of a randomized controlled trial. PLoS One 2008; 3:e3488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/111\">",
"      Lin JS, Whitlock E, O'Connor E, Bauer V. Behavioral counseling to prevent sexually transmitted infections: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 149:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/112\">",
"      U.S. Preventive Services Task Force. Behavioral counseling to prevent sexually transmitted infections: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/113\">",
"      Kamb ML, Fishbein M, Douglas JM Jr, et al. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. Project RESPECT Study Group. JAMA 1998; 280:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/114\">",
"      Dilley JW, Woods WJ, Loeb L, et al. Brief cognitive counseling with HIV testing to reduce sexual risk among men who have sex with men: results from a randomized controlled trial using paraprofessional counselors. J Acquir Immune Defic Syndr 2007; 44:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/115\">",
"      Centers for Disease Control and Prevention (CDC). Primary and secondary syphilis--United States, 2003-2004. MMWR Morb Mortal Wkly Rep 2006; 55:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/116\">",
"      Cronin M, Domegan L, Thornton L, et al. The epidemiology of infectious syphilis in the Republic of Ireland. Euro Surveill 2004; 9:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/117\">",
"      Marcus U, Bremer V, Hamouda O. Syphilis surveillance and trends of the syphilis epidemic in Germany since the mid-90s. Euro Surveill 2004; 9:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/118\">",
"      Middleton MG, Grulich AE, McDonald AM, et al. Could sexually transmissible infections be contributing to the increase in HIV infections among men who have sex with men in Australia? Sex Health 2008; 5:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/119\">",
"      Chesson HW, Heffelfinger JD, Voigt RF, Collins D. Estimates of primary and secondary syphilis rates in persons with HIV in the United States, 2002. Sex Transm Dis 2005; 32:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/120\">",
"      D'Souza G, Lee JH, Paffel JM. Outbreak of syphilis among men who have sex with men in Houston, Texas. Sex Transm Dis 2003; 30:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/121\">",
"      Centers for Disease Control and Prevention (CDC). Outbreak of syphilis among men who have sex with men--Southern California, 2000. MMWR Morb Mortal Wkly Rep 2001; 50:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/122\">",
"      Centers for Disease Control and Prevention (CDC). Primary and secondary syphilis among men who have sex with men--New York City, 2001. MMWR Morb Mortal Wkly Rep 2002; 51:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/123\">",
"      Taylor M, Aynalem G, Smith L, et al. Correlates of Internet use to meet sex partners among men who have sex with men diagnosed with early syphilis in Los Angeles County. Sex Transm Dis 2004; 31:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/124\">",
"      McFarlane M, Bull SS, Rietmeijer CA. The Internet as a newly emerging risk environment for sexually transmitted diseases. JAMA 2000; 284:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/125\">",
"      Elford J, Bolding G, Sherr L. Seeking sex on the Internet and sexual risk behaviour among gay men using London gyms. AIDS 2001; 15:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/126\">",
"      Klausner JD, Levine DK, Kent CK. Internet-based site-specific interventions for syphilis prevention among gay and bisexual men. AIDS Care 2004; 16:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/127\">",
"      McFarlane M, Kachur R, Klausner JD, et al. Internet-based health promotion and disease control in the 8 cities: successes, barriers, and future plans. Sex Transm Dis 2005; 32:S60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/128\">",
"      Swartzendruber A, Zenilman JM. A national strategy to improve sexual health. JAMA 2010; 304:1005.",
"     </a>",
"    </li>",
"    <li>",
"     Michael Harrington. The Other America: Poverty in the United States, Scribner, 1962.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/130\">",
"      Baird SJ, Garfein RS, McIntosh CT, Ozler B. Effect of a cash transfer programme for schooling on prevalence of HIV and herpes simplex type 2 in Malawi: a cluster randomised trial. Lancet 2012; 379:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/131\">",
"      Pettifor A, McCoy SI, Padian N. Paying to prevent HIV infection in young women? Lancet 2012; 379:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/132\">",
"      Golden MR, Whittington WL, Handsfield HH, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med 2005; 352:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/12/35018/abstract/133\">",
"      Kissinger P, Mohammed H, Richardson-Alston G, et al. Patient-delivered partner treatment for male urethritis: a randomized, controlled trial. Clin Infect Dis 2005; 41:623.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7595 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-62FEFCC119-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_12_35018=[""].join("\n");
var outline_f34_12_35018=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H51\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk groups",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Adolescents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3283061\">",
"      - Men who have sex with men",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3280264\">",
"      - HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      VACCINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hepatitis A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hepatitis B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Human papillomavirus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Human immunodeficiency virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3300097\">",
"      Hepatitis C",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CONDOM USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Human immunodeficiency virus (HIV)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Transmission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Effectiveness of condoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Gonorrhea, chlamydia, and trichomonas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Genital herpes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Human papillomavirus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Chancroid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Condom regulations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Patient education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Spermicide use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3300133\">",
"      Other physical barrier methods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3280947\">",
"      MALE CIRCUMCISION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3280974\">",
"      HIV infection in men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3280981\">",
"      HIV infection in women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3280988\">",
"      HIV infection in MSM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3280995\">",
"      Other sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3281002\">",
"      - Herpes simplex virus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3281009\">",
"      - Syphilis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3281016\">",
"      - Gonorrhea, chlamydia, and trichomonas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3281023\">",
"      - Human papillomavirus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3280414\">",
"      ANTIMICROBIAL-BASED PREVENTION STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3280534\">",
"      Post-exposure prophylaxis for victims of sexual assault",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3281470\">",
"      Antiretroviral prophylaxis against HIV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3280541\">",
"      - Post-exposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3280548\">",
"      - Pre-exposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Suppressive therapy for HSV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Prevention of HSV transmission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Prevention of HIV transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Topical microbicides",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Clinical trials of microbicides",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Effect of seminal plasma on efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Other concerns",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Barrier methods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      COUNSELING AND OTHER PREVENTION MODALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4100632\">",
"      Behavioral interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3280245\">",
"      Strategies to improve sexual health",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9473717\">",
"      Anti-poverty measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      PARTNER NOTIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Chlamydia and gonorrhoeae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/28/10696?source=related_link\">",
"      Chancroid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/10/13480?source=related_link\">",
"      Clinical trials of human papillomavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/35/26166?source=related_link\">",
"      Diagnosis of gonococcal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/55/20345?source=related_link\">",
"      Diagnostic assays for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/6/21610?source=related_link\">",
"      Epidemiology of human papillomavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/10/9386?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/49/3865?source=related_link\">",
"      Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/7/20601?source=related_link\">",
"      Evaluation and management of adult sexual assault victims",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/18/18728?source=related_link\">",
"      Genital Chlamydia trachomatis infections in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/46/42728?source=related_link\">",
"      Genital Chlamydia trachomatis infections in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/38/1641?source=related_link\">",
"      Hepatitis A virus vaccination and postexposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37273?source=related_link\">",
"      Immunizations in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/34/5674?source=related_link\">",
"      Immunology of HIV-1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/1/42010?source=related_link\">",
"      Initial prenatal assessment and patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/50/26410?source=related_link\">",
"      Nonoccupational exposure to HIV in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/9/37017?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of early syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/30/1509?source=related_link\">",
"      Patient information: Care after sexual assault (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/14/24802?source=related_link\">",
"      Patient information: Chlamydia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/52/23362?source=related_link\">",
"      Patient information: Chlamydia and gonorrhea (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/3/36916?source=related_link\">",
"      Patient information: Genital herpes (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/25/21906?source=related_link\">",
"      Patient information: Genital herpes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34041?source=related_link\">",
"      Pre-exposure prophylaxis against HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/17/19738?source=related_link\">",
"      Recommendations for the use of human papillomavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/30/490?source=related_link\">",
"      Screening for sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/32/7690?source=related_link\">",
"      Treatment of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16185?source=related_link\">",
"      Treatment of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/3/19514?source=related_link\">",
"      Treatment of uncomplicated gonococcal infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_12_35019="FDA advisory on vacuum";
var content_f34_12_35019=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Food and Drug Administration advisory for caution when using vacuum assisted delivery devices",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. Be sure that persons who use vacuum devices for assisted delivery are versed in their use, and that they are aware of the indications, contraindications and precautions as supported in the accepted literature and current device labeling. See the list of sample references and resources that accompany this advisory.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Before using a vacuum assisted delivery device, read and understand the device's instructions. Pay particular attention to the manufacturer's instructions regarding cup placement, vacuum strength to be used, cumulative duration of applications and number of recommended extraction attempts. The recommended use for all these products is to apply steady traction in the line of the birth canal. Rocking movements or applying torque to the device may be dangerous. Since the instructions may be different for each device type or style, it is important to use the instructions provided by the manufacturer of the particular product being used.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Alert those who will be responsible for the infant's care that a vacuum assisted delivery device has been used, so that they can monitor the infant for signs of complications.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Educate the neonatal care staff about the complications of vacuum assisted delivery devices that have been reported to the FDA and in the literature (see references). They should watch for the signs of these complications in any infant in whom a vacuum assisted delivery device was used.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Report reactions associated with the use of vacuum assisted delivery devices to the FDA.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     United States Food and Drug Adminsitration, May 21, 1998. file://www.fda.gov/cdrh/fetal598.html.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_12_35019=[""].join("\n");
var outline_f34_12_35019=null;
var title_f34_12_35020="Methods to improve compliance";
var content_f34_12_35020=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F77847&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F77847&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    General guidelines to improve patient adherence to antihypertensive therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Be aware of the problem and be alert to signs of patient nonadherance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Establish the goal of therapy: to reduce blood pressure to near normotensive levels with minimal or no side effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Educate the patient about the disease and its treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Involve the patient in decision making",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Encourage family support",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Maintain contact with the patient",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Encourage visits and calls to allied health personnel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Allow the pharmacist to monitor therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Give feedback to the patient via home BP readings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Make contact with patients who do not return",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Keep care inexpensive and simple",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Do the least workup needed to rule out secondary causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Obtain follow-up laboratory data only yearly unless indicated more often",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Use home blood pressure readings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Use nondrug, no-cost therapies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Use the fewest daily doses of drugs needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Use generic and break larger doses of tablets in half",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        If appropriate, use combination tablets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Tailor medication to daily routines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Prescribe according to pharmacological principles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Add one drug at a time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Start with small doses, aiming for 5- to 10-mm Hg reductions at each step",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Have medication taken immediately upon awakening in the morning or after 4 am if patient awakens to void",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Prevent volume overload with adequate diuretic and sodium restriction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Be willing to stop unsuccessful therapy and try a different approach",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Anticipate side effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Adjust therapy to ameliorate side effects that do not spontaneously disappear",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Continue to add effective and tolerated drugs, stepwise, in sufficient doses to achieve the goal of therapy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_12_35020=[""].join("\n");
var outline_f34_12_35020=null;
var title_f34_12_35021="Anticoagulant trials AF";
var content_f34_12_35021=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Trials of warfarin versus newer anticoagulants in AF*",
"    <sup>",
"     &bull;",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"7\">",
"        Baseline characteristics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Study drug and dose",
"       </td>",
"       <td class=\"subtitle2\">",
"        Mean CHADS",
"        <sub>",
"         2",
"        </sub>",
"        score",
"       </td>",
"       <td class=\"subtitle2\">",
"        Percent on aspirin",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Primary outcome",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Major bleeding definition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         RE-LY",
"        </strong>",
"       </td>",
"       <td>",
"        Dabigatran",
"        <br/>",
"        110 mg twice per day",
"        <br/>",
"        150 mg twice per day",
"       </td>",
"       <td>",
"        2.1",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td colspan=\"2\">",
"        All stroke and systemic embolism",
"       </td>",
"       <td colspan=\"2\">",
"        Reduction in hemoglobin of at least 2 g/dL [20 g/L] or symptomatic bleeding in critical organ",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         ROCKET-AF",
"        </strong>",
"       </td>",
"       <td>",
"        Rivaroxaban",
"        <br/>",
"        20 mg once per day",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        3.5",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td colspan=\"2\">",
"        All stroke and systemic embolism",
"       </td>",
"       <td colspan=\"2\">",
"        Major and non-major clinically relevant bleeding",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         ARISTOTLE",
"        </strong>",
"       </td>",
"       <td>",
"        Apixaban",
"        <br/>",
"        5 mg twice per day",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        2.1",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td colspan=\"2\">",
"        All stroke and systemic embolism",
"       </td>",
"       <td colspan=\"2\">",
"        Overt bleeding plus fall in hemoglobin of at least 2 g/dL [20 g/L] or transfusion of 2 units of packed red blood cells, occurring at a critical site, or resulting in death",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist_other\" colspan=\"8\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"7\">",
"        Outcome event rates (percent/yr)",
"        <br/>",
"        (new agent/warfarin)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Primary outcome",
"       </td>",
"       <td class=\"subtitle2\">",
"        Major bleeding",
"       </td>",
"       <td class=\"subtitle2\">",
"        Death",
"       </td>",
"       <td class=\"subtitle2\">",
"        Stroke (all)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Stroke (hemorrhagic)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Percent time in INR range",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        <strong>",
"         RE-LY",
"        </strong>",
"       </td>",
"       <td>",
"        110 mg",
"       </td>",
"       <td>",
"        1.53/1.69 (A)",
"       </td>",
"       <td>",
"        2.71/3.36 (C)",
"       </td>",
"       <td>",
"        3.75/4.13",
"       </td>",
"       <td>",
"        1.44/1.57",
"       </td>",
"       <td>",
"        0.12/0.38 (C)",
"       </td>",
"       <td>",
"        64",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        150 mg",
"       </td>",
"       <td>",
"        1.11/1.69 (B)",
"       </td>",
"       <td>",
"        3.11/3.36",
"       </td>",
"       <td>",
"        3.64/4.13",
"       </td>",
"       <td>",
"        1.01/1.57 (C)",
"       </td>",
"       <td>",
"        0.10/0.38 (C)",
"       </td>",
"       <td>",
"        64",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         ROCKET-AF",
"        </strong>",
"       </td>",
"       <td>",
"        As treated analysis",
"       </td>",
"       <td>",
"        1.70/2.20 (A)",
"       </td>",
"       <td>",
"        3.60/3.40",
"       </td>",
"       <td>",
"        1.90/2.20",
"       </td>",
"       <td>",
"        2.61/3.12",
"       </td>",
"       <td>",
"        0.50/0.70 (C)",
"       </td>",
"       <td>",
"        55",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intention to treat analysis",
"       </td>",
"       <td>",
"        2.10/2.40 (A)",
"       </td>",
"       <td>",
"        ---",
"       </td>",
"       <td>",
"        4.50/4.90",
"       </td>",
"       <td>",
"        ---",
"       </td>",
"       <td>",
"        ---",
"       </td>",
"       <td>",
"        ---",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"2\">",
"        <strong>",
"         ARISTOTLE",
"        </strong>",
"       </td>",
"       <td>",
"        1.27/1.60 (B)",
"       </td>",
"       <td>",
"        2.13/3.09 (C)",
"       </td>",
"       <td>",
"        3.52/3.94 (C)",
"       </td>",
"       <td>",
"        1.19/1.51",
"       </td>",
"       <td>",
"        0.24/0.47 (C)",
"       </td>",
"       <td>",
"        62",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CHADS",
"     <sub>",
"      2",
"     </sub>",
"     : estimate of stroke risk (see UpToDate topic \"Risk of embolization in atrial fibrillation\"); (A): statistically significant for noninferiority; (B): statistically significant for superiority; (C): statistically significant.",
"     <br>",
"      * Target INR 2.0 to 3.0 in each study.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Mean follow up of approximately two years in each study.",
"       <br>",
"        &Delta; Dose of rivaroxaban adjusted to 15 mg per day for renal insufficiency (creatinine clearance 30 to 49 mL/minute [0.5 to 0.82 mL/second]).",
"        <br>",
"         <span class=\"lozenge\">",
"          &loz;",
"         </span>",
"         Dose of apixaban adjusted to 2.5 mg twice per day with two or more of: age &ge;80 years, body weight &le;60 kg, or renal insufficiency (serum creatinine level &ge;1.5 mg/dL [133 &micro;mol/L]).",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Connolly SJ, Ezekowitz MD, Eikelbloom YS, et al. Dabigatran versus warfarin in patients with atrial fibrillation; N Engl J Med 2009; 361:1139.",
"       </li>",
"       <li>",
"        Patel MR, Mahaffey KE, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation; N Engl J Med 2011; 365:883.",
"       </li>",
"       <li>",
"        Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation; N Engl J Med 2011; 365:981.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_12_35021=[""].join("\n");
var outline_f34_12_35021=null;
var title_f34_12_35022="Scabies skin scrapings";
var content_f34_12_35022=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F53294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F53294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scabies skin scraping",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 201px; height: 134px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    S. scabiei mites in potassium hydroxide wet mount of the skin scrapings (magnification, x28.4).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wong, SS, Woo, PC, Yuen KY. Unusual laboratory findings in a case of Norwegian scabies provided a clue to diagnosis. J Clin Microbiol 2005; 43:2542. Copyright &copy; 2005 American Society for Microbiology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_12_35022=[""].join("\n");
var outline_f34_12_35022=null;
var title_f34_12_35023="Corneal alkali burn";
var content_f34_12_35023=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Corneal alkali burn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 342px; height: 232px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADoAVYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDznTbFlcDB9+K6qwtxEgLdutUNHg6M6jPbIrSubkQITnr7dK8Wx9XdvREeqX620LEkA+xzXAatqUlzIQGyKta9qDTyMobisy0tzM/TI71cV1Z1wgoLlW4/T7Rp5BkE/hXYafYrEg4yfcVDpVosSjjtWwqHG3BPpWcp3LatogSLe4wOPT0rasbLYASCM9yelRWUKqASDu9cd627aPIBx04rK92c1Wo7WQRw7FAUEnng/wCNU9XvFtIcK3zDOee9aN1KtvGST+BrkdQka6mJwSucgZrKrU5FbqLDUvaSu9ijEst5cc85PANdbpunLCgbA5HU9aydMtHJ+RcEYORXQaeJEuNsmdme9c0IX1Z1YmenLFmzZQKPmPC9OlN1O+WFMKcf1qvqepxWkHX6Vxl7q8t1K2wcE46V1TqKEeWJ51LDyqPnlsa93qtw0myJOD3qswd2Ek5y3ueKrLqEqQDztgYLgYXGT6n3qk88k5JLYGR0q6OFlU1Yq2JjR0iaFzfRRfLCMsO47VQknmnIDMQp9D0pY7cZHY4x+P8AXir0Vow2gLjHT1/pXq08LGHQ8mrjJSe5Sjh3EEj8vzqxFbnOFAA/P9f89KvR246benf/AD+NWIrckZKnHrjP9fWupQscUqjZSityeuD/AJ71MIAcYGR6kVoJCNxCct1A6YP+RTvJHB2kU7E8zKJhDA8cdTg9DxUghwQACSOxxV1oTySB6YHNPFuSR2HpinYjmKawLg9fp0p6QcZ4wOece9XfKO37n48U5Y/l6Z7dOlJoLme1ue/3fXFJ5JViVA474rR8rA4G0+lAjHTAA9zmolFMtSaKTRLIpDKMnqMd/wDOKbJayRqTDgx9xjirrRkcjA54pgQlflG0jt64rkqUVJanVSryi9BdP1WeyARv3tvnJRuSvuDWwywalB5lsA6EAkqOV+vOKxQgbAYYIpbaF4rmNreT7NIzDDNnY3Uc/nXBOlKGm6O2NWM9VozJ17w78kslq0iP904O0nLZ25HUZHfjpXM4ubeQLKZYGmVgsqMVLDO1lJHB9x6EeuB7RBB5HlprFjJa3BdR50RUxTIeuWbofqMflXM+JNFiXzYURxG5JjaQEKzDIDccdiAwPtyOKidBwjzdPxR24fH3fLI8yul2cs5fjPH8x75rJ8aWq3XiSSO4jY2drap+8tnLI3z5eSMMo4IViF4AJxx0rsBC2m3cf2m18+1WUK0crjkZDbWKnp39Dg+4pdQvkt2ka0M62AbcILiff5UgPyOpAHPPIwAQeQaeGq+xk5df61/z6nXiqSxcVDp8vu/U4jxZ4be+hvLqxjElvbXC2RnUrtlkKeYhCgn7yDPHGeM1g+EHfxEF8Pa54gi06wtIJXsjeBmiWQkER/KCVySTnnGDxXrPgZ7jS/FT2tva2UWm+IREsMjBkRL21IdQu3gN8w6gAgH3ryLUYJYfF2trPAIJkvZVeIDiNg5BX8DkV7lKoqlNNbq39fmj5TEUXSquL69DlLhfslxLGGBUkqcHIyD+oq9HbJPptzPu8qWEhMZz5hJyAQcY4Vzkf3AMc5qxqlhE0uoyWjCLyJBIkTH5gp9PXn+VPDy3+nC6WzuJZc7GkBG0sMe+fTtWlSWt0RQjzXTMEpuPB3Fv1qa4EU1vEymQXYUmQuQFYZ42++Oo9qvPaLbXNlPfhZrSTEkq2sgLqm4hl5HD4GRkdxVC7hktLtkyzqhDozKRuUjcrc9iCD+NCd9hOLjuQwXDwsWhwMjBBHFFEqHO5Mc+lFOxGp9EWqJFDnjgd/Sua8Q6h95Ub2+tamr3aW8BCN7da4q6ka4lJbnJ6V49j7GhD7TIY42nl5zyea6LTbPYq8ciqml23K8Z5610lnDjaOtKUraHQlbVlizt8DdgmrPkPu4xj2q/ZwgqDj685rRhtwcZGSOwrFq6OeVezGada/KA/HUYA61pO6xR4GePekO2OI87SKx7652udpJPasak1BGUIOtIZfytOzLk/TNFhYjAJHX1/wDr07TrSS5ly33ev65rXcrasFbH0Nc0IOb5mdMp8i5Ii2cIhjLbQFxkCq9/qCW24g8+55NTX2pwQwPt6jkCuOkuDe3J3E7Aa2lJL3YmdOne86mwt5PLqMxJyE/KpYbdIgNo+b1z0qeGPCjaSFx3NKAfurg56c+ld2Fwf2pHn4zH/YhsQGMMe5OOpNXILUFc454Oamgt8kk9SPWtCGAnGcgfWvWjBI8SdRsqwWwUAAgHpVmKADHAA74q5HCFHBAwKcFCkevoa0sYORXSD5hnGe1TJEoTgA96lbJxlB7ADrS49se6nNFhXBYwOpwPam4PVR055/8Ar04Da3Qgk+uadhmU8Z49adhXFCHnG3Hbk/lQIwGbG3PvTTxkHI4zgml5Q4YZxz3zSC5Iy7eAwOORnmhVJYZ5PPvTY8t8qfePvgU+RXjYhscc8EEfj/8AXpFXFdRjAwQO2KZtBb1OcUbzjaeefrinRtG+wM5UHkk9BUspDFXng9fWmFc/4jtWvqWjvaW8dxb3Md1EcBgincueBx09PzrNki8nckisj4B2upGR1zUNaXKT6Ff7y/vdwTONwGSM1p6NPpqEWfiS0S509+YryLiaE/7wOSnfbzj0NUI2aOUSR7dw4wRnI7g1rQCzvLdzp6Q2l9tAlsp3zDLjjdGzD5ZCSMLnB9qy5E2aczSOqjsb3w9YrLZyHXvDBQ/utwaSJD1Kj7rj2P6Vg6zdWdpaJfafKbjS3YlQgxLA4HP+2MY6HtnGazrDVdR8PXbNpjSW3/PW3njYJu7hkPIPuMdeDUGq3VvqF6LyztTZXLj99CjZjZvVe/Poenas6rtBpKz/AA+Xb02NaXxpt3X9f1civtLt9U0+T+z7tNksYIkz/rMNwuSp5BJ4HHXrzniPK1HRrxg4cBleLcjMAykEEZUhuh7YxXR+XcWM73GmKocnMlrJ/qpT149G/wAmr0M1p4ghkWIMs8f+tglx5sR56jPT0IrypXemzR7NGryLvFnPW0txf3Dxy2E+o26zLcwW8DFY4G3jb5cYBIIZuNmMD2BryTXonk8aag804Zb2+nQSzNhvMWVhlzjgkc16/q+lXNlHG8KKYgdxIl3KzDPzcAFDjjr/ADrmr3Q4dRupwskCLqEqC4S5d1eOQDiRJArAH5R97vznBNdOGxPs7qfUWKwyrpTh0POtZshbX9tcu0ckJY20zIcqewOeOK56Ke40bVpYVyYmfDx5xkjoR6GvYG8K3+sNe6fILGUSrsMsEm0Bt2FJ3AAcYJI4+mQK8l8QQs6qJ/lvYmMFwP8AbXgN+IH5g16lKoq0XFni16MsNJTWgt06XW9oJWaYDOxgMqB2OfT+VOvcX9rYQW9qYjbW5VmebO/bktgY4yxbHfkdhTfD9mdTLtbXX2fU4BwCARItS6jFqkLf6TaQyf8ATSBsE59vx9KOZKXKt0XZzjztaP8Ar5HPZ546dqKszoXjV1tzCp/vMDmit0cbTTPQ9Tumlc7mJ/GorGHcwPcn0qEKZZK3NPttoBIP5V4zdtD7lI0NNtMBeuT0rorW2yFznPc1R02NcjIxz3ret0UKO49hWb1OetNrQlgiBAzx3z2q+F2phjjH+FMiAUqByT3q1bREmok76I5G+rMy7EzFlTntxxVeHTpHkBbAz1Y10EhjyIwMkVbggAwcZY9cVzugpvcv6y4RskRWNt5MAVev+eax/ETrCuSecc+9bN7dpbxMSRjHc4zXnOt3019dFEyVzzVVWoR5Il4SnKc+d7FWS7lvJyiEhc9ela9jCluqvJGDvHAJ46VDpdh5cWSBgDqe1XiCeo+nHH/167MHhftSOXMsdzPkhsO+8RsG0H9KtW1uuFLc9M54/wA9abbQMx3HHXv/AJ9qvZxt68cnJ5r2IxsfPzmPROpIHrj1qUEKB39ajj7Z46VKqc59s85rRaGLY5DnBJGDz/n+dSxqBx+Yx9f/AK9NVcE9foT3/GpAcj5QcgY5osK4BFCjp6HtikIJ6c5qXCg9cn3OaaFZiAARn0oAjGSTkjNPYYByM8ZHPGKRk7kk/gKXAxzu6dM44oEIRtUKW4PXj9aTgY9PXb3pxVww+TI6YH+eaU5K9F9/moGJu+YFl6c4HWmt+93dR2z6fjSM2Mbo8jpkcUxyNxbacDnJHIosK49hzzj1wD/9amEg/eJOB3pjNyQwGKMYwT97HY9RUtFKRYR5EXyo5JFUsMqpIB/p6Vp376napbDV7GWW2TJA2FQ+Rjll6H/61Yw4borAjnnNdp4X8U31jD5O6OeFSSI5W2lfoe4rOyRonc45JY7i4ZLdW3jLmJAzFV5+pxilG3YHB6DgjtXfjxxqBtpN9pbzIwI3xORtP0PXFcFMd5JHT0HNKSRSbGuzGP5hluBv3NnA7den4UwkKSQxAxn8alRC3PGM/wCeKa8ZBPr7DNZON0aKQ6WJvuzKQW+ZSRnI9Qe9Y+p2DTSLLBKba/gP7mdODn0PqPatOM7dquGaJewPT3H5UsgDgglSM8EYrirUVJHZQruDKmj+JFu5jpetRpaaj6EZinx/d7ZPFZniHS3tpfMgSQIDtL8jqOFfPbODnFSaxpcOo22yQESx8oy8FT7flWfo3iC6sg1jrim6tQCizFT5iD39R/kV50246SPYoa+/S+a/yKDws9ol4sJSJmKD94pKsACVIByCM81xvifw1Dd6jPciXyvtgCrLzsjuBgbX9A+Mhv73HevRNV0ryEF1YMskUoBUg5WRfrjr6HrxzWGGkDNNbllHKsrLnvyCD/nitaGIdKScTorYeni6fLI8SWe50zVUuBGY7mB8OjdGI4IP8jXVHWdN1JxdGT7OEUeZHIQDn29RV7x9pKz28WpRJtlj+S4YDlh/C+O5HQ+vFcpp13c6I5lMKTWUw6gZU+6nsR6fnXs3jXiqkdz521TBVXRn8P8AVn/mPu7ZSWdHDpvKld2Dns2PQj+XPbJW1fxrqKwTaRHNc703MII9zDt8wAOP/wBVFXGpdajlh43PUrT4ez6dpBu9TIFyU3mPPEYx0PvWfAiLASBwBke9elfFLVo7eNdEt2Vr6fElww/5ZJnIX6nH5D3rzkJIrqhAGOwrzq0Y05csXe35nt4OpUrQ56nXb0LdmCF2gn3ragIWPcev+e9Z1nBnk4+pNakS7iB6Ht6Vzt2LqNNluyDSMTxg/hV2S4jiixk5A7Gs+e4S1gAVhuGOBVC3d7mXdI3y5rGdTk0W5mqXP7z2NuyUtJ5mevr/AErSlnEaEA4Psaz45fLixn26VQ1i9a3tmY5DYpRnyrQj2bqSsZXivVCX8pCSW689KztLhVuW6/xZ61nhZJrjzJRnJ4zW9Ev2eAZUg4yBnkVWFpOrPmZrjqyw9L2cdydpcqsIAA74zVq3hDlS3IxwD2qpaxF42kcbSGwu4Hn1qzHg4XOD619HThZHylSpd3LakfdQY9wO3+cU9IyOevcA0yFccgdvxq0i9WyMeuK1Oe9wSMgjuPap1UcZwe/WmKo4+X5venxdAcjbz+PvTEL1PGSScfWngNtOAB2GTQo9Tn6GpViXqTlqAAqdx6dOvU0vzMcEH0wwp0aoSNuB/wACNOxkFVwT1HII60rDIhGCuB976cUxGALAlcY7GpijO7DIY+gpnKOc4GR0WnYlsYcMpI5zwRjOTURQk9APrVibgEFmG7nmojFuBKsoBHcnOPzoSE2RkMB83ykH17daTHI4ye4qQowJwTkc7e34Go9x4wCR93pjnp1p2EQAKJAHUBweB2P5GpQPl4P456e1K4BfnOM4BH5U0AqSDyec+/vik0CYvlgSxruwXIBLdB9fSppmaCbYXjkI6MvpVYdsgDnBPTnNJICrDHIHIINQ0aKVicyOQdj8N1C8VGHLMQcKQMDFIpJ9PqoyQfpn+VNO7IHBP86zaNEyyjlQVBbnGOcZ96Yz55J69c8U5Jd9v5RMZbdkcAGoGztEispUj8c1m0aJknykkYpuDnKnJHHzUkTe54/E1Ipz2DY79OKhq5onYimRdgkjYnPDKccVha1pgvYGkj4nUbuM/N0roCrL8ykjvz+lSzi3fZNCBG7ECSDJwreq/wCyfTtXBiMPz6ndhsS6b0OJ0PUJrMNEVLQNy8Lnhvcehq/fack6fbtO/eKM+dFjDj03DsR2PT86v6zoqygXMIy4OSpqGwZ0k3wP5c6g9+D7H9a8hp0pcstj3I1lNe0hv1OWmjVsyQgFDwVK9COoIPf61galpNtK8s1uxsfO4uIowHimPZihPB+hHtXo1/ZRahDJPbKIrsDdNbBeH46qa5G+spYDGxjdFnXehdSu9eRkZ7ZB59q6qVWUfhZs408QrTWp5Prnh2XTb0wkO+4eZG8KFg6HvjqOcj8KK9HubK1u40S/illjRiUKSlGUnGRkdjxx7D0or1I5jGy5lqeNUyOpzP2bVvNmvb3ry3lxcXjST3UzF2djyzHqTV63UljJJ1znuay4QVOcdatJPhhjpXFOVj2lTv8ACbcLbiAMnnircs628WN2Wx6VlRXAiiz1OPWolkeeXB5/rXPKdtepCpXeuxahR7y43OW2c4FbUMax5C568c5qlbJsUYx+H+frWzaQDALY/Ks4QuzOtMkjhAG4kcc8nrWTqiJcPhwcCte7uRChHAIGOnesC6dmQv0J9K0lFfCjCm2veZALaJcMpAx0INQzMN4Byff/AD+NSBwkYx9BVBCJHJGOmOf8+9evg6SSueNjarbsbUMrSookZcqABjjA7YqzCh2cYz7EntVSz3HIzgnPI/xrQQZzwMf0xXpLQ8qTuySJBxgZ9sc1OOw7Y5x0psYyBxjv0qQAYGP5dKZI5Mcevv3FSY5BKlsH60ijHOOSeuP5U/ChQAeM+tMByBc8cDpgL/nFSjJIUbh7lf8AHtzTYY8uMj37cVOpDccYwB6UgQKo2HIOOnBpx64bfg49MGnlmO4MF4POB14zT0j4GWXk4wRz69qBvyK7BWwSWGeevT+XpSM/yjr0zgr/ACFWm2oFULtBP3jzjmogY2ctg7uvB56d/Y0ySoBGSQg2ljk7l4x9AevvTSoVfn2ZHvjirkiB2wSM9sew9BUMQ3jawDDpkg5WmTYrnG0KSSMgYB6H8aRdpBOcg9cEHHNWWjYDK5+YHDY6j8ah6OxKtyfm6dgMH17/AM6BEE8X708t83t1+nPFRlWLddp7frViUI/AJHAIz2I/yaaY2y+csCQfmPTvRcCBjnDuwBIKkk4zTURlYlM8enbj/Ip/BTJ2gjOcjr+dRsA6EgBTnpn9akdy/pdrb3JlD5yw/drv24b34+n/ANeor6zns7h4Jo1EiYJZW3L+dU8BsbypIHBzyD9fwqzG0gRkEh2sRuGeT+PpUPzNIsiYAE5/Mt1pj8HL4wenpTyuCcLjPHOen41Hz1Gfmxx159ayZqh0QwGGN2OTinxsM5GQB+lQk4xk8E845pxIJJ4+vTPeoZomWHdcdsexqBvmXKn5h0NNEmQBkjn8qM5PHGeeR1rKWprE0rJyykEgjr0zVHWLXy8yhcRnnI/hOKnsGG4qDz1Ocetak0KOmBkqe3bp6V5+Io88WdtCtySuckUJZZlfEiciReGFUru1W9kARYIb4kbvMG1JhnkhscEZyRj866qaxQcKozjp/Ssa/sgquVDA/eGDhlI7ivNUJQ0Z6sKybujiNWszazsQFuEDGMtDluQeo4Bwfp2HrRW1cyCSctdSeTNjBkYEB/r6GitPapdD0Y1XbU5vzctwRUivl1PWs+E456Yq2hwCf8itpu50RikXkYvgE9OMmtWwUBgB97tisaybzH4yfaul06IKAznGfUGsUm2YV5qKsaVrHuZTgke3FayNhcDqtQWwURBl6HvT55BHCxwBxkZrphHlR5Mnzuxk3sxebq2c9u9VZpPMZcbsDnk81B5zTXEnTH1pAGaQkc9jWNL3p3Na65I2INSk2KdpHT19qgskDbT2zjrnPNNvyWfaM+nerdig28+nc/1r6ShFKKR8viJNzZrWy4I5xknOO/8Anmr6qMj1/lUFqAcE59fp/KrSDPsfWt0co5cZJHIHTIp+eeTmlCjhfXk89qcFC4K8gfnTEOUPwcHk/SrKRllA3HAHO3rmmx8YYt2x06VIpbYozgAZyaARLHEDgkOcdgP8+1WVZFQAZJB6Z5qGFWDA5yOufx9qsxBWPyqwxkk+3fvSKQbSFXIOSQOSPzpzZU5Zc4+XIJ5H+fapBG3lhsc9QDxxx+dPWIuXVSoAIX0//XQMiSIAbXwB0ILdfp+pqNwCjbEYglvvtjsOmOauhGLKuzc+dgcfxEk4P6YoMJUg59+R0Bz9aAsUv3iqU2oVf0I9vXFQMeqgLvVc/KcZ/TFaYVDIwDk5cnhQc89fX86qTQxkHeIW4wdwJYDBPFAmitLvxvEaFPuttJbjHB/xqtJJEWyUBJ9+h+n4ZrRDwBShK/Ku0Lk8jnj2qGeMMjFSzchsNnp9fxoTE0VdiyRg7VZTkAlcYPfj/PSonCgq6gpngc8f5zUifKHKZDAncOfr0/rTrjG0DnP3uuR3yf1oJKDgkHseoOOM/wCPemqp+TrgDB5/z61M5GeCisTz370PlXJyOmef60CKhXCZB3FSeR6f5/nSxjrkfLtHQfn/ACqeUjDMFC55I7Djp/Omp/q+wJORnsallx3I2J2jdk47+p9aawPzKcsvUjNSMR8wxyDnleoqMEMMEY+UgnGehFZM1Qw46Dv1/wA/jUWAOAcdiDyamckHDHoc4x9agfGGxnI547+tQy0A4X5s4YfKeKcpPUrkAZzUJwWPPJxkgVIArDLHB69iDWTRomWbSTEy9OOSRXRRn5Qd33hzz1rlY2VZEBIHHTt/KuntpC1ugypCjsc4rnkbxYSghgNxYd/as+6iVwQTznoTWoV3A8cdOnUVUmjOCOenFefUidlOVjlbvTkkPzDv2NFa80G48A57gUVzWl0O9Vnbc8dhGOc9PQ1KGckKM5pIcsAecgVfsLXfkkYA71vLU9zn5Vcn0uJhIDjvnHetjzJXuUjX8e9Os7UJjC84zmtO1twjbiMHORikoO1jhq1k3c0YHZYlRVIOBz3qtqk5SBzwCfSrCN2/iHPX/GqWpjfDgLxTnpE5aaXOY1hIzbzg8nirVpHvhd92Cp6Y/rTLULC3+8cGr1xEI03ouCR69M1WDp83Uzx9VRZhXYHnrk5Prxn6frWnZjPfJNZvJuDkhSfvY4/Ctq1GQq/w9SM4719FBWVj5eq7tmjAgK7iMZ9v51aQdP6VBGG25walVCSd3Ix3+laoxZOuMdh7ZqWNQNoIz/T61Eg4B5xirCqflPOOPw+tMQqpkdcHPp1NWFiOAACvQE5zxTUj5Ye52gD8atw72VCSVYe+M0mxpEkSEsnTdjHBzn0/nVqHATJDBgORjqM9/wAqRV29e5GGGfXpVi3iYEojMAVAxtYZ68HFI0SGwiMMo+6mCQwIx6fhz/KrVtExUySxkMp4DKOOOv69fpT44m84gq+2RAynBHfjnHXIPNXUt8pJ5vORs3+X8zr0wfXPHNJspIoRIGjZWVwSwDBsHYM5GPfk0n2ZJlbEi4Y5z1AyeD+p6VqxKBMrOqME+Qkcg8dT70wBpreOEq+wjaMDPyg5HX3FFwsY62kbklSA8adAoBYnHvk1Ese1iI5BgfNnJ445Ge1a0kJUsjlVAyTnpz64PP8ASq0MJDMsixhSg2qAAQcdOM+1FxWMgxRNIykZbAPIyBx61DuWGWZCxZNoY7eQOOPTrjFX5wEuWO1V9N/Jyfb/AD3ptwmQCScsx+7069vwqiLGXN5RJwTHKACdw64HYf8A6qHBaQ7V5QnIPof06ipJ0WViJBgls7sEYx2PT/Jpgh/enIUllK9B6cfhkUElCQMpAL4+YngAA/X9aSTkoSAVIIJHrirE6lii8gk4HTPQfrUU/KncQGL54GOtBJCeYgCSAWI/T9adsGzrjgEg/h/9eiRAYUHynOcd8Y+tPlJV3OMkDqD056gdPwqGXErspLAc5wBz/CMU3YNoPJJyDjr6VK7HAzywwMk9OvWmtycYIBfH4f07VDNEVnUgngsV6HpUQCjbnr0OMdcVPPwSCeoIIxUZByT90Zz0A5z0FQykQFRtXIwD6im9BnjHpmpcYVR7/wBM81GfkHX/AA+n8qykaRGsQB83AHr710mm8W6YBA9jXNjIXI3Bs5wea6WwAaBQ3rzjpmuaRvFmhAm7oAKWaIGPpRCdjEKeh+lSSSHvwTXNpbU31uYtzGwY4YA570VamHPGGHoB0orndrm6bseGW6hnAHc9a6Cwj2qOo46k1iafGeD+XtXSQYGOCPaqPoKsuhoREIAMEnH51ZVyq5Jx/nmqQILDjPPpQzs+VUcY96GzkUbl+Gbe+1SfoKnvl/cl3OQBn9Kp6TbvHIzSZyBgk9TV+/ikms3EfUDNQ9Ykuymkjko3knvMYO3866GZT9jRQd2BxyBn8Kx9NgKM/mZDA/TFa8RzG6nJK4xj+VPAStL1MszV1p0MULiQEDqc8f5/zmtu1X5QORzj/P8AntWWy7JRnGM8Ajr0rXtR0Pp1wK+lifKT3NBDjJx36dKmj++SSMfXFQxDOOW9fpU/YZ6dhVmZNGo3KCCeMAVYjXdyDkjg4qBIskdSOec1ZUFWbcCM880AkTQJhshWGBknFXYQGbmNWBB4zjP/ANeq0SjJ3Ntznnrj0zVmIgyc4455/wA/pSLRZRBhSCFUjhSep6dPxq2qlo4xH5j4GPlJAP8AjVeMBolKtGUzlc4B5/lWjHHKUXzWKEDgKQQQevPpSLRYtk+6QGXAyfmIHHOMGrEEUm6NVYrJg7gSSG9Kbb5G0v2yvlvnIPqD6Vp2MSyXC7kUADg5yKkoiMEgG4goS3Uc7aia2IjXGdi5UAfxc5+uOa6UKo4VQPbFUb+JQchtgxkexz6UNNDMGaMLIBIjgkFyq9Tj7p/z61QFvhGbyzgjBZSCE47cn/GtXy9rGU3DgtnJbgZ5xWfcsCwV5ZWjHO1UI/mPXnimhMy7gEys8cbKp5OR948c47+tQBo8IAGRQv3iCBgj9KtXDqd26TtgFnJAbJ6DH4VA6szRZYENwW/+vn6VRBnOgLny5Cozuye3+FQuMhWJ3OMFioz/AJ9KuSBJCGYEkHs2ec4yaqMC+VIGM4ye4HX8KCGiGQL5iseo9uh61X3DazFSCo6detXbgKGBIxjg/gTmqpVkJHOT3Izx3ouKwYU56lQMHpxnpmiXJG4E8AcjvxQw2RnDAYIzz+H9KU5CkZz/AA4/rmoLSsV3wVY9OcjrUbAE5GMZz/Pmta2028vi0dnayTMF3EKOcdjzx3/SqV3BLFK8U0TxSI2GjkBVl4BGRUNl2KToSOCCTkDmoioV+pAGBznOKmALKdwGeOD1Heo2z1yM9SfWoY0V2HQkdMHH9P1NJKpwCB8re/b/ADipTgoepYk9ajLEAgKfx5rOTNEhIgC0eMDnOc8V0unjEaZ6E881zkaHfHjOO+eldPbfLEDlW44/l0rlkzeKLCRhmyB8vrTpVIBB7D1zUkA+QMBz6gVDMQWLKACOvHJ7Vyyta5ur3Kci7WwykgcUU5ypPIP4UVxyWuh0JnjdmgAXPHAzWnCS3TPNZVu3A9a1bdcL35x2robPdmu5ZLgKckDPFWLJdxJ6Z9v0qi2XYBR3zjrWpaR+XgD8alamc/dia1lGCCDwKvBVVcKOg/SqkHy8Yx9KtRHOT3rZJWPOk22Zt/ZLC3nKeCcECq8JHmMBxxg89f8AGte+3GBwOuOKwradJLzaOCDk461gmqdRNFyTqU3foR3MIDg+9X7RcxjGOB6VFeId5zkg/rU9m20DPOc54r6KlK6PmqsbSL8OABn1PGalCtnBBAz1zUUYYgcfNzmre35icEZHQVvcwsPRcJkdjxipVALoW6fdwTTY1xkn5cVZVAi7V6H24pXGkOiIChWGezFj36irsSk4HAzzx3quvYk4I9uhq1FJgKBtLZ6s2PyoKRbjchVVgdoyDGBgn3z2q3ayOy7fPVYVG1U2jOOc4IHtVOBWxgRZY8lpOQfTHrVq3uNqLHuUFmyfLTPPtSLNO3G5jtuVcZxnkA/Qf561raasaXShR8/utYkbbYUzIqrxk7c4NaNhL5ByGZjvyeOtSykdD37VT1MhVUsQBg9Rmplu7d+RKo7kE9Kp6hdb28u3cBlHOcc/nTbTQkjNmk812KBXUcc4wPzqhdOohRUTfITnY2Nx9+ecVblZn3fIGccqrZw35dDVQrclSspYAn5sHHYAZFJDKVxNOiKRvhViOAqlQM8kZ/8Ar1QmwZWVnklZ+S/Q57Val3jktkEYX5F5+o646VWmPOA5VejAIAByB26GqRDKzna5ILDdjPbd7cVVnRmuMBQpPB+Uken9Kmzs4HzAdM9Sd1RSISCyggsNo9Cf880EvUjuCZHMuTyM5/L29xVdfvDeAOfSp5D8yqGBAbsf0/z6VERtY7ecY5HOfU1LYJXYw8Kep6lvpTHLAqxJJXA6VI3AGQSTwSec+3t+tRnJCq2ACBkjt7flUtlWO6+GV1bBru2fC3jESKxb764AwOe2B+dJ8VltPKsCzRi/3HPIB8vHOfbOMfU+9cG5yp3HLK3HYjioi+NxwcuTu7k+2fSpUminqMxgkMFXH97PPt9cfhUb/wC1ywJPT+tPYkEhsELxnP8An1pmRtyAc/jWbZSRC68nAzgccEVCwDMcnPHTpU0hUEbuWAxzUK8fdAC9QPU/lWUmaRLNpEHnGeSP8PeultYyyhV9PXP5Vl6TBg7gM4Bwf8K3bdCrM3YDtXLJXN0DERjAXr1zVeYjHC8HnPWp5SWLMT+lUyQeH5Pr6iuWtLlN4K5UflunHt0op7rg8tj3orhdzpR45EwJAUg/jWpG2FA/nxWDp/zRI3U/Ste03b14OPeu19z3pLQ0LRCGBbt07VtWsfHPPHpWXbDLVsROqY6Dv1oicVZtlyMBiRxyOmQaDdIsnljkn0PWqk80rBfJHX0qSztAArscyHqD2/T3q3LsYKCteRrQgSLtI6+tcXqAWx1aZBjPVa7u0ibaCDg9KyPFmii5jW6iHzp1x6VjXg5Q5luhYerGNTllsynbMbi0WT5uhGKkgwpwcdMVX0a8UQLbSAAg8H/61XtoBPUkcZr1cBWU6a1PGx9FwqPQuwduBjPWrSqNgHX8c1Vt8gDP496tqAOoyCMdOvvXpJnmtEsY5K5+oxipUYEEHJxgjmoVJC5GVA7CpkwAWz0wDQBYRQCMnI9c8CrCtsIDKPmPBPJ4qtCQo/dsNq88jvU6DfubOCF7nPNBSLcZV25jdz/T+lXEaVFjjGUAPKHoe+P5VQTnG4GQAZwKsrwQhAXOGyMj6+v8qRRowSOsQYkIFxlsYx6VYWYGUhQ7/wAWeu76/lWcojIld2JTfxwcAY/X/wCvVmOZnc7WYqBuUHp3Bz0pDLSlvOwv39vCkH9O3anyzbAoLZGc9Mn8/wClUoWB+QMo25PYk80NIwPzMXi2gZU9D0z+nWgZLLJm5hKyqCejA4z7fn0qrJJC0hErNkg/KyE4JAxnv+NOllWTcWTz3VMYJ27uctz+v4VXeUjn5i33ldxuDDjgk/40xFWaZUZwFAK4ySc+vp29ajlIGGVgwZuQy5BAxjg9e1WLkySCQCDAXrtCkevAx74/OqMhL7mO9QDtU4HQgHgDOADxyB0PbFBLKsgVQ5UANwBt79OM0Mr+Ww2gMrcgH6cD3xinzfu4/mYlSxZQOQOevWosPvdQMb8EEe3B/wA+1DYrET/KGcAHJGQCOvrUb4YZyeoxj05pzFpF25zkk9+v8jSNxHg5JOQSc9vf8f8AOai4xkuSuWyeew5zUfAbaVBxkfgeP6VID8zdAeuTz2qBjkoQBwe5+tS2VYBgJ7nn06GoWKlR6Hp0/HH409z+8Tj1GcA/zqN+MEk4Zsk9M81DY0GVKtuOCME54qBwCoGfzGQOKe2Aw6YPr71G3zBsjduqGy0Fraz6jf21jZY8+7by0JHCcZZz7KASfYYq1fw26apJFZMHs4ysUL93CgLvJ77jlj9aNMuv7OsbueJs317m1jOeYYOC5+rnaB6BSam0q3MkvmMBtHbPam+RUnfWT/BAuZz8kadlEscQQbcn35rQ+5GAu2oVRTKPQcjpmpmOAcjGPbmuKUtWdUVoVblyqnjIUZPes15o0fa8kROR/ED17fWrtyCTtHf16V0vh/xJax6Y1hrSY2x7IrkKTvXGAGOCQRgDPI4rkcI1Z8s5W8zfmcI3irnJXUM1vDA81uyJMokjkOcSKeeuccen50VDcXARVR5z5KFtgZiVBJ52g8DPXgUVxTaTtE6oRbV2jxfR0IUA5xjAroIIwsasR74xWTYgKAT+JxWqr/Jj/JrukrHsTbb0LcD7e+ew5qcGVpkxux7VUtvnkUZOOnFbyxKkaYwR09qwlLTQxk1FmvawL5G3A3ADk881bt7ZQoJzj1qnayZUYOC3PFaVsf3YA71rCaseZUuWYwF+oHc/59qlGGAVsYI+vFQxli30q2qFiCelaqTexzs4rXdNNpqSTRJ+7PzH09atACSJWX0wRXR39slxEVYDjoT61lRWstsSrLuU9SKeHi6FRtbMdearU0nuitEFznnB6f4VfRQRxyfrVcxPG+cEZ9amjJGCCK9uLuePJWJQAwPvTxnIxjI7e/8ASkyMEDr1IzgVKFGAo4z04HFUShyFsEjG3PTFTBWcKNnHTrURxhd2B0Ge1SKZHbJGV6cHA4oAnUYXaQACBkYyOKngYB4yrIFAyQpHTuM/561WKtuDEnH6CpMrGAByCOpGB+FBRbiVyodhjjGCvT19881KJS2N77VA7DAxnv7c/rVMbduAmFLdM9fqf8alDbgVCHjjkA5P+e1AFxJQHkBDGOJCoGR8+f8AP6UithJEYt5nA9d2M9v1qsjeYjp852DAGBluO9NDgpgqpPOQpweBjP60hlkSS5BAdmHO0dwD+mfT/CoXaWPqrrH9zI5BU9c8fTtUbFNroQSN2RlMnj/9YqAyxkf61wdvK89eOtAhGIjjV2cIQM5VcEjjv+NROPMDDJZtxzkjJ/wp7jYSUjUHb12/ez6HpzUNwNwXzRggbsY9sZHFAhiDKr+7YknqTz35/wA81XYE8sp4xn0/PvU27IIwBuB68DdmoDsBUMoGQOuO+OnpUtjsNcGMAA/KuDkc4HX/ABpi/fPDdOnTnIokYkk84xjr7/8A16a/JkH8WOnPsf6VLYAuCj4JJOB16CouMMFHfPpnin/dBGcgZIz7cU3GwHhsnHB47VDZSRGxJ2kZ6nBz/j9KjfHlhccD36/5/rSzc4RcL7D/AA/Gkk+ZtuQOpwakohJIOScjgEZqvIwKjHTgA1PI3zEK5AI6+vrUW1nJGMH3/lWcnYtK46FTJKBgn2HP+etdPaxeRCqgENjB5xVDTrNowJJOoGRz/n/IrSxlsLjj0rnnPlVzaMbuxYjUKmM896bKxK44wPSmE8YIyfbrUbFguBuUnoa45VLHQokDMQQWHB74qGTk+p798GpJXHf5TUGNzHHGDXLOaZvFWIZDtztOAT2AookLbjg5OexxRWBsjyi3YAA5wamjfzHAB4J7cVmaZukwp4Poa3ktRF84PSvQqS1sj2rRjvuaenWm3awBJ9uK3IdrIu4D61m6Y/nqfl+bvmtHYytgAfUjHNYvRaHnVW3KzNKCJVUY6cdavQoRjHTv3rOtpMDpjnpWhEwJHQelXCzOKpe5djGFA4OOamDnaAMelV1IC88+tP4HHc11LbQ5n5i3EmFCqMk06JMKFPIHWoIctNyOn6VeQDGMV0Uk73M6misVbq38wE456nvWeqlGIwBjvjrW7gBeaq3VuHUnGT7V3xZxSRSjJ5U44Hcf59qmxhs+v4VCARwe3vipAckA5yTV3M7EgwqkEHPajLYOGIzjAIpRyeBnvn604Jk4xxkflTCwBj1YZXpy+KlQ7grMo+Tq2D0qMqVA5AxzgDNAAEbZYj05ouIs78ptCnoDluPypclgWY4I6MDjH1qGJsEgkjAxuJzxTldUADNnt6Y7igZID87lAGySOSfz5qV2Eki/JjocAf41CGB2gAHPfHJ9qRiWVDJjA+XPU0XGPkkCJ8vy5JO5V46df0pjTbzkHIDcdVJ9qR9wPO5c/dx0IpoO5uVYbvmHzZHTv+VK4DeGjJXe/GGx1z9ail4Ax7nIGTSFAUO87SBw2N30FQuCrYYYA7k9/SlcQr72ZlKL90ngDOfxqEcqEUlmI5x3/wA5p8ZXDdX3dAD2qFlYK2RwOBjB4461LYxH2lh/GOQfp9aaB8xwRjjqcg8UjEM449CeP/rUIBtJbqc9ietS2NDHbeOcMOT1OT/nmm7Tu5OVbqD2pxG0EHrnBJH50jKAwJxuGCOMY9KlspIZJnglec5OSQBVeRuOBnr+X+c1K7ldxUjj8vSogmflO4kHOPU1LZSREF9ByTnFaGn2QZt8hO327+9FnZjqxIXqcDrWyiBCSQyjAHP+Fc85dzWCGoNiZwNrcZBp2GEbEDnHTPApQCSNwHPen4IA4yB6DtXDOXNsdUVYiLHGTn+oprNuFLKwIyu78BVcvk8YPHWuWUrGqVwnAI5P1quc7T7Y5xT5ZMjgD0B/pUOSUIJPpjpzXLOV3obxVivMxBOM9ffNFV5VXdgNgfTvRWdzVI83s4EXlQM9BWvCxQBT0PvWLazbZBkjGOa0TKPLycD3r1Ju70PRak9zXjdYQJEBH0Fa9jMsylvXjFcrDeKUC+3rWtp8wCJtPsQe9QY1abtrudIijbkYz3AFWrduhOOB0FZcM6si4OOB9atQyYA5OPpmrjbc8+cWaqtn+VKrhxn0/Cs/7RscAdKmW7jZQCcE+vFbe0W1zH2b3saETYBORk+tWrc9s5PTNZizAvgH/PFXFkC7c11U5IwqRZoDuBj8aSQZBH4c0yNjj3qZcetdkWcckUZYAwY/pVfaUYjgHGOlajoNp7e9QNCGUljtI54FaXMmimpxjryfpUij5uBjjGe9I0TIcAZ56UisRk44qrk2J14wePf2phGGA5Pf1FOAG0AngE9utPBGD398c0XCw0IwGCent+dC5OQOg9+acp3cNxkfWjb6568ZouMABtOepOOf6UR5TKjBBPORwacQCcgg+oxTMbTy2foKAsMPA+6CuOc5pkYxjaoH5gn1qXGAQu3J6jpUe3EZOPXoc9qQDGwA2R3z+mKjcDfuC52/MWBIJqZlIYD5sH0xUZy5JJwMjkDFJsLELFgp+RsseOCT/hTJMFQpUYznBHQYqYxtgA52j+tMcKFHI9sD9KlsLEQ5LZPP/wBfFIxTYeDg4+YClbA4Y49eMk8+9Qlgy/KcEjp+NSykJv6FRjnHNRGQbue3Y88jofzxSjnOD0/iBOfy/wD10xIi2Bz8xzz07VDZSRHyVU4wR8vA4NaFnaMxBfIHQEdT+dSW9r5bBjzwMAjtmryoCcA55znH86ylLuaJBHGqKFQAAHGP605m3E554p4wDnpnuaa5K5zjjr71zVW3sb00NjJGcDgdqY77c9cdeKRypBYHDYqBpD0YAMB1A4/z0rz5tx0OmKuGSWwpzwaQqcHByfr/ADpRJ14yo5z/AJ/GojJsGSRk9x34zWFmzTYik5ILKQScZ71VmIDHo3H9f88VZklRiMj33D3rNlO6VzgAHpz1rN0+rNIyIpM7iRkg0U5MNyAPxwKKXIXzHlEcxPIOe9X4pyw2HHTqfSuetbgrwen0rXtZFc5yMd69eUEetF6GxaQjBJBIPatKIqiEqR+VZVtLhgefoTV+Jty8H8qwcSJtvc1bSfng4P0xWgkpiA5H1xWRC3lgEcA+nT8alkuAVwOSc0tjmlDmehrQzlpNynHcCpbiUAgMBzwcVz8dw6the/arkLF3yx/+vU8wOjyu5rWskyIPLG9D2xVm41AxKFb5ZGPAqC2YxrnB45ORWZrdwrXNu+CQrc9a1hPkjdMwVNVZ2aOp0vUWnUZGCADzW3HKD1z+NcpojLNPJLk7e1dEgyDjivQoVLrU8zE01GVkX1PORj1pSnAHftVaEkNgk1aByOhwPaupSOKUSB48Nz+B61XkiAOR161oleOozUTx4BHBGPrV3IaM4gLywJpxyF+npUsqjrjnpUJQDk9D23cChSFYeGPPJAHNKHyAAcn06VCTgAse2T6U5j8uP/rUcwWJd/IGTk0GUPhjjBAOR+dRFsjBOfY+tB4wcMT2x3p3EPJBOGGc96aT83LfpTeTkt07cUgLDkHr05pXCwrP8+Q3TjOaYzDJH3R/Ohm4zx+FNAwT2b39KTYxoXcNqgHnj8qjYAtjqffmpOWxtGBjvz2pqjJ54I5/zmpchpFbtwTjHUA8H/8AXikcM+QAOOMdquNGeD1APUGpDCu49Tu5zk4OKzcikipHbHeRjI57nqOlWYY1SPIGTj1qeOLcTkEe5PWpkQ/xY6Y/Gs3LsaKJSjkzcGOUFJFG4DOQ6HuPx4q2Pvn1PpVbUYx5RuiVV7f5ww67P4h7jGePYUs8ocBIyCHI568VzObUrM6FBNJokllCRNI5wAMkjmq6SM+Dj5mOSD2FMeDIQTElCeST19KVM+a5XIA+XNTZvU0SSQy4wpG5vwzSM5AwSSpHSoJMvK5IA29vX/PNIOWK/wB3k54/KuSrB3No2sE0oRMfwnI9cVWkyRkvkkfL9amgA3ynayuGwc+3Sq16wUEgkKWA3YqHCxS1dhYAJYwyuScAUy7tY5CGbnb321LbIsY44z0wetLLwxwMN1x/n8aFHQTk1LQo2m2LdByShyN3oaKgvo58IUKuBkY6H/PFFS4tbI2S5tbniduTnI6Vp2smCOeOtFFejVPYpamjFcnIwe9btg28A89MdeKKK5b62LxEUo3Rek+UAjG7/P6UsC+YRyTmiil1OK7UbllYvnUnH4VowQpuQ5z+Of8APSiipcUYTm7GipAiODnPcfWmQpHImHRW5PT8aKK3gldHK20mW9MKrM8agDHIzWyGC4HXniiiuunojkr/ABE0EqMTg9Kto/UfpmiiuiDucs1Zku45oIycE0UVomZMikjDEk8dxyKrunpknoFFFFSxoaY+OvH1prJ7cUUU7isJs6lSOevOKaEIUZz1P1z/AEoopoTAoeQfzzQ0ftyeKKKAsHlZBXg07yhg5xnjgiiigBwQDGMDHIxxmmiLAUgDHTpmiiobuUkSLGdpEuC3bb0/WnFVKrwevNFFZyZokS7eQcjrimthfunpRRSauNbkUQJjOBxjGG5zWTZRNYzi0dsw7S9u2OdgPKH/AHeMH0P1oorlqrS500nvH+tC/O+QDt3HP51XDYIJySSQQD05ooqlsCKd8+U86MnKc4HQr3pjM27fEMjb8wJwCPX60UVlPc1WiI7CMSRm4lXLP8xz29OKsEI67SMjBGO1FFZ2FJtyZTBe3yMM8I6HHP4+tRG4VZAGBAPIyKKKh6I0iubcSdixAJx68UUUU3JoSP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Alkali burn. Significant corneal, conjunctival, and scleral damage occurred after a severe alkali injury. Notice the opacified cornea and the conjunctival and scleral blanching, indicating severe damage to the surrounding blood vessels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2e. Lippincott Williams &amp; Wilkins, 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_12_35023=[""].join("\n");
var outline_f34_12_35023=null;
